 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL CONFIDENTIAL  NCI U.S. RE-SUBMISSION  
 HEALTH CANADA SUBMISSION: 2010- APR -09 
 AMENDMENT #1: 2011- AUG- 15 
 ADMINISTRATIVE UPDATE #1: 2011 -DEC -19 
 AMENDMENT #2: 2012- FEB-20 
 AMENDMENT #3: 2015- JAN- 15 
 AMENDMENT #4: 2016- FEB-04 
 
 
 
 
  
CANADIAN CANCER TRIALS GROUP ( CCTG)  
 
A PHASE III RANDOMIZED TRIAL OF METFORMIN VERSUS PLACEBO  
ON RECURRENCE AND SURVIVAL IN EARLY STAGE BREAST CANCER  
 
NCIC CTG Protocol Number: MA.32  
Participating NCTN Groups: The Alliance, ECOG -ACRIN, NRG, SWOG  
Other Pa rticipating Groups: IBCSG, NCRI -BCSG - ICR- CTSU  
 
 STUDY CHAIR:  Pamela J. Goodwin  
 
 TRIAL COMMITTEE:  Karen Gelmon , Kathleen Pritchard , 
  Timothy Whelan , Lois Shepherd,  
  Jennifer Ligibel , Dawn Hershman , 
  Ingrid Mayer , Timothy Hobday , 
  Priya Rastogi , Dan Rea , Alastair Thompson,  
  Judith Bliss , Manuela Rabaglio  
 
 SENIOR INVESTIGATOR : Wendy Parulekar  
 
 BIOSTATI STICIAN:  Bingshu Chen  
 
 QUALITY OF LIFE COORDINATOR:  Julie Lemieux  
 
 CORRELATIVE SCIENCE CHAIR:  Vuk Stambolic  
 
 STUDY COORDINATOR:  Paul Stos  
 
 SPONSOR:  CCTG  
 
Metformin  (NSC 91485)  and Placebo provided by a generous donation from Apotex  
 
(For contact information of study personnel see Final Page.)  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL CONFIDENTIAL  
This study is supported by the NCI Cancer Trials Support Unit (CTSU).  
 
Institutions not aligned with CCTG will participate through the CTSU mechanism as outlined below and 
detailed in the CTSU logistical appendix.  
 
*The study protocol and all related forms and documents must be downloaded from the protocol -specific 
Web page of the CTSU Member Web site located at https://www.ctsu.org  
 
 Send completed site registration documents to the CTSU Regula tory Office. Refer to the CTSU 
Logistical Appendix for specific instructions and documents to be submitted.  
 Patient enrollments will be done through the CCTG by means of a web -based Electronic Data 
Capture (EDC) System. Refer to the logistical appendix for  specific instructions.  
 Data management will be performed by the C CTG by means of a web- based Electronic Data Capture 
(EDC) System. Electronic case report forms must be submitted through the EDC system; clinical 
reports and supporting documentation may be submitted through the EDC system or sent by mail to 
CCTG unless ot herwise directed by the protocol. Do not send study data or case report forms to the 
CTSU Data Operations.  
 Data query and delinquency reports will be sent directly to the enrolling site by C CTG. Please send 
query response and delinquent data to CCTG and d o not copy the CTSU Data Operations. Please 
note that data queries are both issued and should be responded to directly within the EDC system.  
 Each site should have a designated CTSU Administrator and Data Administrator and must keep their 
CTEP IAM Account contact information current. This will ensure timely communication between 
the clinical site and the CCTG data center.  
 
 
Participating NCTN Groups  
 
Group Name  Group Co- Chair  
 
The Alliance  Dr. Jennifer Ligibel  
 Dana Farber Cancer Institute  
 44 Binney St. Dana 1210  
 Boston, MA  02115  
 Phone: (617) 632- 3428 
 jligibel@partners.org  
 
ECOG -ACRIN  Dr. Ingrid Mayer  
 Vanderbilt University Medical Center  
 Hematology/Oncology 
 777 Preston Research Building  
 2220 Pierce Avenue  
 Nashville TN  37232- 6307  
 Phone: (615) 936- 3524 Fax: (615) 343- 7602 
 Ingrid.mayer@vanderbilt.edu 
   
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL CONFIDENTIAL Participating  NCT0N Groups  continued:  
 
SWOG  Dr. Dawn Hershman  
 Herbert Irving Cancer Center  
 Columbia University  
 161 Fort Washington – 1068  
 New York, NY, USA 10032  
 Phone: 212- 305-1945 Fax: 212- 305-1078 
 dlh23@columbia.edu 
 
NRG  Dr. Priya Rastogi  
 NSABP Foundation , Inc.  
 Four Alleghency Center – 5th Floor  
 Pittsburgh, PA, USA 15212- 5234  
 Phone: 412- 330-4600 Fax: 412- 330-4660 
 rastogip@upmc.edu  
 Other Participating Groups:  
NCRI -BCSG - ICR-CTSU  Dr. Dan Rea /  
Partnership  Professor Judith Bliss  
 The Institute of Cancer Research – Clinical Trials and Statistics Unit  
 Institute of Cancer Research, Division of Clinical Studies  
 Sir Richard Doll Building  
 Cotswold Road,  
 Sutton, Surrey 
 SM2 5NG  
 Phone: +44 (0)208 722 4054  
  d.w.rea@bham.ac.uk  
 Judith. bliss@icr.ac.uk  
 IBCSG  Dr. Manuela Rabaglio  
 IBCSG Coordinating Center  
 Effingerstrasse 40  
 3008 Bern, Switzerland  
 Tel: +41 44 387 2550  
 Fax: +41 44 387 2551  
 manuela.rabaglio@ibcsg.org 
 
Document History  
 
Modification  Version Date  
Amendment #5  2021 -Apr-01 
Amendment #4  2016 -Feb-04 
Amendment #3  2015 -Jan-15 
Amendment #2  2012 -Feb-20 
Administrative Update #1  2011 -Dec-19 
Amendment #1  2011 -Aug-15 
Initial (Activation)  2010 -Apr-09 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL i CONFIDENTIAL TABLE OF CONTENTS  
 
STUDY ACKNOWLEDGMENT/DISCLOSURE .................................................................................................... 1 
 
TREATMENT SCHEMA  ............................................................................................................................................ 2 
 
1.0 OBJECTIVES ................................................................................................................................................. 3 
 2.0 BACKGROUND INFORMATION AND RATIONALE  .......................................................................... 4 
 
3.0 BACKGROUND THERAPEUTIC INFORMATION .............................................................................. 17 
3.1 Name and Chemical Information  ................................................................................................................ 17 
3.2 Chemical Structure ....................................................................................................................................... 17 
3.3 Mechanism of Action  ................................................................................................................................... 17 
3.4 Toxicology  .................................................................................................................................................... 18 
3.5 Phase I & II Trials  ........................................................................................................................................ 19 
3.6 Adverse Effects  ............................................................................................................................................ 19 
3.7 Pharmaceutical Data ..................................................................................................................................... 19 
 4.0 TRIAL DESIGN ........................................................................................................................................... 21 
4.1 Stratification  ................................................................................................................................................. 21 
4.2 Randomization  .............................................................................................................................................. 21 
4.3 Inclusion of Women and Minorities  ........................................................................................................... 22 
 
5.0 STUDY POPULATION  .............................................................................................................................. 23 
5.1 Eligibility Criteria  ........................................................................................................................................ 23 
5.2 Ineligibility Criteria ...................................................................................................................................... 26 
 
6.0 PRE-TREATMENT EVALUATION......................................................................................................... 28 
 7.0 ENTRY/RANDOMIZATION PROCEDURES  ........................................................................................ 29 
7.1 Randomization  .............................................................................................................................................. 29
 
7.2 Stratification  ................................................................................................................................................. 30 
 
8.0 TREATMENT PLAN  .................................................................................................................................. 31 
8.1 Study Treatment Plan  ................................................................................................................................... 31 
 9.0 EVALUATION DURING  AND AFTER  PROTOCOL TREATMENT ................................................. 37 
9.1 Evaluation During Protocol Treatment ....................................................................................................... 37 
9.2 Evaluation After Protocol Treatment  .......................................................................................................... 38 
 
10.0  CRITERIA FOR MEASUREMENT OF STUDY ENDPOINTS  ............................................................ 40 
10.1  Definitions of Evaluability  .......................................................................................................................... 40 
10.2  Criteria for Measurement of Study Endpoints  ........................................................................................... 40 
10.3  Evidence of Disease Recurrence/Progression  ............................................................................................ 41 
10.4  Dating of First Recurrence  .......................................................................................................................... 42 
10.5  Management Following Recurrence ........................................................................................................... 42 
10.6  Contralateral Breast Carcinoma –  Invasive and in situ  ............................................................................. 42 
10.7  Second Malignancy  ...................................................................................................................................... 42 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL ii CONFIDENTIAL 11.0  SERIOUS ADVERSE EVENT REPORTING .......................................................................................... 43 
11.1  Definition of a Reportable Serious Adverse Event .................................................................................... 43 
11.2  Serious Adverse Event Reporting Instructions  .......................................................................................... 43 
11.3  Reporting Malignancies or Myeloid Dysplasia  ......................................................................................... 44 
11.4  CCTG Responsibility for Reporting Serious Adverse Events to Health Canada (Office of Clinical 
Trials)  ............................................................................................................................................................ 46 
11.5  CCTG Reporting Responsibility to Apotex  ............................................................................................... 46 
11.6  Reporting Safety Reports to Local Research Ethics Boards  ..................................................................... 46 
 
12.0  PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER STOPPING ............. 47 
12.1  Criteria for Discontinuing Protocol Treatment  .......................................................................................... 47 
12.2  Therapy After Protocol Treatment is Stopped  ........................................................................................... 47 
12.3  Follow -up Off Protocol Treatment  ............................................................................................................. 47 
 
13.0  CENTRAL REVIEW PROCEDURES AND TISSUE COLLECTION  ................................................. 48 
13.1  Central Pathology Review  ........................................................................................................................... 48 
13.2  Tissue Collection  .......................................................................................................................................... 48 
13.3  MA.32 Use of Tumour Blocks  .................................................................................................................... 48 
13.4  Blood Collection and Analysis  .................................................................................................................... 49 
13.5  MA.32 Use of Blood Samples ..................................................................................................................... 50 
13.6  Central Data Review  .................................................................................................................................... 51 
 14.0  STATISTICAL CONSIDERATIONS  ....................................................................................................... 52 
14.1  Objectives and Design  .................................................................................................................................  52 
14.2  Primary Endpoints and Analysis  ................................................................................................................. 52 
14.3  Sample Size and Duration of Study  ............................................................................................................ 53 
14.4  Safety Monitoring  ........................................................................................................................................ 54 
14.5  Interim Analysis  ........................................................................................................................................... 54 
14.6  Quality Of Life Analysis .............................................................................................................................. 55
 
 
15.0  PUBLICATION POLICY  ........................................................................................................................... 56 
15.1  Authorship of Papers, Meeting Abstracts, Etc  ........................................................................................... 56 
15.2  Responsibility for Publication  ..................................................................................................................... 56 
15.3  Submission of Material for Presentation or Publication  ........................................................................... 56 
 16.0  ETHICAL, REGULATORY AND ADMINISTRATIVE ISSUES ......................................................... 57 
16.1  Institution Eligibility for Participation ........................................................................................................ 57 
16.2  Investigator Qualifications  .......................................................................................................................... 57 
16.3  REB (Research Ethics Board) Approval for Protocols  ............................................................................. 57 
16.4  Informed Consent  ......................................................................................................................................... 59 
16.5  Retention of Patient Records and Study Files  ............................................................................................ 60 
16.6  Centre Performance Monitoring .................................................................................................................. 60 
16.7  On-Site Monitoring/Auditing  ...................................................................................................................... 61 
16.8  Case Report Forms  ....................................................................................................................................... 61 
 17.0  REFERENCES  ............................................................................................................................................. 62 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL iii CONFIDENTIAL APPENDIX I -  PATIENT EVALUATION FLOW SHEET  ......................................................................... 71 
APPENDIX II -  PERFORMANCE STATUS SCALES/SCORES  ................................................................ 72 
APPENDIX III -  DRUG DISTRIBUTION, SUPPLY AND CONTROL ....................................................... 73 
APPENDIX IV -  DOCUMENTATION FOR STUDY ..................................................................................... 75 
APPENDIX V -  NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS  ................... 78 
APPENDIX VI -  QUALITY OF LIFE ASSESSMENT  ................................................................................... 79 
APPENDIX VII -  PHYSICAL ACTIVITY AND DIETARY QUESTIONNAIRES ...................................... 84 
APPENDIX VIII -  7TH EDITION OF THE TNM CLASSIFICATION OF MALIGNANT TUMOURS  .... 91 
APPENDIX IX –   EVALUATION METHODOLOGIES .................................................................................. 92 
APPENDIX X –  CORRELATIVE SCIENCE PROCEDURES, BLOOD SAMPLING, PROCESSING 
AND SHIPPING ..................................................................................................................... 94 
APPENDIX XI –   CANCER TRIALS SUPPORT UNIT (CTSU) PARTICIPATION PROCEDURES  ....... 96 
APPENDIX XII -  A HEALTHY LIFESTYLE AFTER BREAST CANCER  ............................................... 100 
APPENDIX XIII -  EQUIVALENT HEMATOLOGY UNITS  ......................................................................... 108 
APPENDIX XIV -  EMERGENCY SITUATIONS AND COMPLIANCE  ..................................................... 109 
 
LIST OF CONTACTS  .................................................................................................................................. Final Page 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 1 CONFIDENTIAL STUDY ACKNOWLEDGMENT/DISCLOSURE  
 
I understand that this protocol contains information that is confidential and proprietary to C CTG.  
 
I have read the protocol and agree that it contains all necessary details for carrying out the study as described. I will conduct this protocol as outlined therein, and according to Good Clinical Practice and any 
applicable local regulations. I will make a reasonable effort to complete the study within the time 
designated. I confirm that I and study personnel participating under my supervision have adequate r esource 
to fulfill their responsibilities as outlined in this protocol. I will maintain documentation of any investigator 
responsibilities assigned to participating study personnel.  
 
I will provide copies of the protocol and access to all information furni shed by C CTG to study personnel 
under my supervision. I will discuss this material with them to ensure that they are fully informed about the 
investigational product and the study.  
 
I will provide protocol information to my Research Ethics Board (REB), Institutional Review Board(s) 
[IRB(s)] or Independent Ethics Committee(s) [IEC(s)], subject to the following condition: The contents of 
this protocol may not be used in any other clinical trial and may not be disclosed to any other person or 
entity without the prior written permission of C CTG. The foregoing shall not apply to disclosure required 
by governmental regulations or laws; however, I will give prompt notice to  CCTG of any such disclosure.  
 
I understand that I may terminate or suspend enrolment of the study at any time if it becomes necessary to 
protect the best interests of the study subjects, however I will give prompt notice to C CTG. The study may 
be terminated at any time by CCTG with or without cause.  
 
Any supplemental information that may be add ed to this document is also confidential and proprietary to 
CCTG and must be kept in confidence in the same manner as the contents of this protocol.  
 
 
___________________________________________________ _________________________ 
Investigator  Date  
(printed name and signature)  
 
 
Protocol Number: MA.32  
 
Centre: ___________________________________________  
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 2 CONFIDENTIAL Metformin  
850 mg po bid X 5 years  
(includes 4- week ramp -up of 850mg po daily)  
Identical Placebo  
One caplet po bid X 5 years  
(includes 4 week ramp- up of one caplet po daily)  R 
A 
N 
D 
O 
M 
I 
Z 
E TREATMENT SCHEMA  
 
The study population will include subjects with invasive breast cancer who , within the previous 12 months,  
have received the first histologic diagnosis of invasive breast carcinoma and have undergone definitive 
surgical treatment for invasive breast cancer. Subjects may have received, at the discretion of their treating 
physician, standard a djuvant loco- regional radiation, adjuvant endocrine treatment, trastuzumab or other 
biologics or bisphosphonates prior to or during study treatment. Chemotherapy (adjuvant or neo- adjuvant), 
if given, must be co mpleted prior to randomization.  
 
Stratificatio n: 
1. ER and/or PgR positive versus both receptors negative  
2. BMI < 30 versus > 30 (kg/m2) 
3. HER2 positive versus HER2 negative  
4. Chemotherapy – any versus none  
 
 
 
 
 
 
 
T1–3, N0- 3,M0   
Invasive breast cancer  
Surgically removed +/ - 
Radiotherapy, chemotherapy,  
Endocrine therapy, trastuzumab,  
Biologics, bisphosphonates  
 
 
 
 
 
 
Treatment is for 5 years or until primary endpoint is documented  
 
Planned Sample Size: 3582 (80% power to detect HR 0.785  with 2 -tail alpha=0.05)  
 
 
Primary Endpoint: Invasive disease free survival  
 Secondary Endpoints:  
 Overall survival  
 Distant relapse free survival  
 Breast cancer free interval  
 Breast  cancer specific  mortality  
 Incidence of contralateral invasive breast cancer  
 Long- term clinical and laboratory safety  
 Relevant Medical Endpoints (new diabetes; new cardiovascular hospitalizations ) 
 Health -Related Quality of Life, Physical Activity, Diet  
 Change in BMI  
 Correlative Science Outcomes  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 3 CONFIDENTIAL 1.0 OBJECTIVES  
 
Primary objective:  
To compare invasive disease free survival (IDFS) between subjects treated with metformin (850 
mg  po bid for 5 years) versus placebo in additi on to standard adjuvant therapy.  
 
Secondary objective(s):  
To compare the following endpoints between subjects treated with metformin (850 mg po bid for 
5 years) versus placebo:  
 overall survival  
 distant disease -free survival  
 breast cancer free interval  
 breast cancer specific mortality  
 incidence of contralateral invasive breast cancer  
 invasive disease free survival in hormone receptor (ER and PgR) negative and positive (ER 
and/or PgR) sub- groups  
 changes in body mass index (BMI = weight (kg)/height(m)2) 
 adverse events  
 other medical endpoints –  including a new diagnosis of diabetes melli tus or cardiovascular 
hospitalization or death (stroke, myocardial infarction) * 
 health related quality of life, measured using the EORTC QLQ -C30, supplemented by a trial 
specific checklist; the Block Alive Screener; physical activity items from the Nurses Health 
Study Questionnaire II on a sub- set of MA.32 subjects  (sub-set enrollment completed 
2011NOV04)  
 embedded correlative science outcomes including plasma insulin and molecular markers of 
metformin action  
 metabolic parameters, including metabolic compone nts of the insulin resistance syndrome as 
defined by the ATP III criteria, in a subset of subjects (and to be described in a separate 
protocol)  
 
* “hospitalization” includes an emergency room visit or overnight stay(and cardiovascular 
hospitalizations include all ischemic and non -ischemic events)  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 4 CONFIDENTIAL 2.0 BACKGROUND INFORMATION AND RATIONALE  
 
Interest in metformin (an oral agent commonly used to treat diabetes) in the adjuvant setting in 
breast cancer reflects the recent convergence of seve ral streams of research. In epidemiologic 
studies, metformin use in diabetics has been associated with reduced overall cancer risk and mortality 
[Evans, 2005; Bowker, 2006; Monami 2008; Libby, 2009] . Clinically, observational research has 
identified higher  response rates to neoadjuvant systemic therapy in diabetic breast cancer patients 
receiving metformin for their diabetes compared to diabetic breast cancer patients who do not receive metformin or to non -diabetic breast cancer patients  
[Jiralerspong 2009] . Furthermore, obesity 
has been recognized as an adverse prognostic factor in breast cancer [Chlebowski 2006; Goodwin, 2006] . 
Variations in insulin levels within the normal range in breast cancer patients (reflecting varying degrees of underlying insulin r esistance and strongly correlated with obesity) appear to be a  likely 
mediator of this effect 
[Goodwin, 2002; Pasanisi, 2006; Pollak, 2006; Irwin, 2009] . Goodwin has shown that 
metformin reduces insulin levels in breast cancer patients, even in the absence of diabetes and when 
insulin levels are within the normal range  [Goodwin, 2008] . The recent demonstration that metformin 
results in (1) initiation of an AMPK -dependent energy stress response which can adversely affect 
survival of BC cell lines and (2) inhibition of PI3K/Akt/mTOR signaling leading to reduced 
proliferation of breast cancer cell lines, has provided a molecular basis for additional, insulin independent, anti -tumour effects of metformin in breast cancer  
[Zakikhani, 2006] . Thus, metformin 
may exert anti -tumour effects through both insulin- dependent and insulin- independent me chanisms 
in women with a broad range of insulin levels commonly seen in newly diagnosed breast cancer. 
Because metformin is a generic, inexpensive, well known and generally well tolerated oral agent 
that is commonly used to treat diabetes (including breast  cancer patients who have diabetes), its 
evaluation as a potential adjuvant treatment for breast cancer can take place in an accelerated 
fashion.  
 
Clinical Evidence -  Obesity, Insulin and Breast Cancer  
Obesity is a recognized adverse prognostic factor in breast cancer - compared to normal weight 
women, overweight or obese women with breast cancer have a hazard ratio (HR) of distant 
recurrence of 1.7 -1.9 and a HR of death of 1.6 [Goodwin, 1995] . Early postulated mechanisms for this 
effect, including underdos ing of chemotherapy and elevated estradiol in obese women, do not 
explain obesity effects in women not receiving chemotherapy, in premenopausal women (in whom estrogen levels do not reflect obesity) or in estrogen receptor ER/PgR  negative breast cancer. Th ere 
is growing evidence that insulin is an important mediator of this adverse prognostic effect of 
obesity. We reported that insulin was strongly associated with obesity (r=0.58, p<0.001) and that 
it exerted an adverse prognostic effect in locoregional bre ast cancer that extended beyond the 
adverse prognostic effect of obesity 
[Goodwin, 2002] , despite the fact that the vast majority of insulin 
levels (>98%) were in the normal range  [Liu, 2006; Saxena, 2000] . Women with insulin levels in the 
highest (vs lowe st) quartile had a doubled risk of recurrence and tripled risk of death, effects that 
persisted after adjustment for tumour and treatment related factors. These prognostic effects were somewhat greater in women with ER/PgR  negative tumours but they were al so present in ER/PgR  
positive breast cancer (the difference between these groups was not significant). A quantitatively 
similar effect of insulin was subsequently reported by Pasanisi et al  
[Pasanisi, 2006] , who also found 
the insulin resistance syndrome, a clinical syndrome associated with high insulin levels, was 
associated with a tripled risk of recurrence  [Pollak, 2006]  and Irwin et al  [Irwin, 2009]  reported high C -
peptide levels (released when insulin is cleaved from proinsulin) were significantly corr elated with 
reduced disease -free survival (DFS) in ER/PgR positive breast cancer. In a final study; a high waist -
hip ratio (a marker of insulin resistance) was associated with a tripled risk of breast cancer mortality  
[Borugian, 2003] . 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 5 CONFIDENTIAL Table 1  Insulin and Related Factors and Breast Cancer Prognosis  
 
 # Factor Measured  Recurrence  Death  
Goodwin  2002  512 Fasting Insulin  HR=2.0  HR=3.1  
Pasanisi  2006  110 Fasting Insulin  
Insulin Resistance Syndrome  HR=2.42  
HR=3.0   
Pollak  2006  667 Non-fasting C -peptide  p<0.05*   
Irwin  2007  689 Fasting C -peptide   HR=3.0  
Borugian  2004  603 Waist/hip ratio**   HR=3.3 (post)  
* HR not provided  ** non -fasting insulin was not a significant prognostic factor  
Abbreviations:  post=postmenopausal, HR = hazard ratio  
 
Recent analyses by our group have demonstrated that the increased risk of distant recurrence and 
death associated with higher versus lower insulin levels at breast cancer diagnosis persists for the 
first five years after diagnosis, but is no longer present after that time (see Figure 1, unpublished 
data). This pattern of recurrence is similar to that seen with ER /PgR  negative breast cancer. This 
observation has contributed to our decision to administer metformin for 5 years in this trial.  
 
Figure 1  HR Distant Recurrence and Death Over Time for Insulin at Diagnosis  
(midpoint of upper quartile vs. midpoint of lower quartile)  
 
HR for Distant Recurrence (df=3)  
Insulin Univariate 87.5th Percentile  
vs. 12.5th Percentile  HR for Death (df=3)  
Insulin Univariate 87.5th Percentile  
vs. 12.5th Percentile  
 
  
 
 
Time (years)  
Hazard ratio  
0 
 2 
 4 
 6 
 8 
 10 
 12 
0 
 2 
 4 
 6 
 8 
 10 
Time (years)  
Hazard ratio  
0 
 5 
 10 
 15 
0 
 2 
 4 
 6 
 8 
 10 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 6 CONFIDENTIAL Insulin levels in the upper portion of the normal range in women with breast cancer appear to reflect 
the presence of the underlying Insulin Resistance Syndrome, a condition that is improved by 
metformin. The Insulin Resistance Syndrome includes central obesity, hypertension, an abnormal 
lipid profile, coronary artery disease, type 2 diabetes and a group of laboratory markers of 
inflammation  [Reaven, 2005; Bloomgarden, 2007] . We have shown a high prevalence of these conditions 
in women wi th breast cancer who have higher insulin levels (even when these levels are in the 
normal range); we have also shown that these high insulin levels reflect underlying insulin 
resistance [Goodwin, 2009]  as assessed using the Homeostasis Model Assessment (HO MA), a 
validated model of insulin resistance  [Vaccaro, 2004] . Furthermore, women with early breast cancer 
have somewhat higher insulin levels than healthy controls [odds ratio (OR) for breast cancer = 2.83, highest vs. lowest quintile], consistent with the presence of insulin resistance prior to breast cancer 
diagnosis (possibly reflecting lifestyle factors such as obesity, physical inactivity and high fat diets 
that have been linked to breast cancer risk)  
[Del Giudice, 1998] . Similar observations have been 
reported by Pasanisi  [Pasanisi, 2006] . In a recent study, Ge narri et al  [Gennari, 2007]  identified a 15 -
gene set from 143 insulin resistance -related genes, that was predictive of DFS in both a training set 
(102 breast cancer patients) and a validation set (57 breast cancer patients) – they saw 91% 8 year 
DFS for ex pression scores above the median vs. 51% for scores below the median (p<0.001) in the 
training set [97% vs. 54% (p=0.009) in the validation set].  
 
Insulin levels vary widely in relation to nutrient intake and health status (particularly the presence 
of dia betes). A normal reference range for fasting insulin has been defined variably from <  20 
microunits/ml ( < 139 pmol/L) [Liu, 2006]  to < 30 microunits/ml ( < 209 pmol/L) [Saxena, 2000] . In our 
population based cohort study of non- diabetic breast cancer patien ts, [Goodwin, 2002]  the mean 
fasting insulin was 44.6 pmol/L and the range was 8.1 to 339.8 pmol/L; < 2% of our subjects had fasting insulin levels 140 pmol/L or higher. We expect a similar range of insulin levels, mainly in 
the normal range, in MA.32 subj ects. There is evidence that the use of metformin in individuals 
with “normal” insulin levels appears to be safe and it reduces insulin levels. For example, in our 
Phase II study of 6 months of metformin (1500 mg/day) in breast cancer patients, the mean ba seline 
fasting insulin level was in the “normal” range (75.7 pmol/L) and only one woman had an insulin 
level above 140 pmol/L (the level was 150 pmol/L). Insulin levels were reduced by 22% without 
the occurrence of hypoglycemia  
[Goodwin, 2008] , proportiona l reductions in insulin were constant 
across the range of baseline insulin studied. Similar safety and insulin -lowering effects of 
metformin have been reported in non- diabetic, non- breast cancer subjects with normal insulin 
levels. In a recent study of pol ycystic ovary syndrome (PCOS)  [Goldenberg, 2005] , metformin (2250 
mg/day) lowered fasting insulin levels by 18% from a mean baseline insulin of 64.5 pmol/L in women in the lowest quartile of baseline insulin (greater reductions were seen in women with 
insulin levels markedly abo ve normal). Similar results in PCOS subjects were reported by 
Roumaldi 
[Romualdi, 2008]  (mean baseline fasting insulin 47.0 pmol/L, 15% reduction after 
metformin at a low dose of 1000 mg/day for 6 months) and others  [Baillargeon, 2004] . In another 
study, metformin use (2250 mg per day) in sedentary (non- diabetic) subjects having a mean 
baseline fasting insulin of 64.9 pmol/L led to a 17% reduction in insulin levels  [Ou, 2006] . Finally, 
metformin (1700 to 2550 mg/day) safely reduced in sulin levels by 18.5% (from 161.5 pmol/L to 
131.4 pmol/L) in obese subjects with normal glucose tolerance  [Tankova, 2003] . No episodes of 
hypoglycemia were reported in these studies. Thus, at doses similar to those we plan to use, 
metformin safely reduces insulin levels in the normal range, by about 20%. Based on these 
observations, we anticipate that metformin will safely lower insulin levels to a similar degree in 
subjects enrolled onto MA.32.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 7 CONFIDENTIAL The insulin receptor (IR) is commonly expressed in human brea st cancer [Mulligan, 2007]  (see Table 
below), thereby providing a biologic mechanism for a prognostic effect of insulin. IGF -1R is less 
commonly expressed. In our dataset involving 150 women with sporadic breast cancer treated at a 
single institution, IR e xpression on breast tumour tissue was not correlated with circulating insulin 
levels (r= -0.02), indicating absence of downregulation by insulin. Similar to ER, we found that 
high IR expression predicted good breast cancer outcome. If this parallel extends to treatment, 
reduction in insulin (for example by the administration of metformin) may improve breast cancer 
outcomes, similar to improvements seen with reduction in estrogen by aromatase inhibitors (AIs) in ER/PgR  positive breast cancer  
[Baum, 2002] . 
 
Table 2 Insulin, IGF Receptors in Sporadic Locoregional Breast Cancer  n=150 
 
  IR IGF-1R 
Immunohistochemical (IHC)  (Allred Score)    
Negative  
Weak  
Strong  (0-2) 
(3-5) 
(6-8) 1.1%  
11.2%  
87.6%  25.3%  
63.5%  
11.2%  
Spearman r     
Insulin  
IGF-1  -0.02 
-0.11 -0.10 
-0.02 
 
There have been no randomized trials targeting insulin reduction as a means of improving breast 
cancer outcomes. However, the Women’s Intervention Nutrition Study (WINS) [Chlebowski, 2006]  
randomized 2437 postmenopausal women to a low fat diet that was ass ociated with a 2.3 kg weight 
loss (versus usual diet without weight loss). The diet improved 5 year DFS [HR 0.76, 95% 
Confidence Interval (CI) 0.60- 0.98], with the largest effect in ER/PgR  negative breast cancer (HR 
0.58, 95% CI 0.37- 0.91 vs HR 0.85, 95% CI 0.63- 1.14 in ER + breast cancer). In contrast, the 
Women’s Healthy Eating and Living Trial  [Pierce, 2007] , involving 3088 breast cancer patients, 
found no 5 year DFS or overall survival (OS) effects of a high fruit and vegetable, low fat diet that 
was not associated with weight loss. It is possible these divergent results occurred because weight 
loss (typically associated with reduced insulin levels) was critical in influencing DFS in WIN S; if 
correct, the larger effect in ER/PgR  negative breast cancer may reflect enhanced importance of 
insulin signaling in that breast cancer subset. Ligibel et al  [Ligibel, 2008] , have reported that exercise 
(a mixed strength and endurance intervention) pr omoted insulin reduction in women with breast 
cancer, providing evidence that lifestyle interventions targeting conditions such as physical 
inactivity that have been associated with poor breast cancer outcomes in observational studies can 
modify insulin i n the breast cancer population.  
 
There is a large body of work examining insulin- like growth factors (IGFs) and related binding 
proteins (BPs) in breast cancer  [Sachdev, 2007; Ibrahim, 2005] . Although circulating IGFs have been 
associated with BC risk in so me studies  [Hankinson, 1998; Schernhammer, 2005] , evidence of a direct 
prognostic role is weak and inconsistent. Expression of these factors in tumour or stroma have been 
more consistently linked with prognosis and/or prognostic features of tumours, notabl y IGF1 
expression with favourable [Toropainen, 1995; Haffner, 2007]  and insulin- like growth factor binding 
protein 3 (IGFBP3) expression with unfavourable [Rocha, 1996; Holdaway, 2003]  features. The IGF 
pathway is being evaluated as a target for breast can cer therapy in separate research  [Sachdev, 2006] . 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 8 CONFIDENTIAL An IGF -1 gene expression profile has recently been reported in breast cancer [Creighton, 2008]  – this 
profile involved over 800 genes that were up or down regulated by IGF -1 – these genes (which 
were enric hed for transcriptional targets of ER, Ras/extracellular signal- related kinase1/2 and PI3K, 
mTOR pathways) were involved in cell proliferation, metabolism and DNA repair. The expression 
profile was correlated with adverse clinical and pathologic markers ( ER/PgR  negativity, luminal B 
subtype) and it was independently associated with poor outcomes. As noted above, a similar profile 
exists for insulin  [Gennari, 2007] . The key issue may be which ligand (IGF -1, insulin, or both) is 
binding to receptors – clinica l and epidemiologic evidence (reviewed above) provides strong 
support for a clinically relevant role for insulin, the target of our proposed intervention.  
 
Clinical and Epidemiological Evidence –  Metformin and Cancer  
A recent observational study [Jiralerspong , 2009]  examined response rates to neoadjuvant systemic 
therapy in breast cancer patients, some of whom were diabetic receiving metformin (n=68), some 
diabetic not receiving metformin (n=87) and some non- diabetic (n=2374). Pathologic complete 
response (pCR) was 24%, 8% and 16% in these three groups, respectively (p=0.03). Corresponding 39 month overall survival rates were 80.9%, 77.6% and 85.9%, respectively (p=0.02). That is, the 
use of metformin to treat diabetes was associated with higher pCR rates to neoadjuva nt systemic 
therapy in early stage breast cancer patients (although the best survival was seen in non- diabetic 
patients).  
 In observational epidemiologic work, Evans et al. 
[Evans, 2005]  reported the risk of subsequent 
cancer diagnosis (all cancer types, i ncluding BC) was reduced in type 2 diabetics who received 
metformin (OR 0.85 for any vs. no metformin exposure). The protective effect increased with 
greater metformin exposure (measured as total dose prescribed or total duration of use). 
Additionally, Bow ker et al. [Bowker, 2006]  reported cancer mortality was lower in diabetics receiving 
metformin (vs. sulfonylureas or insulin, HR 0.50- 0.77), but they did not study diabetics not 
receiving any drug therapy. Furthermore, while confirming lower cancer risk in diabetics receiving 
metformin (versus those not receiving metformin), Monami et al . [Monami, 2008]  did not find similar 
beneficial effects in diabetics receiving thiazolidenediones; effects of sulfonylureas (another class 
or oral anti -diabetic agents) wer e drug specific rather than a class effect. Libby et al. [Libby, 2009]  
have reported a significantly reduced risk of incident cancers (HR 0.63, 95% CI 0.53- 0.75) in 
diabetics receiving metformin (versus those not receiving metformin); they recommended a 
randomized trial be conducted to “assess whether metformin is protective in a population at high 
risk for cancer”. Finally, Currie et al [Currie, 2009]  reported that diabetics receiving insulin or 
sulfonylureas had a significantly higher risk of subsequent c ancer (HR 1.42 95% CI 1.27- 1.60 and 
HR 1.36 (95% CI 1.27- 1.60 respectively) compared to those receiving metformin alone.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 9 CONFIDENTIAL Several reports recently published in Diabetologia (2009) have addressed a concern that an insulin 
analog (glargine) that is associate d with increased mitogenic effects in vitro may be associated with 
increased risk of cancer in diabetic patients receiving this agent [Hemkens, Jonasson, Colhoun, Currie, 
Home, 2009] . The concern was first raised by Hemkens et al (Germany) who reported a dose 
dependent increased overall cancer risk in those receiving 50 IU/day og glargine (HR 1.31, 95% 
CI 1.20- 1.42 compared to those receiving human insulin). Colhoun et al [Colhoun, 2009]  identified a 
modest increased overall cancer risk in diabetics receivi ng glargine insulin (HR 1.55, 95% CI 1.01-
2.37), and they found a significantly increased breast cancer risk in this group (adjusted HR 3.65, 
95% CI 1.05- 12.68). Jonasson et al [Jonasson, 2009]  failed to identify an increase in overll cancer 
incidence in t hose receiving glargine insulin but they identified an increased risk of breast cancer 
(adjusted HR 1.97, 95% CI 1.29- 3.00). Finally, Currie et al [Currie, 2009]  failed to find an association 
of glargine insulin use with cancer incidence, but reported that  diabetics receiving metformin had 
the lowest cancer risk (see preceding paragraph). In a meta- analysis of glargine insulin trials 
sponsored by Sanofi -Aventis, Home et al [Home, 2009]  failed to identify an increased frequency of 
cancer reported as a seriou s event in diabetics receiving glargine (vs human) insulin. These results 
must for interpreted with caution for several reasons. First, it must be noted that these reports 
involved very short follow -up periods (less than 2.5 years in the observational studies and it was 
less than 1 year in all but one of the trials included in the meta -analysis). As a result, any effect of 
glargine insulin (or other insulins) on cancer risk see in these studies likely reflected an effect on 
progression of undiagnosed cancer s rather than initiation of new cancers. Additionally, baseline 
imbalances between those receiving glargine and those not receiving galrgine (such as more obesity 
in the glargine group seen in some studies) may have accounted for effects on cancer incidenc e 
(representing confounding by indication. Furthermore, metformin (which may lower cancer incidence) was used concurrently with insulin in some studies, often to a differential extent in those 
receiving glargine versus other insulins. As a result, firm conclusions cannot be drawn regarding 
the effect of glargine insulin on cancer risk. Nonetheless, these observations are consistent with an 
adverse effect of insulin on cancer, possibly cancer progression and they strengthen the rationale 
for MA.32.  
 
Evidence  from Animal Models and Cell Culture  
Insulin and Metformin in Laboratory Models of Breast Cancer  
Studies in rodent models and cell culture support the concept that insulin stimulates mammary tumour growth. Early experiments revealed that N -nitroso -N-methylurea - induced mammary carcinomas 
grew more slowly in insulin- deficient diabetic rats; this was reversed with insulin treatment 
[Cocca, 
2003] . Furthermore, chronic administration of a human insulin analogue, Asp B10, caused breast 
cancer in normal rats  [Ish-Shalom, 1997; Milazzo, 1997] . Since this analogue has higher affinity than native 
insulin for IGF -1R, it was not clear whether one or both of IGF -1R and IR were responsible. Work 
by others has shown that IR is expressed in normal mammary epithelial cells and is upregulated in 
breast cancer cells  [Frittitta, 1997] . In cell culture, insulin stimulates mitogenesis in breast cancer cells 
at concen trations which do not bind or stimulate IGF -1R and in the presence of IGF -IR specific 
blocking antibodies  [Papa, 1996] , consistent with a direct role of insulin. Additional data supporting a 
direct role for insulin in mammary tumour growth stems from exper iments examining insulin receptor 
substrate 1 (IRS -1) and insulin receptor substrate 2 (IRS -2), major signaling proteins and substrates 
of the IR tyrosine kinase. Cells expressing a dominant -negative IRS -1 molecule with all 18 Tyr 
phosphorylation sites mut ated to phenylalanine had reduced cancer cell growth  [Chang, 2002] . Breast 
tumours induced in IRS -2−∕− mice expressing the polyanna middle T antigen in mammary gland grew 
as expected, but had a significantly reduced metastatic behaviour, even when the IRS -2 lacking 
tumours were transplanted into wild -type mice  [Nagle, 2004] . These observations are consistent with a 
direct effect of insulin on tumour growth.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 10 CONFIDENTIAL Recent studies have evaluated rodent models of insulin resistance (in which endogenous insulin 
level s are elevated) to provide in vivo  data relevant to humans. In one diet induced model of obesity, 
two transplanted tumour cell lines (Lewis lung carcinoma and mouse colon 38- adenocarcinoma) 
showed increased tumour growth with increased obesity and insulin resistance  [Yakar, 2006] . In 
another, more severely insulin resistant but non- obese “fatless” mouse model, breeding with a 
transgenic mouse mammary gland tumour model, C3(1)/T -Ag, showed a higher tumour incidence 
and multiplicity as well as decreased tumou r latency in insulin resistant mice. Since these “fatless” 
mice lacked adipose tissue -derived hormones, including leptin, the role of insulin and/or IGF -1 (as 
opposed to adipocytokines such as leptin) was supported  [Nunez, 2006] . Our own unpublished 
preliminary data show that a high fat diet in the HER2 overexpressing breast cancer mouse model 
leads to earlier and more frequent appearance of second and multiple tumours. Together, these 
observations strongly support a significant role of elevated insulin as an adverse effector of breast 
cancer growth.  
 The effect of metformin in mouse mammary tumour models has als o been explored. Anisimov et 
al 
[Anisimov, 2005]  have reported that metformin significantly increases latency for mammary tumour 
development, significantly reduces mammary tumour size and significantly increases both mean and maximal life span in a HER2 overexpressing breast cancer mouse model. These ef fects were 
associated with a non- significant reduction in insulin levels. Similar results have recently been 
reported by Huang et al  
[Huang, 2008]  in a PTEN deficient breast cancer mouse model – metformin 
suppressed tumourigenesis via the LKB1- AMPK pathway  (described below). These two studies 
investigated metformin in doses that approximated the dose/plasma levels in humans (i. e: 
metformin 1500- 2250 mg per day) – ranging from approximately 0.5 to 18 times the human dose. 
In contrast, another recent study [Phoenix, 2009]  suggested metformin use in a mouse xenograft model 
was associated with an increase in VEGF production which led to augmented angiogenesis and mammary tumour growth. This study has been criticized because the cell line studied was actually 
derived from melanoma (not breast cancer) 
[Hadad, 2009]  and the doses of metformin used in this 
study were 45 times (or more) that used in humans and plasma metformin levels were 300 times 
the recommended levels in humans  [Stambolic, 2009] . Stimulation of ang iogenesis occurs with other 
mTOR inhibitors and does not appear to be clinically relevant. In the case of metformin, VEGF 
effects appear to be dose and/or model related – large doses may provide excess metabolic stress 
leading to enhanced compensatory VEGF  response. At present, there is no evidence to suggest that 
metformin in doses as high as 18 times the standard clinical dose exerts similar effects on VEGF 
or stimulates tumour growth in animal model systems.  
 
Molecular Mechanism of Metformin Action (see  Figure 2 below)  
By inhibiting transcription of key gluconeogenesis genes in the liver and increasing glucose uptake 
in skeletal muscle, metformin reduces levels of circulating glucose, increases insulin sensitivity 
and reduces hyperinsulinemia  [Cusi, 1998; Witters, 2001] . Activation of AMPK plays a prominent role 
in mediating the effects of this drug  [Zhou, 2001; Vazquez-Martin, 2009; Santomauro Junior, 2009] . AMPK 
is a central cellular energy sensor whose activation leads to suppression of many of the processes highly dependent on ample cellular ATP supply, including gluconeogenesis, protein and fatty acid 
synthesis and cholesterol biosynthesis, while promoting catabolic processes such as fatty acid beta -
oxidation and glycolysis  
[reviewed in Hardie, 2007; Towler, 2007] . Metformin directly inhibits complex 
I of the respiratory chain leading to decreased ATP synthesis and a rise in the cellular AMP:ATP 
ratio, effectively mimicking conditions of cellular energy stress  [El-Mir, 2000; Owen, 2000] . Increased 
association of AMPK with AMP under such conditions facilitates its phosphorylation and 
activation by the upstream kinase LKB1, the protein product of the tumour suppressor gene mutated 
in the Peutz Jeghers cancer predisposition syndrome  [Lizcano, 2004; Shaw, 2004] . 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 11 CONFIDENTIAL While most research into metformin action has focused on insulin- responsive tissues, emerging 
evidence suggests that other cell types, including cancer cells, initiate an AMPK -dependent energy 
stress response to metformin. Metformin -induced AMPK act ivation directly impacts the adaptive 
response of certain cancer cells to nutrient limitation and affects their survival, in part via a p53 -
dependent mechanism in colon cancer cell lines  [Buzzai, 2005; Buzzai,2007] . This p53 dependence has 
not been seen in breast cancer cell lines  [Zhuang, 2008] . In BC cell lines, metformin causes a strong 
growth suppressive response  [Irwin, 2009] . This effect is independent of HER2 status and it has been 
found in a variety of cell lines having characteristics of the spectrum of molecular subtypes of 
breast cancer (e .g. luminal A and B, HER2, basal) [Zhuang, 2008; Alimova, 2009] . In human glioma and  
pancreatic cancer cell lines metformin exhibits an antiproliferative, antimigratory and proapoptotic 
effect  [Wang, 2008; Beckner, 2005; Isakovik, 2007] . Recent data suggest there may be differential effects 
of metformin in hormone receptor and/or Her -2 positive versus triple negative breast cancer cell 
lines, with potential therapeutic activity being seen in all cell lines but a potential unique additional effect that includes enhanced apoptosis occurring in triple negative breast cancer cell lines and 
reduced expression of HER2 in HER2 positive cell lines  
[Alimova, 2009; Liu, 2006] . Because of these 
observations, and because a greater effect of dietary fat reduction (associated with weight loss) was 
reported in ER/PgR  negative versus ER/PgR  positive breast  cancer in WINS (discussed above), we 
plan to conduct a formal subset analysis in the ER/PgR  negative breast cancer subset enrolled onto 
MA.32.  
 
Figure 2  Simplified schematic of the molecular mechanism of metformin action. See text for 
details. Phospho- specific antibody epitopes relevant to key molecular markers are 
highlighted within the black boxes. An additional marker, stathmin 1 (STMN 1), is a recently discovered surrogate marker for the signaling throughput via the PI3K/PTEN signaling pathway that can be monitored by immunohistochemistry  
[Saal, 2007]  
 
 

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 12 CONFIDENTIAL In addition to the effects of metformin and AMPK on metabolic processes, activation of AMPK 
results in rapid inhibition of cellular protein synthesis and growth. Mechanistically, AMPK achieves 
this by phosphorylation and stabilization of the protein product of the tuberous sclerosis complex 2 
(TSC 2) tumour suppressor gene  [Corradetti, 2004; Inoki, 2003] , which serves as an integrator of various 
regulatory inputs implicated in cell growth. TSC2 activity negatively regulates a small GTPase Rheb 
which serves as a binary switch for the master regulator of eukaryotic protein synthesis, the mTOR 
protein  [reviewed in Manning, 2003; Sarbassov, 2005] . In addition to mediating the inhibitory effects of AMPK 
on protein synthesis, TSC2 integrates several activating inputs that impact cellular protein translation, 
notably signals emanating from the availability of amino acids and oxygen and growth factor -
dependent stimulation of PI3K/Akt signaling. Activation of mTOR -dependent protein translation, as 
judged by phosphorylation of its downstream targets, p70S6K and 4E binding protein 1 (4E -BP1), is 
often found in BC specimens and has been shown to correlate with malignant progression and an 
adverse prognosis  [Armengol, 2007; Rojo, 2007] . 
 
Recent work indicates that increased mTOR -dependent protein translation and cell growth are 
hallmarks of tumourigenesis downstream of activated PI3K/Akt signaling. This cellular cascade is 
one of the most frequently deregulate d oncogene/tumour suppressor gene networks in human breast 
cancer. Mutations in one of the genes encoding the PI3K catalytic subunit, PIK3CA, have been found 
in 20- 35% primary breast cancer specimens and been associated with greater tumour size, lymph 
node  metastasis and poor prognosis  [Bachman, 2004; Lee, 2005; Li, 2006; Saal, 2005; Wu, 2005] . Mutations 
and loss of expression of the critical negative regulator of this pathway, the PTEN tumour suppressor, 
have been found in up to 40% of human breast cancers  [Rojo, 2007; Bachman, 2004, Lee, 2005; Li, 2006, Saal, 
2005; Wu, 2005; Perez, 2007; Sansal, 2004; Vivanco, 2002] , while up to 30% overexpress ErbB2, a potent 
activator of the PI3K cascade [Yu, 2000] . Notably, PI3K/Akt/mTOR signaling throughput correlates 
with hyperplastic changes in breast epithelium, increasing from normal epithelium to hyperplasia and 
atypia, to invasive lesions [Zhou, 2004]  and contributes to resistance of breast cancer cells to 
chemotherapy, trastuzumab and tamoxifen [Morgensztern, 2005] . 
 
Clinical Experience with Metformin  
Metformin is a well known, readily available oral agent that is commonly used to treat Type 2 diabetes and, more recently, i nsulin resistance.  It is inexpensive and, in general, it is well -tolerated. Its most 
potenti ally dangerous toxicity is lactic acidosis (estimated incidence: 3 cases per 100,000 patient years); 
when lactic acidosis occurs it is fatal in 50% of cases  
[Kirpichnikov, 2002] . There is considerable debate as 
to whether the lactic acidosis that occurs in  diabetics receiving metformin is due to the use of metformin 
or to the presence of diabetes  [Fantus, 2005; McCormack, 2005 ]. This controversy arises from results of a 
meta -analysis that showed comparable rates of lactic acidosis in diabetics who did, and who did not, 
receive metformin  [Salpeter, 2003] , by failure to demonstrate an association between lactic acidosis and 
metform in levels in diabetics [Lalau, 1995; Jones, 2003]  and by the failure to observe increased lactic 
acidosis rates after the introduction of metformin in the United States  [Brown, 1998] . Regardless, risk of 
lactic acidosis is increased in those over 80 years of age, in those with current or past congestive heart 
failure, renal insufficiency or hepatic insufficiency (including individuals with habitual excess alcohol 
intake), and in those with a prior history of metabolic acidosis. Risk of lactic acidosis is be lieved to be 
increased after surgery and use of radiologic contrast material – metformin should be temporarily 
discontinued for approximately 48 hours in these situations. Lactic acidosis is extremely rare if 
metformin use is restricted to individuals with out any of these predisposing conditions. Additional 
toxicities include: gastrointestinal (> 1/10 - diarrhea, nausea, vomiting, abdominal bloating, flatulence, 
anorexia, metallic taste – usually transient when treatment is started and resolving spontaneous ly with 
continued treatment), rash (<  1/10,000), subnormal vitamin B12 (9% after 6 months –  it is suggested 
that Vitamin B and/or hemoglobin levels be monitored at 6- 12 months), hepatic dysfunction 
(<1/10,000), elevations in TSH (<  1/10,000). Modest weight  loss (up to five pounds) is common.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 13 CONFIDENTIAL Hypoglycemia does not normally occur when metformin is administered – extreme caloric 
restriction or excessive physical activity without adequate caloric intake may rarely lead to 
hypoglycemia. Metformin is commonly us ed for many years in diabetics without cumulative 
adverse effects. It also lowers risk of subsequent diabetes, and complications of the IRS  (Insulin 
Resistance Syndrome)  in individuals with IRS  [Knowler, 2002; Orchard, 2005] . 
 
Quality of Life in Placebo Controlled Metformin Trials  
In this trial, metformin will be compared to a placebo. Clinical experience with metformin  shows 
it is mainly associated with gastro -intestinal side effects. A literature review found six trials 
[DeFronzo, 1995; Grant, 1996; Hoffman, 1997; Horton, 2000; Chiasson, 2001; Mather, 2001]  comparing 
metformin to a placebo that provided information about the fr equency and magnitude of the main 
side effects and the contribution of GI  symptoms to dropout rates. Although these trials reported 
toxicity, they did not formally evaluate QOL . Other trials that have not reported toxicity to date 
have not been included he re. 
 
Clinical Trials Comparing Metformin to Placebo  
 
Study Intervention  # of 
Pts Side-effects  # of drop -outs due to GI 
symptoms/total drop outs  
DeFronzo RA et al.1995  Protocol 1:      
 Metformin titrated up 
to 2250 mg/day  n=143 Severe diarrhea  
Severe nausea  8% 
4% 11/31 pts  
 Placebo  n=146    0/41 pts  
 All for 29 weeks      
Grant PJ 1996  Metformin 3g/day  n=27  GI symptoms, not defined   13/13 pts  
 Metformin 1.5g/day  n=25    8/12 pts  
 Placebo  n=23    2/6 pts  
 All for 6 months      
Hoffman U et al. 1997  Acarbose 100 mg TID  n=31 Flatulence or bloating  
(mild to moderate; ↓ with time)  16 pts  3 pts  
 Metformin 850 mg BID  n=31 GI complaints:    
Nausea, emesis, diarrhea  1 pt 1 pt 
Flatulence  1 pt 1 pt 
 Placebo  n=32     
 All for 24 weeks      
Horton ES et al. 2000  Nateglinide 120 mg a.c.  n=172  Diarrhea  19.7%  1/5 pts  
 Metformin 500 mg TID  n=178  Diarrhea  14.5%  6/12 pts  
 Combination  n=172    6/16 pts  
 Placebo     3/9 pts 
 All for 24 weeks   Other side effects  
(comparable between groups):    
   URTI  
Headache 
Abdominal Pain  
Nausea  Fatigue  
Sinusitis  14.3%  
7.1%  
6.3%  
5.7%  
5.1%  
5.0%   
Table continued on next page  … 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 14 CONFIDENTIAL  
Study Intervention  # of 
Pts Side-effects  # of drop -outs due to GI 
symptoms/total drop outs  
Chiasson J -L 2001  Miglitol 100 mg TID  n=82 Flatulence  
Diarrhea  
Constipation  
Nausea 
Dyspepsia  
Abdominal Cramps  63.2%  
53.3%  
9.2%  
17.1%  
14.5%  
7.9%  11/11 pts*  
      
 Metformin 500 mg TID  n=83 Flatulence  
Diarrhea  
Constipation  
Nausea  14.5%  
10.8%  
6.0%  
2.4%  5/5 pts * 
   Dyspepsia  
Abdominal Cramps  2.4%  
2.4%  19/19* 
 Combination  n=6   2/2 pts  
 Placebo  n=83     
 All for 36 weeks      
Mather KJ et al. 2001  Metformin 500 mg BID n=29 GI symptoms (mild GI 
discomfort)  4 pts  1/2 pts  
 Placebo  n=15 GI symptoms (mild GI 
discomfort)  2 pts  1/2 pts  
 All for 12 weeks      
* It is assumed all drop-outs were due to GI tocicity  
 
It can be seen that gastrointestinal toxicity occurred more frequently in patients receiving metformin 
but, at doses comparable to those we plan to use in this study (we plan to give 1700 mg/day), it 
infrequently led to dropout from the study (0 to 6% dropout rate at doses ≤  2000mg/day).  
 
In other studies of metformin in diabetes patients, QOL has been measured. However, the 
questionnaires used are not relevant for our study. For example, the “Diabetes Specific Quality of 
Life Scale” [Bott, 1998]  and the “Diabetes Treatment Satisfaction Que stionnaire” [Bradley, 1994]  deal 
with the impact of being diabetic on social functioning or glycemic control. Metformin has been used also in polycystic ovary syndrome. A Cochrane review found no study of metformin vs. placebo 
where QOL was  an outcome  
[Costello, 2007] .  
 
Even though it is unlikely that a decision to implement metformin as an adjuvant treatment in early 
stage breast cancer will depend on QOL results, we have elected to include HRQOL measurement in 
a subset of the population of MA.32 because metformin is associated with side -effects that may lead 
to discontinuation of the treatment and may impact QOL (e.g. diarrhea, flatulence). Furthermore, its 
effects on QOL in breast cancer patients receiving standard breast cancer therapy (.e.g. aromatase 
inhibitors, tamoxifen, herceptin) are not known. We will use the EORTC QLQ C -30 (Aaronson NK, 
1993) supplemented by additional items from the CCTG item bank/new items. QOL assessments will 
be conducted at baseline, 6 and 12 months and then annually until 5 years. There is little evidence to 
suggest there are major differences in overall HRQOL according to adjuvant hormone therapy use 
(tamoxifen, aromatase inhibitors, none), however, there may be small but important differences in 
endocrine symptoms and bone  pain similar to those that have been reported in adjuvant randomized 
trials of aromatase inhibitors compared to tamoxifen or placebo. In the CCTG MA.17 randomized trial 
comparing an aromatase inhibitor (letrozole) to a placebo in the extended adjuvant setting, there were 
small differences in favor of the placebo for bodily pain, general health, vasomotor and physical 
symptoms using the SF -36 and the  Menopause Specific Quality of Life Questionnaire [Whelan, 2005] . 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 15 CONFIDENTIAL In the ATAC trial which compared anastrozole to tamoxifen, there was no difference in QOL 
between the two arms, but there were small differences in endocrine symptoms assessed with the 
FACT -B (less cold sweats and vaginal discharge but more vaginal dryness, painful intercourse and 
loss of sexual interest with anastrozole) [Fallowfield, 2004] . In the International Exemestane Study 
(exemestane versus tamoxifen after 2 -3 years of tamoxifen), there was more vaginal discharge in 
those receiving tamoxifen when symptoms were assessed using the FACT -B [Fallowfield, 2006] . 
 
Because endocrine symptoms and bodily pain may differ with different adjuvant endocrine 
therapies, we plan to enroll equal number s of patients in the HRQOL sub -study in each of the 
following groups defined by adjuvant hormone therapy at randomization: no hormone therapy, tamoxifen or aromatase inhibitor.  
 
We will also assess patterns of diet and physical activity in women who partic ipate in the Quality 
of Life sub -study in order to evaluate changes in these behaviours over time in the group as a whole 
and in the participants randomized to Metformin as compared to those randomized to placebo. 
Dietary intakes will be assessed using the  Block Alive Screener. In validation testing, the 
questionnaire was demonstrated to have good reliability (Pearson Correlation Coefficients [PCC] 0.65 – 0.8) construct validity (PCC 0.56 –  0.92) and predictive validity as compared to the full 
Block Food Fr equency Questionnaire (PCC 0.44 –  0.56). The instrument was designed to focus on 
intake of saturated fat, trans - fats, total sugar, added sugars, fruit and fruit juices and vegetables 
along with estimates of Glycemic Load and Glycemic Index. Secondary estimates can be made for kcal, protein, total fat, carbohydrate and dietary fibre. Physical Activity patterns will be assessed 
through the Nurses H ealth Study II Questionnaire which asks participants to indicate the frequency 
with which they participate in a number of common recreational activities. This information will 
be utilized to generate a weekly Metabolic Task Equivalent (MET - hour score) which will provide 
a measure of both duration and intensity of physical activity. The Physical Activity Questionnai re 
has been validated on a number of populations and has been shown to correlate well with 7- day 
activity diaries and seasonal past 4 -week questionnaires (Wolf, A. 1994). It has been widely used 
in observational studies to quantify physical activity patter ns in breast cancer and other populations 
[Holmes, M 2005; Meyerhardt J, 2006: Meyerhardt J, 2006] . 
 
Correlative Studies  
Correlative studies will be an integrated component of the MA.32 clinical trial. Investigations of fasting glucose and insulin levels a t baseline , 6 months post randomization and at the end of study 
treatment will be mandatory and will explore the indirect insulin -mediated effect of metformin on 
protocol defined outcomes. Tumour related factors at baseline, serum and plasma biomarkers wil l 
be evaluated and sample collection for this component will be strongly encouraged but remains optional. Proposed studies are outlined in section 13 of the protocol.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 16 CONFIDENTIAL Summary  
There is strong clinical evidence that fasting insulin levels are associated with poor BC outcomes 
across the normal range of insulin levels that is typically seen in women with early stage breast 
cancer, without evidence of a floor or ceiling effect. At the dose we plan to use in MA.32, 
metformin safely lowers insulin levels by about 20% in non- diabetic BC and non- cancer subjects 
who have baseline fasting insulin levels in the normal range. Observational evidence suggests that 
metformin use in diabetics may reduce cancer risk and mortality and may be associated with 
enhanced responses  to neoadjuvant systemic therapy in diabetic women with BC. We hypothesize 
that metformin will reduce BC growth through its effect on insulin levels and we believe there is 
no justification for selecting subjects by insulin levels based on an insulin dependent action of 
metformin. Growing molecular evidence that metformin may also exert an insulin independent 
effect on breast cancer via activation of an insulin independent, AMPK -dependent energy stress 
response and/or inhibition of PI3K/Akt/mTOR signaling s trengthens the rationale for studying 
metformin in BC. The existence of this direct (non -insulin dependent) metformin effect on 
AMPK/mTOR provides additional justification for inclusion of women with a broad range of insulin levels in MA.32 rather than limiting enrolment to those with insulin levels above an 
arbitrarily chosen cutpoint. Because metformin is a readily available, inexpensive oral agent, with 
known (and easily manageable) toxicities, we believe evaluation of its therapeutic effects in early stage BC can proceed at an accelerated pace.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 17 CONFIDENTIAL 3.0 BACKGROUND THERAPEUTIC INFORMATION 
 
(For a complete summary, please consult your current Metformin Product Monograph.)  
 
3.1 Name and Chemical Information  
 N,N – dimethyl biguanide hydrochloride  
 
3.2 Chemical Structure  
 
 
Molecular mass = 165.6  
 
Metformin HCl is a white crystalline powder soluble in water and 95% ethyl alcohol. It is 
practically insolu ble in ether and in chloroform.  
 Melting Point: 218 -220
o C 
 
3.3 Mechanism of Action  
 
Metformin HCl is a biguanide derivative producing an antihyperglycemic effect which can only be 
observed in man or in the diabetic animal and only when there is insulin secretion. Metformin, at 
therapeutic doses, does not cause hypoglycemia when used alone in man or in the  non-diabetic 
animal, except when using a near lethal dose. Metformin has no effects on the pancreatic beta cells. The mode of action of metformin is not fully understood. It has been postulated that metformin 
might potentiate the effect of insulin or redu ce hepatic gluconeogenesis . 
 
 Metformin absorption is relatively slow and may extend over about 6 hours. The drug is excreted in urine at high renal clearance rate of about 450 mL/min. The initial elimination of 
metformin is rapid with a half -life varying between 1.7 and 3 hours. The terminal elimination 
phase accounting for about 4 to 5 % of the absorbed dose is slow with a halflife between 9 
and 17 hours. Metformin is not metabolized. Its main sites of concentration are the intestinal mucosa and the saliva ry glands. The plasma concentration at steady- state ranges about 1 to 
2 mcg/mL.  
 
Certain drugs may potentiate the effect of metformin HCl, particularly sulfonylurea type of drugs 
in the treatment of diabetes. The simultaneous administration of these two ty pes of drugs could 
produce a hypoglycemic reaction, especially if they are given in patients already receiving other drugs which, themselves, can potentiate the effect of sulfonylureas. These drugs can be: long- acting 
sulfonamides, tubercolostatics, phenyl butazone, clofibrate, monoamine oxidase inhibitors, 
salicylates, probenecid and propanolol.  
 In healthy volunteers, the pharmacokinetics of propranolol and ibuprofen were not affected by 
metformin when co -administered in single -dose interaction studies.  

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 18 CONFIDENTIAL Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with 
highly protein- bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as 
compared to sulfonylureas, which are extensively bound to serum proteins.  
 
3.4 Toxicology 
 
3.4.1  Human Toxicity  
 In man, no adverse effect has been reported on liver or kidney function, the hematopoietic system 
or on the blood vessels.  
 The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low 
(approximately 0.03 cases / 1000 patient/years with approximately 0.015 fatal cases / 1000 
patient/years).  
 
The consecutive administration of both phenformin and metformin to the same patient has allowed 
for th e demonstration of a fundamental difference between these two biguanides in relation to 
lactacidemia. In some instances, patients developed hyperlactacidemia with phenformin when the 
same patients were presenting normal lactic acid levels while being treated with metformin. In other 
instances, hyperlactacidemia observed during a treatment with phenformin did regress when 
metformin was substituted for phenformin. Metformin may increase lactacidemia but to a degree 
that is clinically less significant than the  elevation seen after phenformin.  
 
3.4.2  Teratology  
 Teratological studies were carried out in albino rats divided in three groups:  
 
No abnormalities were found, even when high doses were administered. The number of anim als 
was the same in each group.  
 
Death rate in the three groups of treated animals and controls was approximately the same. 
However, the number of living animals in each group treated was slightly lower than in the control 
group. Also, the frequency of litters exceeding 10 live animals was s lightly higher in the control 
group. A loss of weight at the time of weaning has been observed when c ompared to the control 
group.  
 
Nevertheless, on a statistical basis, differences were shown to be non -significant. There is no 
difference between the group s of treated animals and the control group regarding the number of 
stillborn. The number of deaths after birth was slightly higher in metformin treated groups than in the control group, but the comparison of average death rates is not significant (p >  0.05).  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 19 CONFIDENTIAL 3.5 Phase I & II Trials  
 
Goodwin studied physiologic and quality of life effects of metformin (500 mg po three times daily 
for 6 months) in a single arm Phase II study involving 32 women with early BC who had completed 
their primary therapy; > 95% had baseline insulin levels in the  normal range (see table below)  
[Goodwin PJ, 2008] . Insulin levels fell by 22.4% and insulin sensitivity [evidenced by the Homeostasis 
Model Assessment (HOMA)] [Vaccaro, 2004]  improved by 25% after 6 months of metformin. 
Becau se participants were disease -free, effects on tumour proliferation could not be assessed. In 
general, metformin was well tolerated. There were no significant changes in HRQOL as measured 
using the EORTC QLQ C -30 (overall physical condition, global health, overall QOL, physical 
functioning, social functioning) or specific symptoms (nausea, appetite, diarrhea, constipation, 
pain) during the study. Mild to moderate GI toxicity led to discontinuation of the drug in 4 (12%) 
of the women. This compares to an arom atase inhibitor discontinuation rate of 22%  in a recent 
clinic -based study [Ohsako, 2006] . An additional 6 (19%) did not complete the study for other reasons 
– vacation (2), development of diabetes requiring withdrawal from the study (1), pneumonia (1), 
family physician preference (1), scheduling problems (one woman completed six months of 
metformin but did not attend for final study measurements). Non- completion of the study was 
significantly associated with lower baseline HRQOL (global health, overall phy sical condition, 
overall QOL, physical or social functioning, pain). We believe non- completion rates will be lower 
in the phase III  trial proposed here because we will gradually ramp up the metformin dose (850 mg 
po daily for 4  weeks, then 850 mg bid for the remainder of the 5 year intervention) and because we 
will explain to participants that we are hypothesizing metformin may influe nce breast cancer 
outcomes (no such claims were made in the Phase II study), thereby enhancing motivation to 
continue though intercurrent illnesses and vacations.  
 
Phase II – Metformin in Locoregional Breast Cancer  
(post surgery, chemotherapy)   n=32  
 Baseline  6 months  % Change  p 
Insulin (pmol/L)  70.7 54.9 -22.4 0.02 
Glucose (mmol/L)  5.0 4.9 -2.3 0.29 
HOMA  2.24 1.67 -25.6 0.02 
Weight (kg)  75.4 73.5 -2.5 0.01 
BMI (kg/m2)  28.1 27.4 -2.5 0.007  
 
3.6 Adverse Effects  
 Please refer to protocol section 2, heading “Clinical Experience with Metformin” for a summary of 
adverse effects.  
 
3.7 Pharmaceutical Data
 
 
Metformin  
 
Supplied:  850 mg caplet , white to off -white, capsule -shaped, biconvex, film -coated. Engraved APO 
850 on one side, plain on the other side  
 
Stability : 2 year expiration  
 
Storage : Store at room temperature (15° to 30°C) in well- closed containers  
 
Route of Administration : Metformin is  administered orally, with food  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 20 CONFIDENTIAL Placebo  
 
Supplied: caplet,  white to off -white, capsule -shaped, biconvex, film coated. Engraved APO 850 on 
one side, plain on other side  
 
Stability : 3 year expiration  
 
Storage : Store at room temperature (15° to 30° C) in well- closed containers  
 
Route of Administration : Placebo is administered orally, with food  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 21 CONFIDENTIAL 4.0 TRIAL DESIGN  
 
The trial population will consist of subjects with inva sive breast cancer who , within the previous 
12 months , have received the first histologic diagnosis of invasive breast carcinoma and have 
undergone definitive surgical treatment for invasive breast cancer. Subjects may have received, at 
the discretion of their treating physician, standard adjuvant loco- regional radiation, adjuvant 
endocrine treatment, trastuzumab or other biologics or bisphosphonates prior to or during study treatment. Chemotherapy (adjuvant or neoadjuvant), if given, must be  completed at least 4 weeks 
prior to randomizat ion. 
 The first 888 eligible English/French - speaking MA.32 subjects will complete questionnaires 
dealing with Quality of Life. English -speaking subjects from the Quality of Life sub- study will also 
complete the Physical Activity and Diet Questionnaires. (Appendices VI and VII) . 
 
All subjects (regardless of randomization) will be given basic information on healthy lifestyle (diet, 
physical activity) developed by the American Cancer Society ( www.cancer.org ). The information 
to be provided is included as Appendix XII.  
 
4.1 Stratification  
 Patients will be stratified by:  
• Receptor Status (ER and/or PgR positive versus both negative*)  
• BMI (<  30 versus >30 kg/m2) 
• HER2 Status (positive versus nega tive**)  
• Chemotherapy (any versus none)  
*  It is recommended that ER and PgR assays be considered positive if there are at least 1% 
positive tumour nuclei in the sample on testing in the presence of expected reactivity of internal [nor mal epithelial elements] and external control
[Hammond 2010] .  
** Positive = 3+ over -expression by IHC in > 30% of invasive tumour cells  
 OR  HER2 gene amplification by FISH/CISH > 6 HER2 gene copies per nucleus  
 OR  a FISH/CISH ratio: HER2 gene copies to c hromosome 17 signals of >  2.2 
All other results will be considered negative.  
 
4.2 Randomization  
 
Subjects will be randomized (in a 1:1 ratio) to receive one of the following treatments:  
 
Metformin or placebo, to a planned sample size of 3582.  
 
Patients will be randomized to one of the following two arms:  
Arm Agent(s)  Dose  Route  Duration  
1 Metformin  850 mg p.o (with food)  b.i.d. X 5 years  (includes 4 week ramp -up*) 
2 Placebo  One caplet  p.o. (with food)  b.i.d. X 5 years  (includes 4 week ramp -up*) 
 
*The “ramp -up” to protocol dose and schedule will occur as follows:  
• 1 caplet po daily for 4 weeks, then  
• 1 caplet po bid for the balance of 5 years  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 22 CONFIDENTIAL 4.3 Inclusion of Women and Minorities  
 
There are no exclusions based on race or ethnicity in this trial. In the Canadian Cancer Trials Group 
as a whole, 60% of patients have been female and 40% have been male. The female preponderance 
reflects the number of studies performed in breast cancer. Insufficient data has been collected to 
test whether recruitment to breast cancer trials reflects race/ethnicity incidence in the Canadian 
population. This study, however, will be presented to patients through the major cancer -treatment 
institution s of the Canadian provinces, to which all racial/ethnic groups have equal access. The 
intention, therefore, is to recruit subjects from racial/ethnic groups in close approximation to the incidence of the disease in these groups. It will also be presented t o patients of any race or ethnicity 
through participating centres of major American Cooperative Groups. Patients at participating 
American sites will have equal access to this study regardless of race or ethnicity; furthermore, 
Minority Outreach is a component of all CTEP -sponsor ed trials.  
 
Within the United States, lower breast cancer incidence rates have been reported for blacks, Asians, 
American Indians, and Hispanics in comparison to non- Hispanic whites. Yet, blacks tend to have 
lower breast cancer survival rates. Several factors are thought to explain this difference. Among them are age at diagnosis, delay between onset of symptoms and diagnosis/treatment, stage, hormone receptor levels and socio- economic levels. During 1996, the racial composition of the 
women enrolled on NCCTG breast cancer protocols was non- Hispanic white (95%), black (4%) 
and Hispanic (1%).  
 
Although there is some evidence that obesity and/or insulin resistance may occur more frequently 
in African Americans than in Caucasi ans, and that breast cancer outcomes may be poorer in African 
Americans 
[Rose, 2007] , there is insufficient evidence to conclude that these are causally linked, nor 
is there evidence that metformin has different biologic effects or efficacy in different ra cial groups. 
As a result, we will recruit subjects of all ethnic and racial groups to approximate the racial 
distribution of breast cancer  seen at participating centers.  
 
Accrual Targets  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino  358 + 1 = 359 
Not Hispanic or Latino  3188  + 35 = 3223  
Ethnic Category: Total of all subjects  3546  (A1)  + 36 (B1) = 3582(C1)  
Racial Category   
American Indian or Alaskan Native  36 + 
1 = 36.25  
Asian  107 + = 107.25  
Black or African American  180 + = 180.25  
Native Hawaiian or other Pacific Islander  107 + = 107.25  
White  3116  + 35 = 3151  
Racial Category: Total of all subjects  3546  (A2)  + 36 (B2) = 3582(C2)  
 (A1 = A2)   (B1 = B2)   (C1 = C2)  
 
Accrual Rate:  100 pts/month  Total Expected 
Accrual:   358
2 Min 358
2 Max 
Projected Start Date of Study:  Q1    2010       
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 23 CONFIDENTIAL 5.0 STUDY POPULATION  
 
The study population will consist of subjects with invasive breast cancer who , within the previous 
12 months , have received the first histologic diagnosis of invasive breast carcinoma and have 
undergone definitive surgical treatment for invasive breast cancer. Subjects may have received, at 
the discretion of their treating physician, standard a djuvant loco- regional radiation, adjuvant 
endocrine treatment, trastuzumab or other biologics or bisphosphonates prior to or during study treatment. Chemotherapy (adjuvant or neoadjuvant), if given, must be completed at least 4 weeks 
prior to randomization.  
 
5.1 Eligibility Criteria  
 
There will be NO EXCEPTIONS to eligibility requirements at the time of randomization. 
Questions about eligibility criteria should be addressed PRI OR to calling for randomization . 
 The eligibility criteria for this study have be en carefully considered. Eligibility criteria are 
standards used to ensure that subjects who enter this study are medically appropriate candidates for this therapy. For the safety of the subjects, as well as to ensure that the results of this study can be useful for making treatment decisions regarding other patients with similar diseases, it is important 
that no exceptions be made to these criteria for admission to the study . 
 
5.1.1  Subjects must have histologically confirmed invasive breast cancer  and be enrolled in the trial 
within 12 months after the first histologic diagnosis of invasive breast cancer. A core biopsy 
interpreted as invasive cancer meets this criterion; otherwise, the date of first histologic diagnosis 
will be the date of first surgical p rocedure that identifies invasive cancer (biopsy, lumpectomy or 
mastectomy) . TNM Stage (AJCC Version 7) must be one of  the combinations presented in Section 
5.1.4. Neoadjuvant subjects should have no evidence of clinical T4 disease prior to chemotherapy 
and surgery. Please refer to 5.1.4 for eligible cTNM classifications. Bilateral breast carcinoma is 
allowed provided diagnoses are synchronous – that is, within 3 months of one another – and at least 
one of the two breast carcinomas  meet the eligibility crite ria and neither violates the eligibility 
criteria . 
 
5.1.2  All s ubjects (both adjuvant and neo- adjuvant)  must have sentinel lymph node biopsy and/or axillary 
lymph node dissection.  
 Sentinel lymph node biopsy alone is allowed in the following instances:  
a)  sentinel lymph node biopsy is negative: pN0  
b)  sentinel lymph node biopsy is positive for isolated tumour cells only: pN0 (i+)  
c)*  clinically node negative, T1 -2 tumours with sentinel lymph node biopsy positive in <  2 lymph 
nodes without extra -capsular extension or matted nodes and undergoing breast conserving 
surgery and tangential whole breast irradiation  
 
(* excludes subjects trea ted with neo -adjuvant systemic therapy)  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 24 CONFIDENTIAL 5.1.3  Definitive surgery and/or chemotherapy have been completed at least 4 weeks prior to 
randomization. Surgical margins must be clear of invasive carcinoma. If there is microscopic 
residual  ductal  in situ disease present at lumpectomy or total mastectomy margins, further excision 
is highly recommended. If further excision is not undertaken, the subject may still be entered on 
study, provided that in addition to breast or chest wall irradiation, a boost to the tumour bed is 
delivered . In situ lobular disease at the margin is acceptable.  
 
5.1.4  Adjuvant s ubjects with the following pT pN combinations are eligible:  
• pT1c, pN0 AND  negative estrogen and progesterone receptors AND  HER2 negative  
OR 
• pT2N0 and at least one of the following tumour characteristics: histologic grade 3, 
lymphovascular invasion, negative estrogen and progesterone receptors, HER2 positive, 
Oncotype Dx recurre nce score > 25 (or if Oncotype Dx recurrence score i s not available, Ki67 
> 14%)  
OR 
• Subjects with pT3, pN0  
OR 
• Subjects with pT1 -3, pN1- 3 
 
The eligibility of neo -adjuvant subjects is assessed on the basis of cTNM. The same eligible TNM 
combinations apply.  
 
5.1.5  Estrogen and progesterone receptor status must be known. ( Receptor positive by 
immunohistochemistry: ERICA or PgRICA versus both receptors negative . It is recommended that 
ER and PgR assays be considered positive if there are at least 1% positive tumour nuclei in the sample on testing in the presence of expected reactivity of internal [normal epithelial elements] 
and external control. 
[Hammond 2010]  
 
5.1.6  HER2 status must be known. ( Positive = 3+ over -expression by IHC in > 30% of invasive tumour 
cells OR HER2 gene amplification by FISH/CISH > 6 HER2 gene copies per nucleus, OR  a 
FISH/CISH ratio: HER2 gene copies to chromosome 17 signals of >  2.2. All other res ults will be 
considered negative ). 
 
5.1.7  Patients must have had a bilateral mammogram within 12 months prior to randomization, unless 
the initial surgery was a total mastectomy, in which case only a mammogram of the remaining 
breast is required.  (Subjects with bilateral total ma stectomies and no mammogram within 12 
months prior to randomization must, instead, have a physical examination of the chest wall to 
ensure there is no residual or recurrent disease at the time of randomization. The date of this 
examination is used in place  of the mammogram date on the eligibility checklist.)  
 
5.1.8  Investigations, including chest X -ray or CT chest, bone scan (with radiographs of suspicious areas) 
and abdominal ultrasound or liver scan or CT abdomen have been performed between the first 
histologic diagnosis and the time of randomization.  
• Chest X -Ray, 2 view  (or Chest CT) is mandatory  
• Bone scans (with x -rays of abnormal areas) are required only if there are signs or symptoms 
of metastatic disease  
• Abdominal imaging is required only if there are  signs or symptoms of metastatic disease  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 25 CONFIDENTIAL 5.1.9  Hematology investigations (WBC, Granul ocytes, Platelets, Hemoglobin) have been completed 
within 28 days prior to randomi zation an d results  are available . 
 
5.1.10  Biochemistry investigations have been completed within 28 days prior to randomization and values 
are within the para meters required by the protocol . 
 
AST < 1.8 X ULN  
ALT < 1.8 X ULN  
Alkaline Phosphatase < 2 X ULN  
Serum Creati nine < 115  μmol/L  (1.3mg/dL)  
Serum Bilirubin < institution ULN ( except for subjects with Gilbert’s Disease who are eligible 
despite elevated serum bilirubin level ) 
 
5.1.11  ECOG Performance Status of 0,1 or 2 (at baseline evaluation visit within 28 days pri or to 
randomization) . 
 
5.1.12  Age > 18 and  < 75 and life expectancy of at least 5 years  (18 years of age was used as a cut -off due 
to the lack of data indicating that breast cancer is a health issue in the < 18 years age group and 
metformin safety in pedia tric patients has not been confirmed. A ge > 80 carries increased risk of 
lactic acidosis and study intervention is for 5 years) . 
 
5.1.13  Subjects must be accessible for treatment and follow -up. Investigators must assure themselves the 
subjects randomized on this trial will be available for complete documentation of the treatment, 
adverse events, and follow -up. 
 
5.1.14 In accordance with CCTG policy, protocol treatment is to begin within 10  working days of patient 
randomization . 
 
5.1.15  Subject consent must be obtained according to local Institutional and/or University Human 
Experimentation Committee requirements. It will be the responsibility of the local participating 
investigators to obtain the necessary local clearance, and to indicat e in writing to the C CTG Study 
Coordinator that such clearance has been obtained, before the trial can commence in that centre. 
Because of differing requirements, a standard consent form for the trial will not be provided but a 
sample form is given in Appe ndix XII. A copy of the initial full board REB approval and  approved 
consent form must be sent to the central office. The patient must sign the consent form prior to 
randomization or registration. Please note that the consent form for this study must conta in a 
statement which gives permission for the C CTG and monitoring agencies to review patient records 
(see Section  16 for further details).  
 
For the first 888 eligible English or French- speaking subjects only  (sub-set enrollment completed 
2011NOV04) : 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 26 CONFIDENTIAL 5.1.16  Subject is able (i. e. sufficiently fluent) and willing to complete the Quality of Life (EORTC QLQ 
C-30 and Trial Specific Checklist) in English or French. The baseline assessment must already have 
been comple ted at the time of enrolment. Inability (illiteracy in English or French, loss of sight or 
other equivalent reason) to complete questionnaires will not make the patient ineligible for the 
study; however, ability but unwillingness to complete the questionna ires will make the patient 
ineligible. (Once the target number of 888 subjects is achieved, this criterion will no longer need 
to be fulfilled.) [See Appendix VI] . Sub-set enrollment completed 2011NOV04.  
 
5.1.17  English -speaking subjects who have completed the Quality of Life Questionnaire who are able (i .e. 
sufficiently fluent) and willing to complete Nurses Health Study II Physical Activity Questionnaire 
and Block Alive Screener in English. The baseline assessment must already have been completed  
at the time of enrolment. Inability (illiteracy in English, loss of sight or other equivalent reason) to 
complete questionnaires will not make the patient ineligible for the study; however, ability but 
unwillingness to complete the questionnaires will mak e the patient ineligible. (This component of 
the study will close at the same time as the Quality Of Life sub -study.) [See Appendix VII] . Sub-
set enrollment completed 2011NOV04.  
  
5.2 Ineligibility Criteria  
 Subjects who fulfill  any of the following criter ia are not eligible for admission to the study.  
 
5.2.1  Subjects with a history of other malignancies, except: adequately treated non- melanoma skin 
cancer, curatively treated in -situ cancer of the cervix, or other solid tumours curatively treated with 
no evidence of disease for >  5 years . 
 
5.2.2  Subjects with locally recurrent or metastatic breast carcinoma. (Subjects with prior invasive breast cancer at any time are not eligible.  Subjects with prior DCIS only in either breast are eligible 
provided the DCIS has been curatively treated including surgery, radiotherapy and/or Tamoxifen).  
 
5.2.3  Subjects whose axillary node status is unknown.  
 
5.2.4  Known diabetes (type 1 or 2) or baseline fasting glucose > 7.0 mmol/L  (126 mg/dL) . (Sampled and 
assayed according to local institution’s procedures.)  
 
5.2.5  Known hypersensitivity or intolerance to metformin.  
 
5.2.6  Any condition associated with increased risk of metformin -associated lactic acidosis (e .g. 
congestive heart failure define d as New York Heart Association {NYHA} Class III or IV functional 
status [see Appendix IX], history of acidosis of any type; habitual intake of 3 or more alcoholic 
beverages per day) . 
 
5.2.7  Currently taking metformin, sulfonylureas, thiazolidenediones or insulin for any reason.  
 
5.2.8  Current or planned pregnancy or lactation in women of child- bearing potential. Men should not 
father a child. (An effective method of birth control should be used while on study treatment which 
could include  abstinence,  IUD, condoms or other barrier methods of birth control because the safety 
of metformin in pregnancy or in male ferti lity has not been established ). 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 27 CONFIDENTIAL 5.2.9  Concurrent or planned participation in randomized trials of weight loss or exercise interventions or  
trials targeting insulin , IGF-1 or their receptors , or involving  P13K inhibitors  (at the time of 
randomization) *. 
 
* These interventions would interfere with the primary endpoint . (Also, in general, double 
randomizations in breast cancer trials for MA.32 patients are permitted only if the patient meets 
all the eligibility criteria for MA.32 and the sponsor of the previous trial has no objection to the 
patient also being enrolled in MA.32).  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 28 CONFIDENTIAL 6.0 PRE-TREATMENT EVALUATION  
(See Appendix I)  
 
Investigations  Timing  
History and Physical Exam 
including:  • Date of LMP, Menopausal status, Height, 
Weight , Waist and Hip Circumference, Blood Pressure, Performance Status (ECOG) , BMI , 
smoking history, alcohol intake  Within 28 days prior to randomization  
Pathology of Primary 
Tumour  • Histology, ER/PgR, HER2, pTNM , Histologic 
Grade   
Hematology  • WBC, Granulocytes, Platelets, Hemoglobin, 
MCV  Within 28 days prior to 
randomization  
Biochemistry  • AST, ALT, Alkaline Phosphatase, Serum 
Creatinine, Serum Bilirubin, Serum Vitamin B12 
• Fasting Glucose , Fasting Insulin (same draw ; 
Fasting Glucose measured locally; Fasting 
insulin measured centrally ) Within 28 days prior to randomization  
Radiology  • Bilateral mammogram (please note that MRI 
may not be substituted for mammogram but 
may be done in addition to a mammogram)  Within 12 months prior to randomization  
• Chest X -ray(2 view) , chest CT (mandatory)  
• Bone scan (with x- rays of abnormal  areas) if 
there are signs or symptoms of metastatic disease  
• Abdominal imaging if there are signs or 
symptoms of metastatic disease  Between the date of first histologic diagnosis and the date of randomization.  
Other Investigations  • Women of child- bearing potential  not pregnant  Within 7 days prior to 
randomization  
• Blood samples for correlative science 
(optional)  Within 28 days prior to 
randomization * 
• Tumour block submission (for subjects who 
consent)  When requested by Queen’s 
University Department of 
Pathology  
Concomitant Medications  • Current medications/Indications  Within 14 days prior to 
randomization  
Adverse Event  • Baseline adverse event evaluation (to 
document residual adverse event from previous therapy and baseline symptoms) 
using CTC AE version 4 Within 14 days prior to randomization  
Quality of Life  
(N = first eligible 888 English/French speaking 
subjects ) • EORTC QLQ- C30, Trial Specific Checklist,  Within 28 days prior to randomization (sample size 
achieved by 2011NOV04)  
Physical Activity and Diet 
Questionnaires  
(English -speaking subjects 
of QoL sub -set) • Physical Activity items (Nurses’ Health Study II), Block Alive Screener  Within 28 days prior to randomization (sample size 
achieved by 2011NOV04)  
* Optional correlative science s amples going to the central lab and not required for eligibility may be draw n after 
randomization and prior to start of study treatment so that they can be labeled appropriately with patient ID#.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 29 CONFIDENTIAL 7.0 ENTRY/RANDOMIZATION PROCEDURES  
(CTSU sites please refer to the CTSU Logistical Appendix )  
 
7.1 Randomization  
 
All randomizations will be done through the CCTG web -based, password- operated Electronic Data 
Capture (EDC) system. Complete details regarding obtaining a password, accessing the system and 
carrying out randomizati ons will be provided at the time of study activation and will also be included 
in the CCTG EDC Generic Data Management Guidebook, posted on the MA.32 trial specific web -
site. If sites experience difficulties accessing the system and/or  randomizing subjects  please contact 
the help desk (link in EDC) or the MA.32 Study Coordinator.  
 
All eligible subjects  enrolled on the study by the participating treatment centre will be assigned a 
serial number which must be used on all documentation and correspondence with CCTG.  
 
The following information will be required:  
• trial code ( CCTG MA.32)  
• treatment centre and investigator  
• date of REB approval* for study at participating centre  
• version of the informed consent that the patient signed  
• patient's initials, hospital number (if permitted by the local REB) and CCTG serial number  
• confirmation of the requirements listed in Section 5.0, including dates of essential questionnaires and tests and actual values  
• completed eligibility checklist  
• stratification parameters  
 
* Initial approval of all studies must be Full Board.  
 
Randomization will be performed electronically. Randomization will be given by the EDC system 
and confirmed by e -mail.  
 
Note : The validity of results of the trial depends on the  authenticity of and the follow -up of all 
subjects entered into the trial. Under no circumstances, therefore, may an allocated 
patient’s data be withdrawn prior to final analysis unless the subject withdraws 
participation from the trial and  requests that data collection/submission cease from the 
point in time of withdrawal . 
 All eligible subjects admitted to the trial will be followed by the coordinating centre. It is 
the responsibility of the physician in charge to satisfy him/herself that the patient is indeed 
eligible before requesting randomization.  
 All randomized subjects are to be followed until death  or until sites are informed by CCTG 
that further follow -up is no longer required . The follow -up requirements for ineligible 
subjects who have received no study treatment whatsoever are submission of the Baseline 
Report plus an annual Short Follow -up Report. Ineligible subjects who have had study 
treatment should also be followed with the Short Follow -up Report to allow for  treatment 
and adverse events ass essment . 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 30 CONFIDENTIAL 7.2 Stratification  
 
Subjects will be stratified by:  
• Receptor Status (ER and/or PgR positive versus both negative)  
• BMI (< 30 versus >30 kg/m2) 
• HER2 Status (positive versus negative)  
• Chemotherapy (any versus none)  
 
CTSU sites should refer to Appendix XI for CTSU -specific procedures.  
ICR-CTSU  sites should refer to the ICR -CTSU specific appendix for Group- specific procedures.  
IBCSG sites should refer to the IBCSG -specific appendix for Gr oup-specific procedures.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 31 CONFIDENTIAL 8.0 TREATMENT PLAN  
 
Although the Canadian Cancer Trials Group acts as the coordinating agency for the trial, the 
responsibility for treatment of subjects rests with the individual investigator.  
 
8.1 Study Treatment Plan  
 
Breast cancers must have been completely resected by lumpectomy (resection margins must be 
clear of invasive cancer) or mastectomy. If there is microscopic residual in situ disease present at 
lumpectomy or total mastectomy margins, further excision is highly recommended. If further 
excision is not undertaken, the patient may still be entered on study, provided that in addition to breast or chest wall irradiation, a boost to the tumour bed is  delivered.  
 Radiation is to be administered according to pre -specified institutional guidelines  either prior to or 
during protocol treatment . Either neo -adjuvant and/or adjuvant chemotherapy is allowed providing 
the last dose was administered at least 4 weeks prior to randomization. Other adjuvant therapies 
(including endocrine, biologic agents such as trastuzumab or lapatinib or bevacizumab, radiation, 
bisphosphonates) may be given before, during or after randomization and study treatment with 
metformin or placebo.  
 
All s ubjects (both adjuvant and neo- adjuvant)  must have sentinel lymph node biopsy and/or axillary 
lymph node dissection.  
 Sentinel lymph node biopsy alone is allowed in the following instances:  
a)  sentinel lymph node biopsy is negative: pN0  
b)  sentinel lymph node biopsy is positive for isolated tumour cells only: pN0 (i+)  
c)*  clinically node negative, T1 -2 tumours with sentinel lymph node biopsy positive in <  2 lymph 
nodes without extra -capsular extension or matted nodes and u ndergoing breast conserving 
surgery and tangential whole breast irradiation  
 
(* excludes subjects treated with neo -adjuvant systemic therapy)  
 All subjects (regardless of randomization) will be given basic information on healthy lifestyle (diet, 
physical activity) developed by the American Cancer Society ( www.cancer.org ). The information 
to be provided is included as Appendix XII.  
 
8.1.1  Drug Administration  
 
Arm Agent(s)  Strength  Route  Duration  Schedule  
1 Metformin  850 mg p.o 5 years or until 
primary endpoint  850 mg p.o.  b.i.d with food 
(includes 4 week ramp -up*) 
2 Placebo  One caplet  p.o. 5 years or until 
primary endpoint  One caplet p.o. b.i.d with food 
(includes 4 week ramp -up*) 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 32 CONFIDENTIAL In accordance with CCTG policy, protocol treatment is to begin within 10  working days of patient 
randomization.  
 
* The “ramp -up” to protocol dose and schedule will occur as follows:  
• 1 caplet po daily for 4 weeks, then  
• 1 caplet po bid for the balance of 5 years  
 
Please see protocol section 12.1 for a complete list of criteria for stopping protocol treatment.  
 
8.1.2  Patient Monitoring  
 
A calendar schedule will be provided for each patient for the ramp -up period and  telephone 
contact will be made with the patient one m onth after enrolment to assess compliance, toxicity and 
to ensure the patient has  increased medication to twice daily . (The calendar is intended only as a 
tool to assist subjects in adjusting to full dose at the correct time after starting study treatment.) A 
record of the telephone contact will be made, by the CRA, on the Telephone Follow -up report. 
(Please see Appendix I V.) Any problems identified by the CRA will be communicated to the 
responsible Investigator.  
 
8.1.3  Dose Adjustments  
 
The major toxic effects of metformin  which limit dose are gastrointestinal (nausea, abdominal 
bloating, diarrhea). During the ramp- up peri od, subjects experiencing gastrointestinal symptoms 
should be encouraged to take tablets with food. If no improvement, subjects should try taking study 
medication every other day for two weeks, once per day for two weeks and then twice per day 
thereafter.  Subjects not tolerating study medication after this approach may go off study treatment 
but Investigators are urged to re -challenge willing subjects 3 months later. Dose adjustments, for 
reasons of toxicity, will be as in the tables below. (Please note th at none of the recommended dose 
adjustments require splitting of study medication pills.  Pills are not to be split or crushed, prior to 
taking, for any reason. ) Breaks of up to 4 weeks consecutively or 8 weeks overall are allowed to 
ascertain the cause of unpleasant symptoms. Beyond this, treatment is at the discretion of the Investigator.   
 
Gastrointestinal Toxicity  
 
Toxicity / Adverse Event  Grade  Investigator Action  
Gastrointestinal Toxicity 
of any type  Grade 1  Patient should be encouraged to remain on full dose. If patient is 
unwilling, stop study treatment for one week.  
 
For subjects who were unwilling to remain on full dose, after one week 
without study drug, follow the ramp- up procedure. If Grade 1 
symptoms persist or recur during the ramp -up or at full dose and the 
patient is unwilling to continue, follow instructions for Grade 2 
toxicity.  
From the Gastrointestinal 
Category of CTC AE  
 
Nausea 
Distension/Bloating  
Diarrhea  
Gastrointestinal - Other  Grade 2  
(or higher)  Reduce to one tablet  per day for one week. If symptoms resolve or are 
Grade 1 only, after one week, resume full dose (2 tablets per day).  
 
If symptoms persist or recur at Grade 2 or higher, stop study treatment 
for 4 weeks, then resume study treatment as follows:  
 
Re-start study drug according to original ramp- up schedule (one tablet 
per day for 4 weeks then 2 tablets per day if tolerated). If toxicity 
persists or recurs, the study drug should be adjusted to the maximum 
dose that is tolerated with Grade 1 toxicity o r lower. A second attempt 
to increase to full dose should be made 3 months later and if the full 
dose is not tolerated at that time, the maximum tolerated dose should 
be used for the remainder of the 5 -year intervention.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 33 CONFIDENTIAL Other Toxi cities / Event s 
 
Toxicity / Event  Grade  Investigator Action  
Hepatic dysfunction*  
(bilirubin > ULN except 
for Gilbert’s Disease)  Grade 1  
(or greater)  Hold study drug for up to 4 weeks. If bilirubin returns to normal 
within that time frame, begin one tablet per day for 4 weeks, then 2 
tablets per day.  
Hepatic dysfunction*  
 
AST or ALT =1.8- 3.0 X 
ULN  Please consult 
CTC AE for 
precise grading  Repeat AST & ALT in 2 weeks. If either AST or ALT > 1.8 X ULN, 
continue at discretion of Investigator, monitoring AST & ALT every 
two weeks until both < 1.8 X ULN – then resume annual testing.  
 
If Investigator decides to stop medication , resume once AST &ALT 
< 1.8 X ULN, starting with one tablet per day for 4 weeks, then 
increasing to 2 table ts per day with annual AST & ALT assessments  
Hepatic dysfunction*  
 
AST or ALT > 3.0 X 
ULN  Please consult 
CTC AE for 
precise grading  Hold study drug.  
Repeat LFTs in 2 weeks.  
 
If AST and ALT < 1.8 ULN, resume medication.  
Resumption involves 1 tablet per day for 4 weeks, then increase to 2 
tablets per day, at the discretion of the Investigator, with resumption 
of protocol specified monitoring if both AST and ALT remain at  < 
1.8 x ULN.  
 
If repeat AST and ALT are 1.8 -3.0 x ULN, follow steps as described 
in section above  or resume study medication at the discretion of the 
Investigator . 
 
If AST and/or ALT > 3.0 x ULN, initiate workup for liver disease.  
If AST or ALT =1.8-3.0 resume medication at the discretion of the 
investigator.  
Renal dysfunction  
 
Creatinine >  115 μmol/L  
 1.3 mg/dL  Please consult 
your 
institution’s 
ULN and  CTC 
AE for precise 
grade  Hold study drug for up to 4 weeks.  
 
After resolution of event, using 4- week ramp -up schedule (one caplet 
per day for 4 weeks, then 2 caplet per day)  
Clinical diagnosis of 
congestive heart failure  > Grade 3 
(Please consult 
CTC AE for 
precise grade)  Hold study drug for up to 4 weeks.  
 
Re-start may be considered if underlying condition (e .g. acute MI) has 
resolved. If Metformin is started after CHF, the r amp-up schedule (one 
caplet per day for 4 weeks then two caplets per day) should be used. 
Do not re -start if symptoms persist or ongoing treatment of CHF is 
required.  
Acidosis  
(Lactate >  5.0 mM)  
(pH < 7.3)  Grade 3  Stop study drug  and do not re -start. 
 
Report  as a serious adverse event. Please consult protocol section 11.  
Anemia  
Hgb < 110 or MCV > 
105 > Grade 1  Perform CBC and serum B 12 level. Initiate anemia workup if cause of 
anemia not apparent. Continue at full dose. (Treatment is not held for 
anemia regardless of toxicity grade.)  
Skin Reactions  
 
Major – generalized 
urticaria, bullous rashes, 
exfoliative dermatitis  Generalized  Stop study drug. and do not re -start.  
Continued on next page …  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 34 CONFIDENTIAL Other Toxicities / Events ( continued ) 
Toxicity / Event  Grade  Investigator Action  
Stevens Johnson 
Syndrome  
 
Localized  Localized  Hold study drug for up to 4 weeks  
if possibly, probably or definitely related to study drug.  
 
When rash clears, one caplet per day for 4 weeks, then 2 caplets per 
day – if rash recurs, and is thought to be possibly, probably or 
definitely related to study medication, disconti nue study medication.  
Hospitalization for any 
reason  As per grade of 
event causing 
hospitalization  Hold study drug for up to 4 weeks.  The Investigator  is to determine  
when it is safe to re -start.  The drug should be re -started using a 4- week 
ramp -up schedu le (one caplet per day for 4 weeks then two caplets per 
day) if the hospitalization resulted in discontinuation of the drug for 2 
weeks or longer. If the discontinuation of the drug was less than 2 
weeks, the drug should be re -started at full dose (two cap lets per day) 
without a ramp -up. 
* Be alert to signs of acidosis! : protocol specific biochemistry should be checked annually. If subject develops malaise, nausea, 
dark urine, jaundice or right upper quadrant pain, study medication should be stopped until biochemistry is performed. 
Medication should be resumed according to the algorithms above (if first biochemistry results are normal, resume immediately 
at full dose)  
 
Other Situations  
 
Diagnostic Imaging:  
If the subject is scheduled for any CT scans requiring intravenous contrast material, metformin 
should not be taken for 24 hours prior to the investigation nor for 48 hours after the procedure. 
(This does not include contrast used for MRI or nuclear medicine scans, including MUGA.) Study medica tion may then be resumed at full dose (without ramp- up) provided there is no concern about 
renal function. If there is concern about renal function, creatinine should be checked prior to resumption of study medication.  
 
General Anaesthetic:  
If general anaesthetic is required for surgery, study drug should not be taken on the morning of 
surgery nor for 48 hours after anaesthetic and surgery. Study medication may then be resumed at 
full dose (without ramp -up) provided there is no concern about renal function.  The drug is restarted 
at full dose if the duration of interruption was less than 2 weeks. If the duration of drug interruption 
was more than 2 weeks, it should be restarted using a 4 week ramp- up schedule (one caplet per day for 
4 weeks, then two caplets per day). If there is concern about renal function, creatinine should be 
checked prior to resumption of study medication.  
 
Any Situation Considered Medically Necessary:  
Study medication may be held in any situation which the Investigator considers it medic ally 
necessary, for up to 4 weeks, and may be resumed at Investigator discretion, using the 4- week 
ramp -up if re -starting.  
 Adverse  events  will be graded using the NCI Common Terminology Criteria for Adverse Events, 
version 4 (CTCAE) . Only events of Grade 3, 4 and 5 will be collected.  (Please consult Appendix 
V). 
 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 35 CONFIDENTIAL 8.1.4  Concomitant Therapy  
 
Permitted  
Subjects may receive loco -regional radiation, adjuvant endocrine treatment, trastuzumab or other 
biologics or bisphosphonates, at the discretion of their treating physician, before during or after 
randomization and study treatment with metformin or placebo. Chemotherapy (or neoadjuvant 
chemotherapy), if given, must be completed at least 4 weeks prior to randomization.  
 
Not permitted  
Sulfonylureas, thiazolidenediones or insulin for any reason unless these drugs become necessary to 
treat a new diagnosis while on study therapy in which case the patient will discontinue study 
treatment. Subjects should avoid excessive alcohol intake (i .e. less than 3 alcoholic beverages on 
any given day).  
 
8.1.5  Duration of Therapy  
 
Subjects will take their allocated therapy o rally, twice daily, with food.  
 
The DSMC recommended, as an outcome of the second interim analysis, that all ER and PgR 
negative subjects discontinue study medication. Specifically, the results indicated that continuation 
of protocol therapy will not provide additional information about the benefit of metformin in this 
sub-population. Please see protocol section 14 for details.  
 Treatment will be continued for 5 years in receptor positive (ER and/or PgR positive) subjects 
unless unacceptable toxicity occurs or the subject has recurrent tumour, new invasive primary 
cancer (other than adequately treated basal cell carcinoma or squamous cell carcinoma of the skin), 
or concurrent illness that necessitates withdrawal or subject decides to withdraw from particip ation 
for any reason.  (For details concerning toxicity and intercurrent illness, please consult protocol 
section 8. For a complete list of general criteria for stopping study treatment, please see protocol 
section 12.1.)  
 
If the subject’s immediate manage ment for the new diagnosis is influenced by the knowledge of 
which treatment she/he was assigned, study medication will be unblinded upon the Inves tigator’s 
request, by C CTG.  
 
8.1.6  Blinding/Unblinding
 
 
Metformin and matching placebo are identical in appearance as are the bottles in which they are provided. Blinding is critical to the integrity of this clinical drug trial. However, in the event of a 
medical emergency in an individual subject, in which knowledge of the investigational product is 
critical to the subject's management , the blind for that subject may be broken by the treating 
physician. Before breaking the blind of an individual subject's blinded treatment, the Investigator should have  determined that the  information is necessary, i.e.  that it will alter the subject's 
immediate management. In many cases, particularly when the emergency is clearly not 
investigational product -related, the problem may be properly managed by assuming that t he subject 
is receiving active product without the need for unblinding. The need to break the blind must first 
be discussed with the CCTG. For any treatment code unblinding, the reason and parties involved 
must be documented in the patient’s medical record . Treatment identification information should 
be kept confidential and should be disseminated only to those individuals that must be informed for medical management of the patient. The C CTG must be notified as soon as possible of any 
emergency situation in  which the drug code was broken.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 36 CONFIDENTIAL To request an unblinding of patient treatment during regular office hours (8am to 6pm eastern time), 
please contact the MA.32 Study Coordinator, at 613- 533-6430. For emergency after hours 
unblinding requests : 
Toll Free number: 877- 617-2810 (North America Only)  
International Calls: 613 -541-3280  
 
The Investigator requesting the unblinding of a patient treatment must provide : 
1) the trial code (MA.32);  
2) the patient ID number ; 
3) patient initials;  
4) reason for unblinding;  
5) the last treatment kit number . 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 37 CONFIDENTIAL 9.0 EVALUATION DURING AND AFTER  PROTOCOL TREATMENT  
 
All subjects entered on study must be evaluated according to the schedule outlined in Appendix I 
with documentation submitted according to the schedule in Appendix IV.  
 
Subjects are to be followed every 6 months for the first year and then annually until 5 years from 
randomization while on study treatment. Treatment is for 5 years or until disease 
recurrence/progression, new invasive primary cancer (other than BCC or SCC of the skin that has 
been adequately treated), intolerable toxicity or subject w ithdrawal for whatever reason. After study 
treatment discon tinuation, subjects should be followed annually for delayed/persistent toxicity and 
disease status.  
 
9.1 Evaluation During Protocol Treatment 
 
Investigations  Timing  
History and Physical Exam 
including:  • Weight, Waist  and Hip Circumference, 
Blood pressure , BMI , Compliance (patient 
reported and pill count) , Cardiovascular  
hospitalizations, New diagnosis of diabetes  • At each clinic visit  
Hematology*  • WBC, Granulocytes, Platelets, Hemoglobin, MCV  • At 6, 12, 24, 36, 48 and 60 months while on study treatment  
Biochemistry * • ALT, AST, Alkaline Phosphatase, Serum Creatinine, Serum Bilirubin  
• Serum Vitamin B12*  
• Fasting Glucose , Fasting Insulin (same 
draw ; Fasting Glucose measured locally; 
Fasting insulin measured centrally) ) • At 6, 12, 24, 36, 48 and 60 
months while on study treatment  
• At 12, 36 and 60 months while on study treatment  
• At 6 month visit & at 48 months (or just prior to end of study 
treatment  if not at 48 months) *** 
Radiology  • Annual mammogram ( please note that MRI 
cannot be substituted for mammogram but 
may be done in addition to mammogram ) • Annually from baseline mammogram  
Other Investigations  • Serum, plasma, DNA (optional)  • At 6 month visit  & at 48 months 
(or just prior to end of study 
treatment  if not at 48 months)  
• As needed to assess for 
recurrence/progression  • As needed, at Investigator 
discretion  
Adverse Events ** 
(Appendix V)  • Subjects must be evaluated at each clinic 
visit for adverse events  • At each clinic visit  
Quality of Life  
(888 patient subset)  • EORTC QLQ- C30, Trial Specific 
Checklist,  • At 6, 12, 24, 36, 48 and 60 
months while on study treatment  
Physical Activity and Diet  
(Quality of Life subset)  • Physical Activity Items (Nurses’ Health 
Study II), Block Alive Screener  • At 6, 12, 24, 36, 48 and 60 months while on study treatment  
* Vitamin B 12 deficiency should be managed according to Investigator discretion.  
** Adverse events will be recorded and graded according to the NCI Common Terminology Criteria for Adverse Events , version 4.  
*** For subjects who discontinue study treatment anytime prior  to 4 years, the mandatory fasting glucose and fasting insulin should 
be drawn just prior to study treatment discontinuation. For subjects who complete 4  years of therapy, a 4 -year treatment  should 
be done at the 48 month visit. Subjects who have passed the 48 month mark may have their samples drawn at the 60 month visit 
prior to treatment discontinuation.   
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 38 CONFIDENTIAL 9.2 Evaluation After Protocol Treatment 
 
Subjects are seen annually, after cessation of study treatment  
 
Prior to reaching primary endpoint  
Investigations  Timing  
History and Physical 
Exam including:  • Clinical assessment for recurrence/progression  
• Weight , BMI, Cardiovascular hospitalizations, New diabetes  At each clinic visit  
Radiology  • Annual mammogram ( Please note that MRI may not be 
substituted for a mammogram  but may be done in addition to 
mammogram ) Annually from 
baseline 
mammogram  
Other Investigations  • As necessary to assess for recurrence/progression , 
Contralateral breast carcinoma, DCIS alone, New invasiv e 
non-breast primary  At each clinic visit  
Adverse Events  Adverse events (related to study treatment only) will be recorded 
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit 
There will be no QoL, Physical Activity or Diet Questionnaires after protocol treatment.  
 
After experiencing invasive loca l/regional recurrence (a primary endpoint) but no distant recurrence  
Investigations  Timing  
History and Physical Exam including:  • Clinical assessment for distant recurrence/progression , 
Contralateral breast carcinoma, New invasive non- breast 
primary  At each clinic visit  
Radiology  • Annual mammogram ( Please note that MRI may not be 
substituted for a mammogram  but may be done in addition to 
mammogram ) if there is breast tissue remaining  Annually from 
baseline 
mammogram  
Other Investigations  • As necessary to assess for recurrence/progression , New 
primaries (breast or non -breast)  At each clinic visit  
Adverse Events  Adverse events (related to study treatment only) will be recorded 
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit  
There will be no QoL, Physical Activity or Diet Questionnaires after local recurrence.  
 
After distant recurrence/progression  (a primary endpoint)  
Investigations  Timing  
History and Physical Exam including:  • Clinical assessment  At each clinic visit  
Other Investigations  • As necessary  (& to assess for new invasive non- breast 
primary)  At each clinic visit  
Adverse Events  Adverse events (related to study treatment only) will be recorded 
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit  
There will be no QoL, Physical Activity or Diet Questionnaires after distant  recurrence.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 39 CONFIDENTIAL After Contralateral Invasive Breast Carcinoma (a primary endpoint)  
Investigations  Timing  
History and Physical 
Exam including:  • Clinical assessment for local/regional recurrence, distant recurrence  At each clinic visit  
Other Investigations  • Annual mammogram ( Please note that MRI may not be 
substituted for a mammogram  but may be done in addition to 
mammogram)  if there is breast tissue remaining  
• As necessary  (& to assess for new invasive non- breast 
primary)  Annually from baseline mammogram  
Adverse Events  Adverse events (related to study treatment only) will be recorded  
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit  
There will be no QoL, Physical Activity or Diet Questionnaires after distant  recurrence.  
 
New invasive non- breast primary , treated with curative intent (a primary endpoint)  
Investigations  Timing  
History and Physical 
Exam including:  • Clinical assessment  for breast recurrence/progression, 
contralateral breast carcinoma and DCIS alone At each clinic visit  
Other Investigations  • Annual mammogram ( Please note that MRI may not be 
substituted for a mammogram  but may be done in addition to 
mammogram)  
• Other investigations, a s necessary   Annually from baseline mammogram  
Adverse Events  Adverse events (related to study treatment only) will be recorded 
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit  
There will be no QoL, Physical Activity or Diet Questionnaires after a new invasive non -breast primary . 
 
Other n ew invasive non- breast primary , incurable (a primary endpoint)  
Investigations  Timing  
History and Physical 
Exam including:  • Clinical assessment  At each clinic visit  
Other Investigations  • As necessary   At each clinic visit  
Adverse Events  Adverse events (related to study treatment only) will be recorded 
and graded according to the NCI Common Terminology Criteria 
for Adverse Events (Version  4 CTCAE - Appendix  V). At each clinic visit  
There will be no QoL, Physical Activity or Diet Questionnaires after a new invasive non -breast primary . 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 40 CONFIDENTIAL 10.0 CRITERIA FOR MEASUREMENT OF STUDY ENDPOINTS  
 
10.1 Definitions of Evaluability  
 
10.1.1  Evaluable for A dverse Events . All subjects will be evaluable for adverse event evaluation from the 
first date of their metformin/placebo.  
 
10.1.2  Evaluable for Quality o f Life Assessment . All subjects who have completed the quality of life 
questionnaires a re evaluable for quality of life. The quality of life questionnaires are being done in 
a def ined sub- set of MA.32 subjects.  (Sub-set closed to accrual 2011NOV04; follow -up continues.)  
 
10.1.3  Evaluable for Physical Activity and Nutrition Assessment . All su bjects who have completed the 
Physical Activity and Nutrition Questionnaires are evaluable for these items. The Physical Activity 
and Nutrition Questionnaires are being done in a def ined sub- set of MA.32 subjects.  
 
10.2 Criteria for Measurement of Study Endpoints  
 
As invasive disease free survival is an important endpoint in this study, it is vital that it be adequately and precisely documented. The definitions used are from the STEEP System  
[Hudis, 
2007] . 
 
10.2.1  Definitions of Endpoints  
 
Primary Endpoint  
Invasive Disease Free Survival  is defined as the time from randomization to the time of any of the 
following events: ipsilateral and contralateral invasive breast tumour, local/regional invasive 
recurrence, distant recurre nce, death from breast cancer, dea th from no n-breast cancer cause, death 
from  unknown cause, diagnosis of a second primary invasive non- breast cancer (except squamous 
cell carcinoma and basal cell carcinoma of skin, completely excised and presumed cured).  
 
Secondary Endpoints  
Overall Survival  is defined as the time from randomiza tion to the time of death from breast cancer, 
death from a non breast cancer cause or death from an unknown cause.  
 
Distant Relapse  Free  Survival  is defined as the time from randomization to  the time of  distant 
recurrence, death from breast cancer, death from a non breast cancer cause or death from an 
unknown cause.  
 
Breast Cancer F ree Interval  is defined as the time fro m randomization to the time of diagnosis of 
invasive ipsilateral breast tumour recur rence, local/regional invasive recurrence, distant recurrence, 
death from breast cancer, invasive contralateral breast cancer, ipsilateral DCIS, contralateral DCIS . 
 
Breast Cancer Specific Mortality  is defined as the time from randomization to the time of d eath 
from breast cancer . 
 
Contralateral Invasive Breast Cancer  is defined as the diagnosis of a primary invasive breast 
cancer in the opposite breast after randomization . 
 
Other Medical Endpoints  – including one or more of:  
1. Diabetes: initiation of new anti- diabetes medication (or confirmed MD diagnosis of diabetes)  
2. Cardiovascular hospitalization or cardiovascular death (stroke, myocardial infarction)  
3. Changes in BMI (Please see Appendix IX)  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 41 CONFIDENTIAL 10.3 Evidence of Disease Recu rrence/Progression  
 
As defined below, definite  evidence of disease recurrence is required to determ ine that disease has 
recurred.  
 
Recurrence will be categorized as local, regional or distant.  
 
Local (Breast) Recurrence  is defined as recurrence within the breast, following partial mastectomy. 
See 10.5 for management.  
 
Local (Chest Wall) Recurrence  is defined as recurrent cutaneous or subcutaneous tumour occurring 
in an area bounded superiorly by the clavicle, inferiorly by a horizontal line at the level of the 
xiphisternum, medially by the midline and laterally by the posterior axillary line.  
 
Regional (Nodal) Recurrence  is defined as recurrent tumour in the lymph nodes in the homolateral 
axilla, homolateral supraclavicul ar fossa or ipsilateral internal mammary chain.  
 
Distant Recurrence  is defined as spread of disease beyond the limits specified in those above.  
 
10.3.1  Local - Regional Sites  
 
1. Definite - positive cytology, aspiration or biopsy  
2. Suspicious - a visible or palpable lesion  
 
10.3.2  Distant Recurrence  
 
a) Bone Marrow  
1. Definite - positive cytology, aspiration or biopsy  
2. Suspicious - leukoerythroblastic blood picture  
b) Lungs and Pleural  
1. Definite - 
i) Positive cytology, aspiration or biopsy, or  
ii) Presence of multiple pulmonary nodules which are felt to be consistent with pulmonary 
metastases  
 
Note: If a solitary lung lesion is found and no other lesions are present on lung tomograms, further 
investigation, such as CT scan, biopsy or needle aspiration, or thoracic diseases 
consultation should be performed.  
 
c) Skeletal  
1. Definite - 
i) X-ray evidence of lytic, blastic, or mixed lytic -blastic lesions on skeletal films with or 
without bone scan confirmation or  
ii) Biopsy proof of bone metastases or  
iii) Progressive bone scan changes over at least a four week period showing development 
of new lesions is necessary in asymptomatic subjects with only bone scan 
abnormalities  
 
Note: In the absence of progressive disease by scan a biopsy is strongly recommended. Any 
positive bone scan in joints or in a recent area of trauma (surgical or otherwise) cannot be 
used as a criterion of treatment failure.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 42 CONFIDENTIAL d) Ascites and Pleural Effusions  
1. Definite - positive cytology or  
2. Suspicious - roentgenographic or clinical evidence  
 
e) Liver  
1. Definite - 
i) Liver enlargement, especially if the liver is nodular, with additional confirmation by an 
abnormal liver scan, ultrasound or CT scan demonstrating solid space occupying lesions 
or 
ii) Liver biopsy confirmation of metastatic disease  
 
Note: If the liver scan, ultrasound or CT scan findings are not definitive a liver biopsy is mandatory.  
 
f) Central Nervous System  
1. Definite - 
i) Positive CT scan or MRI, usually in a patient with neurological symptoms or  
ii) Biopsy or cytology (for a diagnosis of meningeal involvement)  
 
10.4 Dating of First Recurrence  
 
This should always be based on the onset of a sign but never on the onset of a symptom. The date of 
first detection of a palpable lesion is acceptable only when the diagnosis of tumour involvement is 
subsequently established.  
 
The diagnosis of recurrent disease by radiographs or scans should be dated from the first positive 
record, even if th is is determined in retrospect.  
 
Initial re cording of dates of first recurrence and death should be made as they occur by those who are 
responsible for the care of the patient. Dates that are based on suspicion alone will be reviewed by 
the CCTG coordinating office in order to establish their accur acy through subsequent behaviour. In 
addition, the case records of those subjects not reported as having recurrent disease will be scrutinized 
regularly to check that review is continuing and to ensure consistent recording.  
 
10.5 Management Following Recurrence  
 
Subject management following recurrence (breast, chest wall, regional and/or distant) is at the discretion of the Investigator but the subject must come off study treatment when recurrence is 
confirmed by the Investigator.  (Subjects need not come off study treatment for new in situ  breast 
carcinoma only) . 
 
10.6 Contralateral Breast Carcinoma – Invasive and in situ  
 
A lesion in the opposite breast will be assumed to be a new primary malignancy unless obviously 
contiguous with recurrent chest wall disease or proven o n cytology/biopsy to be of meta static origin. 
Subjects must come off study treatment upon the diagnosis of invasive disease in the contralateral 
breast. (Subjects need not come off study treatment for ne w in situ bre ast carcinoma only ). 
 
10.7 Second Malignancy  
 
Subjects developing any new non- breast primary malignancies, except for adequately treated 
superficial squamous or basal cell carcinoma of the skin or in situ carcinoma of the cervix will discontinue protocol t reatment (the exceptions based on the assumption that disease has been 
completely surgically excised and presumed cured).  
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 43 CONFIDENTIAL 11.0 SERIOUS ADVERSE EVENT REPORTING  
 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE)  version 4  will be utilized for Adverse Event (AE) reporting. All 
appropriate treatment areas should have access to a copy of the CTCAE  Versi on 4. A copy of the 
CTCAE version 4.0 can be downloaded from the CTEP website ( http://ctep.cancer.gov ). 
 
All serious  adverse events (SAE) defined as per ICH guidelines (see below) and other adverse 
events must be recorded on case report forms. In addition, all “reportable” serious adverse events are subject to expedited reporting using the CCTG SAE form. The term ‘reportable SAE’ is used 
in the definitions which follow to describe those SAEs which are subject to expedi ted reporting to 
CCTG.  
 
11.1 Definition of a Reportable Serious Adverse Event  
(Serious, Unexpected AND Related)  
 
• All serious  adverse events which are unexpected  and related to protocol treatment  must be 
reported in an expedited manner (see Section 11.2 for reporting instructions).  These include 
events occurring during the treatment period (until 30 days after  last protocol treatment 
administration) and at any time afterwards.  
• Unexpected  adverse e vents are those which are not consistent in either nature or severity with 
information contained in the P roduct Monograph . 
• Adverse events considered related to protocol treatment are those for which a relationship to 
the protocol agent cannot reasonably be  ruled out.  
• A serious  adverse event (SAE) is any adverse event that at any dose:  
− results in death  
− is life -threatening  
− requires inpatient hospitalization or prolongation of existing hospitalization (excluding 
hospital admissions for study drug administration, transfusional support, scheduled 
elective surgery and admissions for palliative or terminal care)  
− results in persistent or significant disability or incapacity  
− is a congenital anomaly/birth defect  
 
Medical and scientific judgement should be exercised in deciding whether expedited reporting is 
appropriate in other situations such as important medical events that may not be immediately life -
threatening or result in death or hospitalization but may jeopardize the patient or may require 
intervent ion to prevent one of the events listed above.  
 
11.2 Serious Adverse Event Reporting Instructions  
 
Please report only events that are serious, unexpected AND related to study treatment as serious 
adverse events. All reportable serious adverse events must be reported using a web- based 
Electronic Data Capture (EDC) system being used for this trial. For details about accessing the 
EDC system and completing the on- line SAE report form,  please refer to the CCTG Generic Data 
Management Guidebook for EDC Studies posted on the MA.32 section of the C CTG website 
(www.ctg.queensu.ca ). 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 44 CONFIDENTIAL Within 24 hours:  Complete preliminary  Serious Adverse Event Report and submit to C CTG 
via EDC system.  
 
Within 10 days:  Update  Serious Adverse Event Report as much as possible and submit 
report to C CTG via EDC system.  
 
EDC SAE web application interruption:  
In the rare event that internet connectivity to the EDC SAE system is disrupted, please print and 
complete a paper copy of the SAE Report, available from the trial specific website.  
 FAX paper SAE Report  to: 
 
MA.32  Study Coordinator  
Canadian Cancer Trials Group  
Fax No.: 613- 533-2814  
 
Please use the same timelines for submission as for direct EDC reporting.  
 
Once internet connectivity is restored, the information that was  FAXED to C CTG on the  paper 
SAE Report must also be enter ed by the site  into the EDC SAE web application.  
 
Local internet interruption : 
If you are unable to access the EDC SAE system, and cannot access a paper copy of the SAE Report 
from the trial website, please phone the MA.32 trial team (613 -533-6430) to obtain a copy of the 
SAE Report by FAX. Once completed, the report must be FAXED back to C CTG as indicated 
above. Once internet connectivity is restored, the information that was FAXED to C CTG on the  
paper SAE Report must also be enter ed by the site  into the EDC SAE web ap plication.  
 
In cases of prolonged internet interruptions, please contact the CCTG Safety Desk for further 
instructions (613- 533-6430).  
 
11.3 Reporting Malignancies or Myeloid Dysplasia  
 
Malignancies or myeloid dysplasia that are unexpected AND related to protocol treatment in the 
opinion of the investigator must be reported as Serious Adverse Events as described in Section 11.0 
and 11.2, within 15 working days of when diagnosis is known t o the investigator. Other 
malignancies occurring or recurring during the trial, which are considered unrelated or expected 
should only be reported on the case report form.  
 
11.3.1  Other Protocol Reportable Events –  Pregnancy Reporting and Exposure Reporting 
 
a. Pregnancy Prevention 
 WOCBP and males who are enrolled in the trial must have agreed to use contraceptive 
method(s) as described in Ineligibility Criterion 5.2.8.  Investigators may wish to additionally 
advise the female partners of male participants  about pregnancy prevention guidelines when 
appropriate and compliant with local policy.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 45 CONFIDENTIAL b. Pregnancy Reporting  
 
The investigator is required to report to C CTG any pregnancy occurring in female participants, 
and female partners of male participants. Pregnancies occurring up to 30 days  after the 
completion of study treatment must also be reported.  
 
The investigator should report the pregnancy in a timely manne r, within 24 hours of learning 
of the pregnancy using the C CTG Pregnancy Reporting Form  available from the trial webpage.  
 
Once informed consent has been obtained, the form should be updated to provide further 
pregnancy information and to reflect the outc ome of the pregnancy.  All follow -up reports must 
be submitted to C CTG in a timely manner.  For pregnant partner of trial participant (and 
pregnant participants, if required by local policy), a copy of the signed signature page of the pregnancy follow -up consent must be submitted to CCTG.  
 
Documents outlined above (including updates) must be sent to the CCTG safety desk (613-
533-2812/ safety -desk@ctg.queensu.ca ).  
 
If the pregnancy results in death; is life -threatening; requires inpatient hospitalization or 
prolongation of existing hospitalization; results in persistent or significant disability/incapacity; 
is a congenital anomaly/birth defect, then an SAE report must be additionally submitted as 
describ ed above.  Please note, hospitalization for labour/delivery alone does not constitute an 
‘inpatient hospitalization’ for the purposes of pregnancy reporting.  
 
c.  Exposure Reporting (non- study participants)  
The investigator is required to report to CCTG any incidence of exposure to study agent(s).  
Exposure is defined as significant, direct, contact/inhalation/consumption of agent(s) by non-  
study participant (an individual who is not otherwise participating i n this clinical trial).  An 
example of an exposure includes a non- study participant swallowing study medication.  The 
investigator is responsible for determining significance, based on the agent to which the 
individual is exposed.   
 
The investigator should r eport the exposure in a timely manner, within 24 hours of learning of 
the exposure , using the C CTG Exposure Reporting Form available from the trial webpage.   
 
Once informed consent has been obtained, the form should be updated to provide further 
exposure i nformation and to reflect the outcome of the exposure as the information becomes 
available upon appropriate follow -up of the exposed individual (follow -up for at least 30 days 
after exposure) . All follow -up reports must be submitted to C CTG in a timely man ner. A copy 
of the signed exposure follow -up consent signature page must also be submitted to CCTG.  
 
Documents outlined above (including updates) must be sent to the CCTG safety desk (613-
533-2812/ safety -desk@ctg.queensu.ca ).  
 
If the exposure results in death; is life -threatening; requires inpatient hospitalization or 
prolongation of existing hospitalization; results in persistent or significant disability/incapacity; 
is a congenital anomaly/birth defect, then an SAE report must be additionally submitted as 
described above.   
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 46 CONFIDENTIAL 11.3.4  Blinded Studies and Patient Unblinding  
 
Centre requests for participant unblinding as a result of a pregnancy or exposure are acceptable.  
However, the usual unblinding rules (see section 8.1.6 ) must be followed.  
 
11.4 CCTG Responsibility for Reporting Serious Adverse Events to Health Canada (Office of Clinical 
Trials)  
 
The CCTG will provide expedited reports of SAEs to Health Canada (Office of Clinical Trials) for 
those events which meet regulatory requirements for expedited reporting, i.e. events which are 
BOTH serious  AND unexpected , AND which are thought to be related to protocol treatment  (or 
for which a causal relationship wi th protocol treatment can not be ruled out).  
 
11.5 CCTG Reporting Responsibility to Apotex  
 All serious adverse events that are judged to be serious, unexpected and related to study treatment 
(that is, regulatory reportable) will also be reported to Apotex, the provider of the metformin and 
placebo for this clinical trial.  
 
11.6 Reporting Safety Reports to Local Research Ethics Boards  
 
CCTG will notify all Investigators of all Safety Reports (Serious Adverse Events (SAEs) from this 
trial and Safety Up dates (SUs) from other clinical trials) that are reportable to regulatory authorities 
in Canada as reported to the C CTG. This includes all serious events that are unexpected and related 
(i.e. possibly, probably, or definitely) to protocol treatment. Invest igators must notify their 
Research Ethics Boards (REBs) and file the report with their Product Monograph. The date of REB 
Submission for SAEs and SUs will need to be entered into the CCTG trial MA.32  web based safety 
monitoring utility and documentation of  REB submission must be retained in the study binder on 
site. 
 
For this purpose, the REB submission template letter provided by C CTG should be used. Please 
note:  
• this letter must be either printed on institutional letterhead or contain the centre identific ation/REB name;  
• the date of REB submission must be provided;  
• this form must be signed by one of the approved participants (according to the participants list) 
for this trial.  
 
The submission of these events to your ethics board should be done as soon as possible ( we suggest 
within 30 days) . REB submissions greater than 90 days from the date of notification will be 
regarded as delinquent and a major deficiency will be assigned.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 47 CONFIDENTIAL 12.0 PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER  STOPPING  
 
Interruption of Discontinuation of Treatment  
 
Subjects whose treatment is interrupted for any reason except intolerable toxicity will be 
encouraged to resume and continue with their assigned therapy.  
 
Compliance (and reasons for non- compliance) should be noted on the follow -up report. A formal 
pill count will be done for this trial. Patient reported compliance will be employed and unused pills (returned by the patient at each dispensation of a new treat ment kit) will be counted and recorded. 
The visit schedule for those subjects who discontinue therapy should not be modified as endpoints will be assessed for as long as the patient can be followed and an intent -to-treat analysis will be 
performed.  
 
12.1 Criteria for Discontinuing Protocol Treatment  
 
Subjects may stop protocol treatment in the following instances:  
• Intercurrent illness which would, in the judgement of the investigator, affect assessments of 
clinical status to a significant degree, and requir e discontinuation of protocol therapy (Please 
consult protocol section 8).  
• Unacceptable toxicity as defined in Section 8  
• Intercurrent illness (e .g. including diabetes, congestive heart failure) precluding continuation 
of study medication. (Please consult protocol section 8.)  
• Tumour progression or disease recurrence as defined in Section 10.0.  
• Development of a new invasive primary cancer (other than basal cell carcinoma or squamous cell carcinoma of the skin that has been adequately treated)  
• Request by the patient.  
• Completion of therapy as outlined in Section 8.0. Efforts should be made to maintain the 
investigations schedule and continue follow -up, even if subjects discontinue protocol treatment 
prematurely and/or no longer attend the participating institut ion. 
 
12.2 Therapy After Protocol Treatment is Stopped  
 
Patient management following stoppage of protocol treatment is at the discretion of the 
Investigator. Metformin and matching placebo are identical in appearance as are the bottles in 
which they are pr ovided. Blinding is critical to the integrity of this clinical drug trial. However, in 
the event of a medical emergency in an individual subject, in which knowledge of the 
investigational product is critical to the subject's management, the blind for that subject may be 
broken by the treating physician. Before breaking the blind of an individual subject's blinded 
treatment, the Investigator should have determined that the  information is necessary, i.e.  that it will 
alter the subject's immediate management. In many cases, particularly when the emergency is 
clearly not investigational product -related, the problem may be properly managed by assuming that 
the subject is receiving active product without the need for unblinding. The need to break the blind 
must first be discussed with the CCTG. For any treatment code unblinding, the reason and parties 
involved must be documented in the patient’s medical record. Treatment identification information should be kept confidential and should be disseminated only to those  individuals that must be 
informed for medical management of the patient. The C CTG must be notified as soon as possible 
of any emergency situation in which the drug code was broken. See List of Contacts for details.  
 
12.3 Follow -up Off Protocol Treatment  
 
Follow -up will continue after treatment completion according to the plan described in protocol 
section  9. 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 48 CONFIDENTIAL 13.0 CENTRAL REVIEW PROCEDURES AND TISSUE COLLECTION  
 
13.1 Central Pathology Review  
 
There will be no central pathology review for this study.  
 
13.2 Tissue Collection  
 
The collection of a representative block of the diagnostic tumour tissue (if available) and the 
adjacent normal tissue (part of the standard resection) is an important part of this trial. This is 
mandatory for site participation in the study, but the parti cipation of subjects is optional . Blocks 
will be carefully banked as part of the C CTG tissue/tumour bank at Queen’s University in Kingston, 
Ontario. Tumour blocks will be the preferred material to collect, as one of the objectives will be to create tissue micro arrays. These will optimize the amount of tissue available to investigators and 
permit the preservation of the tumour block submitted. If, at any time, the submitting hospital requires the block to be returned for medical or legal concerns, it will b e returned by courier on 
request.  
 
The tissue may be used by researchers now or in the future to better understand the nature of breast cancer and how patients respond to treatment. Samples will be used for research purposes only and 
will not be sold. A sc ientific review process of any proposals to use the tissue will take place and 
any proposals approved will have undergone ethics approval. Patients will not be identified by 
name. The only identification of tissue will be by a patient study number assigned at the time of 
randomization to the trial the surgical/ histology number and/or patient initials. Material issued to 
researchers will be anonymized and only identified by a coded number.  
 
Diagnostic pathology reports are received as part of the supporting documentation required for this 
trial. Receipt of these will initiate a request directly from the Queen’s Department of Pathology to pathology departments for a representative tumour block.  
 
Testing for hereditary genetic defects predisposing to malignant  disease will not be carried out 
without the expressed consent of the subject.  
 
All subjects on whom a diagnostic tumour block is collected will be aware of this retrieval and will 
have given their consent.  
 
13.3 MA.32 Use of Tumour Blocks  
 
As part of the  embedded correlative science for the  MA.32 protocol, the following research is to 
be conducted on submitted tumour blocks:  
 
Insulin Receptor (IR)  
 
Our core analyses will examine IR expression on formalin fixed, paraffin embedded breast cancer 
tissue collected at breast cancer diagnosis. IR is commonly expressed on breast cancer cells 
[Mulligan, 2007] , and is believed to mediate insulin action on brea st tissue; activation of the receptor 
by insulin initiates signaling via the PI3Kinase pathway, leading to proliferation. IR expression is essential for indirect (insulin dependent) metformin effects. Given reports that IGF -1R may 
dimerize with IR in breas t cancer 
[Frasca, 2003]  we will evaluate IGF -1R in secondary analyses.  
 
LKB1  
 
LKB1 expression is key to the ability of metformin to affect AMPK activity within tumors and to suppress the growth- promoting outputs of this signaling pathway (i .e. mTOR -regulated protein 
translation). 
[Lizcano, 2004; Shaw, 2004]  LKB1 expression is essential for direct (insulin independent) 
effects of metformin.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 49 CONFIDENTIAL  AMEND #1: 2011- AUG- 15; AMEND #2: 2012- FEB-20;  
Phosphoantibody Markers of Activation of Key Signaling Pa thways  
 
Expression of IR and LKB1 will be indicative of the capacity of tumor cells to respond to indirect 
(insulin and IR mediated) and direct (insulin independent, LKB1 mediated) effects of metformin 
respectively, however , the expression of these factors  cannot distinguish whether the pathways 
underling these responses are actually activated. Multiple other genetic factors may alter pathway 
activation. As a result, activation markers of these pathways [PI3K (STMN1), PKB/Akt (P -
PKB/Akt,) mTOR (P -4E-BP1) an d IRS -1 (P-IRS-1)] will be evaluated as predictors of metformin 
benefit. If one or more of these biomarkers are activated at breast cancer diagnosis, it is predicted 
that metformin benefit is possible. If none of these pathways is activated, it is predicte d that 
metformin benefit will not be seen, regardless of IR and/or LKB1 expression.  
 
Genomic/Gene Expression Profile Predictive of Metformin Benefit  
 
Large -scale genomic studies over the past two decades have identified numerous recurrent genetic 
events i n breast cancer, such as the amplification of HER2 oncogene or the mutations of the BRCA1 
and BRCA2 tumor suppressor genes, defining specific subgroups of patients and influencing their 
clinical management. More recent studies are focusing on building a comprehensive, genome -wide 
understanding of various types of breast cancer. We plan to use such analyses to search for a genomic/gene expression profile predictive of metformin benefit. In the case of observed 
metformin benefit, we will perform comprehensive  genomic/gene expression analysis of peripheral 
blood and available tumour material. Considering rapid technical advances in the genomic analysis 
arena, at the time of analysis, we will choose the most appropriate methodology to delineate the 
genetic/gene expression predictors of metformin benefit.  
 
13.4 Blood Collection and Analysis  
 
Investigation of a core group of blood variables (at baseline , 6 months after enrolment  and at 48 
months of treatment) and tumor related factors (at diagnosis) that will be e xamined as predictors of 
metformin benefit in this trial is outlined below. We will also collect additional samples that will allow us to examine a broader array of both prognostic and predictive factors in future work. The 
blood collection for fasting glucose and insulin is a mandatory part of the baseline , 6-month  and 48 
months of treatment measurements of MA.32.  
 
After an overnight fast of at least 12 hours, participants will provide the following blood specimens: 1 tube for immediate glucose analysis  (performed according to established institutional practice) , 
light green topped tubes (containing lithium heparin - for plasma), red topped tubes (for serum) and 
lavender topped tube (for DNA). Lavender topped tubes for DNA should be collected eve n for patients 
who consent to blood banking but refuse genetic testing. DNA may be used to study gene expression without fitting the definition of genetic testing. (Please see the MA.32 Sample Consent Form for 
definitions.)  The green topped tubes will be c entrifuged within half an hour of collection and the plasma 
collected frozen immediately in 1  ml aliquots at -80°C. The red topped tubes will sit for 30 minutes at 
room temperature and then be centrifuged and the collected serum frozen immediately in 1  ml aliquots 
at -80°C. Lavender topped tubes (whole blood in EDTA) will be collected and frozen at - 80°C in 1 ml 
aliquots for subsequent thawing and DNA extraction. Specimens will be stored at participating centers 
immediately after collection and then shipped to a central laboratory, frozen on dry ice, in batches  of 10 
sets or more  (1 set = entire blood collection at one patient  visit) , for subsequent storage and ultimate 
analysis. Our plan to collect lymphocytes for DNA at both baseline and 6 months will provi de the 
necessary sample to evaluate not only germline DNA but also potential changes in DNA methylation as a result of the metformin intervention.  
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 50 CONFIDENTIAL 13.5 MA.32 Use of Blood Samples  
 
Insulin (plasma)  
 
Our core analyses will explore the indirect, insulin mediated, effect of metformin as a predictor of 
invasive disease free survival (primarily), overall survival and breast cancer free interval, including 
an evaluation of both baseline fa sting insulin (primarily) , change in insulin over 6 months 
(secondarily)  and at 48 months of treatment . This primary focus on insulin reflects the recognition 
that insulin at diagnosis is a prognostic factor in breast cancer, and it reflects the major impa ct 
metformin has on insulin levels; our primary hypothesis is that higher insulin level at baseline will 
predict metformin benefit in the overall study population. Additionally, in exploratory analyses we 
will examine the relationship between change in ins ulin during the first 6 months of metformin 
administration and invasive disease free survival and overall survival in women randomized to 
metformin (change in insulin is expected to occur primarily in the metformin arm).  
 
Glucose (plasma)  
 Fasting glucose levels have been associated with breast cancer risk in some but not all studies; their 
effect on prognosis is unknown. It is not clear whether the effect on risk is a direct one or whether 
glucose is a surrogate for insulin in these published studies. We plan to examine whether baseline 
glucose predicts metformin benefit independent of insulin or whether glucose modifies effects of insulin as a predictor of metformin benefit. We will also investigate Homeostasis Model 
Assessment (HOMA) 
[Vaccaro O, 2004] , an empirically derived estimate of insulin sensitivity 
calculated from a single measure of fasting insulin and glucose that correlates well with the gold 
standard frequently sampled intravenous glucose tolerance test, as a predictor of metformin benefit, focusing on whether it provides additional prediction beyond insulin alone.  
 
Research Blood Samples Taken at Baseline and Again at 6 Months   
and at 48 Months of Study Treatment  
 
Type of 
Tube  One Tube     (7 ml)  
(1.4 teaspoons)  Light Green Top Tubes  
(3 x 4.5 m l) 
(2.7 teaspoons)  Red Top Tube  
(2 x 6 ml)  
(2.4 teaspoons)  Lavender Top Tube  
(1 x 6 ml)  
(1.2 teaspoons)  
To be 
used for  Plasma for Fasting 
Glucose  
(done locally 
according to 
institution’s 
procedures & 
mandatory)  Insulin 
(done centrally & 
mandatory)  
 
Plasma for storage for 
future research  
(optional)  Serum for storage 
for future research  
(optional)  DNA extraction  
(done centrally & optional)  
Lavender topped tubes for DNA should 
be collected even for patients who 
consent to blood banking but refuse 
genetic testing. DNA may be used to 
study gene expression without fitting 
the definition of genetic testing. (Please 
see the MA.32 Sample Consent Form 
for definitions ). 
TOTAL VOLUME DRAWN = 38.5 ML ( 7.8 Teaspoons, 2.6 Tablespoons)  
 
Please see also Appendix X  and Correlative Sciences Lab Manual posted on the web- site Trial Page .  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 51 CONFIDENTIAL 13.6 Central Data Review  
 
CCTG receives core support from the Canadian Cancer Society. To ensure efficient use of limited 
funding, the CCTG has, over the past 40 years, optimized their risk based trial oversight and 
monitoring program. A critical component is central data review of submitted deidentified  source 
documents, allowing source data verification and confirmation of key aspects including eligibility, 
endpoints and safety outcomes. Depending on the trial’s design, these source  documents may 
include such source documents as surgical and histopathology reports to  confirm disease stage and 
type, imaging reports to confirm extent of disease and assess  efficacy, or include submission of 
tumour samples (to confirm diagnosis and eligibility or  DICOM images (to verify response or 
radiation therapy planning). These source documents are  reviewed by experienced data managers 
and physicians and are crit ical to ensuring the  accuracy of the data and consistency of conclusions 
drawn.  
 
The collection of this critical data involves submission of source documents by mail and/or fax.  
 
See Appendix III (Documentation for Study) for details of supporting document  requirements for 
this trial and for requirements for the redaction of personal identifiers.  Although it remains the 
centres responsibility to ensure adequate redaction of any information provided to CCTG, 
submitted source documents are reviewed prior to a cceptance at CCTG; in  the case of incomplete 
redaction, documents are destroyed and the site assigned a violation and required to resubmit.  
 All patients will provide written informed consent for submission of source documents, and the  
rationale and docume nts to be collected will be detailed in the informed consent document.  
 
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 52 CONFIDENTIAL 14.0 STATISTICAL CONSIDERATIONS  
 
14.1 Objectives and Design  
 
The primary objective of this study is to compare invasive disease -free survival (IDFS) in pre - and 
post-menopausal women with T1- T3, N+/ -, ER/PgR+/ -, HER2 +/ - invasive breast cancer. Eligible 
subjects will be randomized to one of the following two treatment groups: metformin (850 mg po 
bid for 5 years, experiment al arm) or placebo (one caplet po bid for 5 years, control arm). Subjects 
will be stratified by: 1) ER and PgR status (both negative vs. either ER or PgR positive), 2) Body 
Mass Index ( < 30 kg/m2 versus > 30 kg/m2), 3) HER2 (Positive = 3+ over -expression by IHC in > 
30% of invasive tumour cells OR  HER2 gene amplification by FISH/CISH> 6 HER2 gene copies 
per nucleus, OR  a FISH/CISH ratio: HER2 gene copies to chromosome 17 signals of >  2.2. All 
other results will be considered negative.) and 4) Chemotherapy a dministration (any versus none ). 
We will also compare overall survival, distant relapse free survival, breast cancer free survival, 
breast cancer specific mortality, incidence of contralateral invasive breast cancer,  health -related 
quality of life, body ma ss index between metformin and placebo arm. The intent -to-treat (ITT) 
population will comprise all randomized patients, will be based on the allocated treatment 
regardless of whether the patient received the assigned treatment, and will be based on the at -
randomization values of the stratification factors. The adverse events in the two different treatment 
groups will also be compared. The embedded correlative science studies are described in Section 
13 of this protocol.  
 
A minimization procedure [White,1978]  will be used to allocate patients with equal probabilities to 
one of the two treatment groups.  
 Based on recommendation from DSMC after the second interim analysis, only the study subjects 
with ER/PgR+ will be included as the primary analysis in the fina l analysis.  
 
14.2 Primary Endpoints and Analysis  
 The primary endpoint of this study is invasive disease -free survival. It is defined as the time from 
randomization to the time of documented ipsilateral and contralateral invasive breast tumour, 
local/regional invasive recurrence, distant recurrence, death from breast cancer, death from non -
breast cause, death from unknown cause, second primary invasive cancer (non- breast, except for 
adequately treated BCC or SCC of the skin). If a subject has not  had invasive disease or died at the 
time of data cut- off for final analysis  of the primary endpoint , IDFS will be censored on the date of 
last follow -up. The survival experiences of subjects in both treatment arms will be described by the 
Kaplan -Meier met hod. Stratified two -sided log -rank tests adjusting for stratification factors as 
defined in the protocol will be the primary method to compare IDFS between metformin and placebo arm. As an exploratory analysis, a Cox proportional hazards model will be use d to identify 
and adjust for factors significantly related to invasive disease -free survival.  
 All subjects will be evaluated for toxicity from the time of their first oral dose of study medication. 
Toxicities will be graded using the current CTCAE version (as per protocol Appendix V). The incidence of toxicities by arm will be summarized by type of adverse event. A F isher’s Exact Test 
will be use d to compare toxicities between two arms.  
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 53 CONFIDENTIAL 14.3 Sample Size and Dur ation of Study  
 
The sample size for this study is calculated in order to compare invasive disease -free survival 
(IDFS) between subjects randomized to receive metformin versus placebo. At the time of study 
initiation, the 5 year IDFS for subjects allocated to the placebo a rm was estimated to be 85.0%, 
based on a population of pre - and post -menopausal women with T1- T3, N+/ -, ER/PgR +/ -, HER2 
+/- invasive breast cancer. With an overall two -sided alpha of 0.05 a total of 431 events were 
required to provide 80% power to detect a hazard ratio (HR) of 0.76 between the two treatment 
arms after taking into account two planned interim analyses. This HR was selected because it was 
the HR seen in the WINS study of dietary fat reduction/weight loss in the adjuvant breast cancer 
setting , described in protocol Section 2.  
 
Analysis of compliance for the first 241 patients was performed. The drug discontinuation rate at 
6 months in MA.32 is 8.3% in the first 241 subjects; an additional 1.7% discontinuation was seen 
beyond 6 months (total 10 %). Rates are likely higher on the metformin (vs placebo) arm because 
most discontinuations were due to Gl toxicity. Although MA.32 is a pragmatic study, and thus will assess effectiveness that includes non-  compliance, we believe these drug discontinuation rates are 
higher than will be seen in future clinical practice (due to investigator inexperience with metformin 
and patient reluctance to continue a drug with side effects in the absence of documented benefit) 
and thus a more conservative HR should be ta rgeted for this study. The issue of drug non-
compliance was discussed by the Trial Committee in December 2011 and the option of enrolling a 
higher risk population to target a more conservative HR was endorsed. This would be achieved by 
restricting enrolmen t of subjects with T1cN0 tumours to those with ER/PR and HER2 negative 
(triple negative) status and requiring the presence of at least  one adverse prognostic factor for T2N0 
tumours (i.e. at least one of: ER and PgR negative, HER2 positive, histologic grade 3, Ki67 > 14%, 
Oncotype Recurrence Score >  25 or lymphovascular invasion). The changes in eligibility criteria 
would increase the IDFS event rate for entire study population from an estimated 15% to 19%. The resulting higher event rate (554 events ) would  allow detection of a HR 0.785 given our current 
sample size of 3582 assuming 3 years of accrual and an additional 3 years of follow -up, with an 
overall two -sided alpha of 0.05 and 80% power after taking into account two interim analyses (see 
Section 14.5 for details). This is the HR one obtains when we adjust our original HR of 0.76 for a 
10% drug discontinuation rate. The HR of 0.785 represents an absolute improvement of 3.7% in 5 
year IDFS from 81% to 84.7% for those allocated to metformin. The total dur ation of the trial 
would be six years.  
 
Based on the recommendation of DSMC after the second interim analysis, the final analysis will 
include only study subjects who were ER/PgR+ and be performed when 554 events are observed 
from these subjects. Because of the alpha spending during the first two interim analyses, the 
nominal two -sided significant level for the final analysis will be 0.037. With 554 events in the final 
analysis, there will be 78% power to detect the hazard ratio of 0.785 at two- sided 3.7% level or 
80% power to detect a hazard ratio of 0.78. It is expected that additional 4 years of follow -up from 
November 2015 would be required to observe the required number of events.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 54 CONFIDENTIAL 2021 Update  
As of October 31, 2020, the event number for the IDFS endpoint was 446 and an additional 40 
months is estimated to reach the target number of events (554) based on the current event rate. 
Analysis of data based on 446 events is associated with 68% power (reduced 10% from 78%) to 
detect a target HR of 0.785 at two -sided 0.037 level or 80% power to detect a hazard ratio of 0.757. 
The HR of 0.757 represents an absolute improvement of 3.8% in 5 year IDFS from 83.0% to 86.8% 
for ER/PgR+ patients  allocated to metformin and approximates the target HR proposed in the 
overall population at the time of study initiation.  
 Given the estimated retention of power to detect the target HR using a time based analysis with a 
last contact date of October 31 2020 compared to the additional time and resources to reach 554 events to trigger the final analysis of the primary endpoint the study design  will be amended to 
incorporate a time based analysis. The critical p value for the final analysis will be 0.037 to account 
for the prior interim analyses. As of October 31, 2020, the median followup for the patients in the 
hormone receptor positive study population is estimated to be 95 months. The change in study design has been endorsed by an independent statistician.  
 In addition to the time based analysis described above, the protocol will be amended to include two 
new secondary endpoints that provi de additional information regarding the anticancer and cancer 
prevention impact of metformin by measurement of breast cancer specific mortality and incidence 
of contralateral invasive breast cancer respectively.  
 
14.4 Safety Monitoring 
 
Adverse events will be monitored on an ongoing basis by the central office and their frequencies reported annually at investigators' meetings.  
 
14.5 Interim Analysis  
 
Two interim analyses are planned for this study when 185  and 370 events are observed, to allow 
early termination of the study if the results are extreme. Lan -DeMets error spending function will 
be used to assess for superiority, and futility for superiority [Lan 1983] . The early stopping 
boundaries are based on a pow er family with power 3, which approximates the O’Brien -Flemming 
boundaries [Jennison 2000] . The actual p -values for superiority and futility will be calculated based 
on the number of events observed at the time of interim analysis, controlling the two- sided Type I 
error of 0.05 and the power of 80% at the end of the study.  
 If exactly 1 85 events are observed for the first interim analysis, the null hypothesis would be 
rejected early due to evidence of superiority at the first interim analysis if the p -value is less than 
or equal to 0.00185. The alternative hypothesis would be rejected for futility if the p -value is at 
least 0.971. If exactly 370events are observed for the second interim analysis, the nominal critical p-values for rejecting the null hypothesis and the alternative hypothesis would be 0.0138 and 0.468, 
respectively. The nomina l significant level for the final analysis of the primary endpoint is 0.0463 
when 554events are observed, to maintain the overall two- sided alpha of 0.05.  
 Results of the interim analysis will be supplied to DSMC who will make their recommendation regardin g continuation of the trial.  
 No additional interim analysis will be performed.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 55 CONFIDENTIAL 2021 update:  
After the second interim analysis and the change of the study population to the hormone positive 
patients, no additional interim analysis is planned and the critical p -value for the final analysis will 
be 0.037 as described in Section 14.3.  
 
14.6 Quality O f Life Analysis  
 
The EORTC QLQ -30 Global Score will be used for our primary assessment of quality of life but 
subscales and specific symptoms (diarrhea, bloating, flatulence, dyspepsia, abdominal cramps, 
nausea and vomiting, taste alteration, limitation of  activities because of gastrointestinal symptoms, 
joint/musculoskeletal symptoms) will be used for our secondary hypothesis.  
 Since QOL is not part of the primary outcome, we will measure QOL on a proportion of 
participants. We want to detect a small to medium effect size of ~0.3 in either the primary 
assessment or the 10 subscales (diarrhea, bloating, flatulence, dyspepsia, abdominal cramps, 
nausea, vomiting, metallic taste, limitation of activities by gastrointestinal symptoms, 
joint/musculoskeletal symp toms) of quality of life in the overall quality of life sub -study 
population. We also want to detect an effect size of 0.5 for these outcomes in each of the sub- study 
groups defined by adjuvant endocrine therapy use at the time of randomization (tamoxifen,  
aromatase inhibitor, no endocrine therapy). With significance at the 5% level and 80% power, we 
will need a total of 296 subjects (148/arm) in each of the 3 hormone therapy defined groups (888 or 444/arm in the full HRQOL sub- study) to detect an effect si ze of 0.5 in each hormonal group; 
this sample size will allow us to detect an effect size of 0.289 for the entire HRQOL sub -study 
population. (Although subjects in the Quality of Life sub- group will not be stratified by endocrine 
therapy use, it is expecte d that, given the diversity inherent in the enrolment process, these three 
groups of subjects will be more or less evenly balanced between the metformin and placebo 
groups.) These estimates have taken into account expected dropouts (10%) and non- completion  
rates (20%). we have applied the Bonferroni correction to account for the multiplicity problem.  
 
 
It is anticipated that approximately 90% of the Quality of Life participants  will also contribute 
Physical Activity and Diet Data yielding a sample size of about 800 subjects and an 80% power to detect an effect size of 0.304 for either the primary assessment or the 10 subscales.  
 
The EORTC QLQ -C30 and the Trial Specific Checklist will be mandatory prior to randomization, 
at 6 months  and then annually in subjects participating in the HRQOL portion of the study. Scoring 
of questionnaires will be conducted by the central office of CCTG according to the scoring manual 
of the EORTC QLQ -C30. The Trial Specific Checklist ite ms will be score d individually.  
 
Analyses of HRQOL data will be conducted and presented according to the standard approach of 
the CCTG. The levels of fatigue and overall QoL will be evaluated according to diet and physical 
activity in the metformin and placebo groups in the subset of QoL participants with diet and 
physical activity assessment.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 56 CONFIDENTIAL 15.0 PUBLICATION POLICY  
 
15.1 Authorship of Papers, Meeting Abstracts, Etc  
 
15.1.1  The results of this study will be published. Prior to trial activation, the chair will decide whether to 
publish the trial under a group title, or with naming of individual authors. If the latter approach is 
taken, the following rules will apply:  
• The first author will generally be the chair of the study.  
• A limited number of the members of the Canadian Cancer  Trials Group and may be credited 
as authors depending upon their level of involvement in the study.  
• Additional authors, up to a maximum of 15, will be those who have made the most significant 
contribution to the  overall success of the study. This contribution will be assessed, in part but 
not entirely, in terms of patients enrolled and will be reviewed at the end of the trial by the 
study chair.  
• In the event of a separate paper dealing with the quality of life outcomes, the first author will 
generally be the Quality of Life Coordinator on the trial committee.  
 
15.1.2  In an appropriate footnote, or at the end of the article, the following statement will be made:  
 
"A study coordinated by the Canadian Cancer Trials G roup. Participating 
investigators included: (a  list of the individuals who have contributed 
patients and their institutions)."  
 
15.2 Responsibility for Publication  
 It will be the responsibility of the study chair to write up the results of the study within a reasonable 
time of its completion. If after a period of six months following the analysis of study results the 
draft is not substantially complete, the central office reserves the right to make other arrangements 
to ensure timely publication.  
 
15.3 Submission of Material for Presentation or Publication  
 
Any manuscripts reporting the results of this clinical trial should be provided to CTEP for 
immediate delivery to Collaborator(s) for advisory review and comment prior to submission for 
publication. C ollaborator(s) will have 30 days from the date of receipt for review. Collaborator 
shall have the right to request that publication be delayed for up to an additional 30 days in order 
to ensure that Collaborator’s confidential and proprietary data, in addi tion to Collaborator(s)’s 
intellectual property rights, are protected. Copies of abstracts should be provided to CTEP for 
forwarding to Collaborator(s) for courtesy review as soon as possible and preferably at least three 
(3) days prior to submission, but in any case, prior to presentation at the meeting or publication in 
the proceedings. Press releases and other media presentations must also be forwarded to CTEP 
prior to release.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 57 CONFIDENTIAL 16.0 ETHICAL, REGULATORY AND ADMINISTRATIVE ISSUES  
 
(This section applies to Canadian Sites only; CTSU sites please refer to the CTSU Logistical 
Appendix. ICR -CTSU  sites please refer to the ICR - CTSU -specific Appendix. IBCSG sites please 
refer to the IBCSG -specific Appendix. ) 
 
16.1 Institution Eligibility for Participation  
 Selected member centres in good standing of the CCTG are eligible to participate in this study.  
Any centre joining the C CTG is required to sign a Participating Centre Study Agreement and have 
Standard Operating Procedures regarding the conduct of clinical trials.  
 
The CCTG will submit via fax to Health Canada for each participating Canadian centre prior to 
local activation a completed Health Canada Clinical Trial Site Informa tion Form.  
 
Because this trial is affected by U.S. legislation, U.S. federal regulations for the protection of 
human subjects apply. Canadian and U.S. institution s must have a Federalwide Assurance (FWA) 
number issued by the Office for Human Research Prote ctions (OHRP) of the Department of Health 
and Human Services. By means of this assurance, the institution and its REB agree to abide by U.S. standards regarding, for example, constitution of the REB.  
 
16.2 Investigator Qualifications  
 
For all investigators (principal investigators and co- investigators) the following documentation 
must be on file with the C CTG:  
• A current curriculum vitae, updated and submitted within two years at the time of 
randomization . 
• Documentation indicating comple tion of training in the protection of human research 
participants (e.g. NCI U.S. Completion Certificate).  
• Completion of the required C CTG GCP training module s. 
• A current NCI U.S. investigator number. An NCI U.S. investigator number is obtained by 
completin g and signing a FDA 1572 form, a Supplemental Investigator Data Form, and a 
Financial Disclosure Form. These forms and a current CV are submitted to the NCI U.S. by the 
investigator.  
 
For the principal investigator only:  
• A Health Canada Qualified Investiga tor Undertaking Form must be completed and signed by 
the principal investigator of the study at participating Canadian centres and received by the 
CCTG central office before that centre can be locally activated.  
 
16.3 REB (Research Ethics Board) Approval f or Protocols  
 
Each participating centre will have on file with the C CTG central office, as part of its membership/ 
agreement documents, a description of its ethics review process and composition of its REB.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 58 CONFIDENTIAL REB Composition 
Membership of an REB approving this protocol must be consistent with Canadian regulatory 
requirements, summarized as follows:  
• at least 5 members;  
• majority of members are Canadian citizens or permanent residents;  
• includes 2 members whose primary expertise and experience are in a scientific discipline with 
broad experience in the methods and areas of research to be approved (1 of these is from a 
medical discipline);  
• includes 1 member knowledgeable in ethics;  
• includes 1 member knowledgeable in Canadian laws relevant to the biomedical research to be approved;  
• includes 1 member whose primary experience and expertise are in a non -scientific discipline;  
• includes 1 member who is from the community or is a representative of an organiz ation 
interested in the areas of research to be approved and who is not affiliated with the CCTG or 
the centre where the clinical trial is to be conducted.  
 
A Health Canada REB Attestation Form must be completed and signed by the REB representative. 
Altern atively, an attestation to the following may be included in the signed local ethics approval 
document:  
• The membership of the Research Ethics Board complies with the membership requirements for Research Ethics Boards defined in Division 5 of the Food and Dr ug Regulations;  
• The Research Ethics Board carries out its functions in a manner consistent with Good Clinical 
Practice; and  
• The Research Ethics Board has reviewed and approved the clinical trial protocol and informed 
consent for the trial which is to be conducted by the qualified investigator named at the 
specified clinical trial site. This approval and the views of this Research Ethics Board have 
been documented in writing.  
 
This documentation must be received by the CCTG central office before the centre c an be locally 
activated.  
 
Initial Approval  
Member centres wishing to participate in a trial are required to obtain full board local ethics approval of the protocol and consent form (see below) by the appropriate REB.  
 
Annual Re -Approvals  
This trial is NCI  US affiliated and therefore U.S. regulations regarding the Protection of Human 
Subjects apply (U.S. Code of Federal Regulations Title 45, Part 46). These regulations require that 
re-approvals of research be conducted at least once per year for as long as data are being submitted 
on trial patients, even through the follow -up period. Furthermore, these regulations require that 
annual re -approvals must be full board as long as the study is open to accrual or patients are 
receiving protocol treatment or undergoing protocol mandated interventions.  
 
Amendments/ Administrative Updates  
All amendments or administrative updates to the protocol must undergo review by local REBs. 
Amendments/administrative updates will be circulated to all participating sites in a standard format 
with clear instructions regarding REB review. If full board approval of an amendment is required 
it will be specified.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 59 CONFIDENTIAL Amendments will be reviewed and approved by Health Canada prior to  central implementation of 
the amendment, and by REBs prior to  local implementation, EXCEPT when the amendment 
eliminates an immediate hazard to clinical trial subjects. Amendments will be distributed with 
Health Canada REB attestation forms which must be completed. For each amendment C CTG will 
collect documentation of REB approval, a completed REB attestation form . 
 
REB Refusals  
If an REB refuses to approve this protocol (or an amendment/ administrative update to this protocol) 
the CCTG must be notified immediately of the date of refusal and the reason(s) for the refusal. 
Notification will then be made to Health Canada.  
 
Serious Adverse Events, Safety Updates , Investigator Brochure Updates  and Product Monograph 
Updates  
During the course of the study serious adverse events, safety updates , investigator brochure updates 
or product monographs may be sent to you for reporting to your REB. The date of REB submission 
for these documents will need  to be entered into the MA.32  web based safety monitoring utility 
and documentation of REB submission must be retained in the study binder on site.   
 
16.4 Informed Consent  
 
Informed Consent Document  
The REB of an institution must approve the consent form document which will be used at that 
centre prior to its local activation; changes to the consent form in the course of the study will also 
require REB approval.  
 It is essential that the consent form contain a clear statement which gives permission for 1) 
information to be sent to and 2) source medical records to be reviewed by the C CTG and other 
agencies as necessary. The consent form must include all ICH -GCP consent elements. In addition, 
the consent form should include all elements required by CCTG  policy , and centres receiving funding 
from NCEHR, SSHRC and/or CIHR should include elements from the  Tri Council Policy Statement 
(TCPS) . 
 Informed consent forms that do not contain all ICH-GCP required elements will require an 
amendment and will lead to the delay of local activation.  A complete list of the elements required 
by regulations, guidelines and C CTG policy can be found by accessing the C CTG website at 
http://www.ctg.queensu.ca/private/ethics/consent_RE_Checklists.html.  
 
Because this study is NCI U.S. affiliated, U.S. regulations regarding consent form content also apply.  
 
The sample consent form provided in the protocol includes all the required elements, as well as the 
"additional" and "suggested" elements relevant to this study. REBs must consider the sample 
consent as the basis for review, as this form has been approved by the U.S. Na tional Institutes of 
Health. Significant changes of wording or deletions of the adverse event or alternative therapy 
sections of the sample consent must be justified by the REB in writing; note however that additions 
to these sections are rarely a problem.  
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 60 CONFIDENTIAL Consent Process/Patient Eligibility  
Patients who cannot give informed consent (i.e. mentally incompetent patients, or those physically 
incapacitated such as comatose patients) are not to be recruited into the study. Patients competent 
but physically unable to sign the consent form may have the document signed by their nearest 
relative or legal guardian. Each patient will be provided with a full explanation of the study before 
consent is requested.  
 
16.4.1  Obtaining Consent for Pregnancy/Exposure Reporting  
 
Information from and/or about the subject (i.e. the pregnant female, the newborn infant, male 
partner, exposed individual) should not be collected about or from them unless or until they are a 
willing participant in the research. The rights and protections  offered to participants in research 
apply and consent must be obtained prior to collecting any information about or from them. If the main consent form adequately addresses the collection of information regarding the outcome of a 
pregnancy of a trial part icipant, a “Pregnancy Follow -up” consent form will not be required by 
CCTG.  
 
Trial -specific consent forms for “Pregnancy Follow -up” and “Exposure Follow -up” can be found 
on the trial webpage.  The appropriate consent form must be used to obtain consent from any non-
trial participant (such as the pregnant partner or exposed individual).   
 Participants will not be withdrawn from the main trial as a result of refusing or withdrawing 
permission to provide information related to the pregnancy/exposure. Similarly, male participants 
will not be withdrawn from the main study should their partner refuse/withdraw permission.  
 
Obtaining Consent for Research on Children  
In the case of collecting information about a child (i.e. the child resulting from a pregnant 
participant/partner or an exposed child), consent must be obtained from the parent/legal guardian.  
 
For reporting an exposure, the parent/guardian is required to  sign an “exposure follow -up” consent 
form (even if they are a participant in the main study) prior to collecting information about the 
child.  
 
16.5 Retention of Patient Records and Study Files  
 ICH Good Clinical Practice guidelines apply  to CCTG studies . It is the responsibility of C CTG to 
inform the investigator/institution as to when trial related records no longer need to be retained. 
The investigator/institution should take measures to prevent accidental or premature destruction of 
these documents.  
 CCTG will notify all the trial investigators/institutions and all the regulatory authorities if clinical 
development of an investigational product discontinues or when trial related records no longer need 
to be retained.  
 
16.6 Centre Performance Monitoring  
 This study is eligible for inclusion in the Centre Performance Index (CPI). Reports are to be 
submitted according to the schedule in Appendix IV (Documentation for Study).  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 61 CONFIDENTIAL 16.7 On-Site Monitoring/Auditing  
 
CCTG site monitoring/auditing will be conducted at participating centres in the course of the study 
as part of the overall quality assurance programme. The monitors/auditors will require access to 
patient medical records to verify the data, as well as essential docu ments, standard operating 
procedures (including electronic information), ethics and pharmacy documentation (as applicable)  
 
As this trial is conducted under a CTA with Health Canada, your site may be subject to an inspection by the Health Canada Inspectora te. In addition, as this trial is NCI US affiliated, findings 
will be reported to the NCI US Clinical Trials Monitoring Branch as required.  
 The above mentioned documentation, in addition to any submitted source documents, may be 
accessed remotely in the event of a public health emergency either through remote access to 
Electronic Medical Records or through a secure file sharing portal.  
 
16.8 Case Report Forms  
 
A list of reports  to be submitted, as well as expectation dates, are to be found in Appendix IV  – 
DOCUMENTATION FOR STUDY.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 62 CONFIDENTIAL 17.0 REFERENCES  
Aaronson NK, Ahmedzai S, Bergman B, et. al. The European Organization for Research and Treatment of Cancer 
QLQ- C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer  Inst 85:365-
376, 1993. 
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, 
colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909- 915. PMID 19221498 
Anisimov VN, Berstei n LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina 
TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER -2/neu transgenic mice. Exp Gerontol 2005; 40:685- 693. PMID: 16125352 
Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon y Cajal S. 4E -binding protein 
1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Research 2007; 67:7551- 7555. 
PMID: 17699757  
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772- 775. PMID: 15254419 
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensiti vity. 
Fertil Steril 2004; 82:893 -902. PMID: 15482765 
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131- 2139. PMID: 12090977  
Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF. Glycolytic glioma cells with active glycogen s ynthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Laboratory Investigation; 
a Journal of Technical Methods and Pathology 2005; 85:1457- 1470. PMID: 16170333 
Bloomgarden ZT. Insulin resistance, dyslipidemia, and cardiovascular disease . Diabetes Care 2007; 30:2164- 2170. 
PMID: 17855278  
Borugian MJ, Sheps SB, Kim -Sing C, Olivotto IA, Van Patten C, Dunn BP, Coldman AJ, Potter JD, Gallagher RP, 
Hislop TG. Waist -to-hip ratio and breast cancer mortality. Am J Epidemiol 2003; 158:963- 968. PMID : 14607804  
Bott U, Muhlhauser I, Overmann H, et al: Validation of a diabetes -specific quality- of-life scale for patients with type 
1 diabetes. Diabetes Care 1998;21:757- 769. PMID: 9589237 
Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer -related mortality for patients with type 2 
diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254- 258. PMID: 16443869 
Bradley C, Gamsu DS: Guidelines for encouraging psychological well- being: Report of a working group of the world 
health organization regional office for europe and international diabetes federation european region st vincent declaration action programme for diabetes. Diabet Med 1994; 11:510 -516. PMID: 8088133 
Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 
21:1659- 63. PMID: 9773726 
Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. The glucose dependence of Akt -transformed cells can be reversed by pharmacologic activation of fatty acid beta -oxidation. 
Oncogene 2005; 24:4165- 4173. PMID: 15806154  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 63 CONFIDENTIAL Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment 
with the antidiabetic drug metformin selectively impairs p53- deficient tumor cell growth. Cancer Research 2007; 
67:6745- 6752. PMID: 17638885 
Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive activation of insulin receptor substrate 1 is a frequent even t in human tumors: therapeutic implications. Cancer Res 2002; 62:6035- 6038. PMID: 12414625 
Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group: The synergistic effect of miglitol plus metformin combination therapy in the treatment of ty pe 2 diabetes. Diabetes Care 2001; 24:989- 994. PMID: 11375358 
Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128- 1143. PMID: 11844838 
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM. Dietary fat reduction and breast cancer outcome: inter im efficacy 
results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006; 98:1767- 1776. PMID: 17179478  
Cocca C, Gutierrez A, Nunez M, Croci M, Martin G, Cricco G, Rivera E, Bergoc R. Suppression of mammary gland tumorigenesis in diabetic rats. Cancer Detect Prev 2003; 27:37 -46. PMID: 12600416 
Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research network Epidemiology Group. Diabetologica 2009: 52: 1755- 1765  
Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz -Jeghers syndrome. Genes & Development 2004; 
18:1533- 1538. PMID: 15231735 
Costello M, Shrestha B, Eden J, et al: Insulin- sensitising drugs versus the combined oral contraceptive pill for 
hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; 1:CD005552. PMID: 17253562 
Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin- like growth 
factor -I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 
2008; 26;4078- 4085. PMID: 18757322  
Currie CJ, Poole CD, Gale EAM. The influence of glucose -lowering therapies on cancer risk in type 2 diabetes. 
Diabetologica 2009; 52 1766 -1777  
Cusi K, DeFronzo RA. Metformin: A review of its metabolic effects. Diabetes Reviews 1998; 6:89 -131. 
DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non- insulin- dependent diabetes mellitus. the 
multicenter metformin study group. N Engl J Med 1995; 333:541- 549. PMID: 7623902  
Del Giudice ME, Fantus IG, Ezzat S, McKeown -Eyssen G, Pa ge D, Goodwin PJ. Insulin and related factors in 
premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47:111- 120. PMID: 9497099  
El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. (2000). Dimethylbiguanide inhibits cell 
respirati on via an indirect effect targeted on the respiratory chain complex I. The Journal of Biological Chemistry 
2000; 275:223- 228. PMID: 10617608  
Evans JM, Donnelly LA, Emslie -Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic 
patients. BMJ 2005; 330:1304- 1305. PMID: 15849206  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 64 CONFIDENTIAL Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer  Trial. J Clin Oncol 2004; 22:4261-
4271. PMID: 15514369  
Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of 
tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006; 24:910- 917. PMID: 16484701 
Fantus GI. Metformin’s contraindications: needed for now. CMAJ 2005;173.505- 507. PMID: 16129872  
Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators of breast 
cancer cells. Breast Dis 2003; 17:73 -89. PMID: 15687679 
Frittitta L, Cerrato A, Sacco MG, Weidner N, Goldfine ID, Vigneri R. The insulin receptor content is increased i n 
breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat 1997; 45:141 -147. 
PMID: 9342439  
Gennari A, Sormani M, Pronzato P, Bruzzi P, Ferrannini E, Iozzo M, Roncella M, Ghilli M, Mirisola V, Pfeffer U. Association between expression of insulin resistance (IR) related genes and breast cancer outcome. Journal of Clinical 
Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No.18S (June 20 Supplement), 2007: 589.  
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall 
LM, Morrow M. Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis – A Randomized Clinical Trial. JAMA 2011; 305 (6), 569 - 575 
Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin- diet benefits in women with polycystic 
ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005; 54:113- 121. PMID: 
15562389 
Goodwin PJ, Ennis M, Bahl M, Fantus  IG, Pritchard KI, Trudeau ME, Koo J, Hood N. Evidence for insulin resistance 
in a cohort of newly diagnosed breast cancer patients. Breast Cancer Res Treat 2009;114:517- 525. PMID: 18437560 
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42- 51. 
PMID: 11773152  
Goodwin PJ, Esplen MJ, Winocur J, Butler K, Pritchard KI. Development of a weight ma nagement program in women 
with newly diagnosed locoregional breast cancer. In: Bitzer J. and Stauber M. eds. International Society of Psychosomatic Obstetrics and Gynaecology: Psychosomatic Obstetrics and Gynecology. Italy: Monduzzi Editore, International Proceedings 1995: 491- 496 
Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin- lowering effect of metformin in 
women with early breast cancer. Clin Breast Cancer, 2008; 8: 501 -505 PMID: 19073504 
Goodwin PJ. Energy balance and prognosi s: Breast Cancer. In: Cancer Prevention and Management Through Exercise 
and Weight Control, Ed. McTiernan, A., Taylor and Francis Group, 2006, p405- 435. 
Grant PJ: The effects of high - and medium -dose metformin therapy on cardiovascular risk factors in pati ents with type 
II diabetes. Diabetes Care 1996; 19:64 -66. PMID: 8720537 
Hadad SM, Appleyard V, Thompson AM. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ER negative MDA -MB-435 breast cancer model. Breast Cancer Res Treat 2 009; 114:391 PMID: 
18421577 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 65 CONFIDENTIAL Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller -Holzner E, Daxenbichler G, March C, Doppler W. Favorable 
prognostic value of SOCS2 and IGF -I in breast cancer. BMC Cancer 2007; 7:136. PMID: 17651480 
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve s, Fitzgibbons PL, Francis G, Goldstein NS, 
Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller, K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, T aube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, 
Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunological Testing of Estrogen and Progesterone  Receptors in Breast Cancer 
JCO 2010; 28 (16): 2784- 2795  
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin- like growth factor -I and risk of breast cancer. Lancet 1998; 351:1393- 1396. 
PMID: 9593409  
Hardie DG. AMP -activated/S NF1 protein kinases: conserved guardians of cellular energy. Nature Reviews 2007; 
8:774- 785. PMID: 17712357 
Hemkens, LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin analogues: a cohort study, Diabetologica 2009; 52: 1732- 1734  
Hoffmann J, Spengler M: Efficacy of 24- week monotherapy with acarbose, metformin, or placebo in dietary- treated 
NIDDM patients: The Essen -II Study. Am J Med 1997; 103:483 -490. PMID: 9428831 
Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, Evans BD. Serum insulin -like growth 
factor -I and insulin- like growth factor binding protein- 3 following chemotherapy for advanced breast cancer. ANZ J 
Surg 2003; 73:905- 908. PMID: 14616567 
Holmes M, Chen W, Feskanich D et al,: Physical acyivity and survival after breast cancer diagnosis Journal of the American medical association 2005; 293:2479- 2486  
Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in s tudies using insulin 
glargine. Diabetologica e pub 2009  
Horton ES, Clinkingbeard C, Gatlin M, et al: Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660- 1665. PMID: 11092289  
Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR. Important role of the LKB1- AMPK pathway in suppressing tumorigenesis in PTEN -deficient mice. Biochem J 2008; 
412: 211- 221. PM ID: 18387000 
Hudis, CA, Barlow, WE, Constantino, JP et al Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System JCO 25 (15) 2007 p. 2127- 2132  
Ibrahim YH, Yee D. Insulin- like growth factor -I and bre ast cancer therapy. Clin Cancer Res 2005; 11(2 Pt 2):944s -
950s. PMID: 15701891 
Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 
115:577- 590. PMID: 14651849 
Irwin ML, Varma K, Alvarez -Reeves M, Cadmus L, Wiley A, Chung GG, Dipietro L, Mayne ST, Yu H. Randomized 
controlled trial of aerobic exercise on insulin and insulin- like growth factors in breast cancer survivors: the Yale 
Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev, 2009; 18:306- 313 PMID: 19124513 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 66 CONFIDENTIAL Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac -Dumanovic M, Starcevic V, Micic D, Trajkovic V. Dual 
antiglioma action of metformin: cell cycle arrest and mitochondria -dependent apoptosis. Cell Mol Life Sci 2007; 
64:1290- 1302. PMID: 17447005 
Ish-Shalom D, Cristoffersen CT, Vorwerk P, Sacerdoti -Sierra N, Shymko RM, Naor D, DeMeyts P. Mitogenic 
properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40:S25- S31. PMID: 
9248698 
Jennison C, Turnbull BW. Group sequential methods with application to clinical trials. Chapman and Hill, New York, 
NY, 2000  
Jiralerspong S, Palla SL, Giordano SH, Meric -Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi 
GN, Gonzalez -Angulo AM. Metformin and pathologic comple te responses to neoadjuvant chemotherapy in diabetic 
patients with breast cancer. J Clin Oncol 2009; 27:3297- 302. PMID: 19487376 
Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir G, Steineck G. Insulin glargine use short -term 
incidence of maligna ncies – a population based follow -up study in Sweden. Diabetologica 2009; 52: 1745- 1754  
Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326:4- 5. PMID: 
12511434 Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 237:25- 33 PMID: 12093242 
Knowler WC, Barrett -Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention 
Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New  Engl J Med 2002; 
346:393- 403. PMID: 11832527 
Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G. Role of metformin accumulation in 
metformin -associated lactic acidosis. Diabetes Care 1995; 18:779- 84. PMID: 7555503 
Lan KK, DeMets DL. Disc rete sequential boundaries for clinical trials. Biometrika 1983;70: 659 -663 
Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24:1477- 1480. PMID: 
15608678 
Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast 
Cancer Res Treat 2006; 96:91- 95. PMID: 16317585 
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM . New users of metformin are at low risk of 
incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009 Jun 29 [epub ahead of print]. PMID: 19564453  
Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J Hawley SA, Udd L, Makela TP, Hardie DG, Alessi DR. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR -1. The 
EMBO Journal 2004; 23: 833 -843. PMID: 14976552 
Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a mixed strength and endurance exercise intervention program on insulin levels in breast cancer survivors. J Clin 
Oncol 2008; 26:907- 912. PMID 18281663  
Liu KE, Tataryn IV, Sagle M. Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. J Obstet Gynaecol Can 2006; 28:595- 599. PMID: 16916482  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 67 CONFIDENTIAL Liu KE, Tataryn IV, Sagle M. Use of metformin for ovulation induction in women who have polycystic ovary 
syndrome with or without evidence of insulin resistance. J Obstet Gynaecol Can 2006; 28:595- 599. PMID: 16916482  
Lizcano JM, Göransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG, Alessi DR. LKB1 is a master kinase that act ivates 13 kinases of the AMPK subfamily, including MARK/PAR -1. The 
EMBO Journal 2004; 23:833 -843. PMID: 14976552 
Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends in Biochemical Sciences 2003; 28:573-576. PMID: 14607085  
Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37:1344 -1350. PMID: 11300445 
McCormack J, Johns K, Tildesley H. Metformin’s contraindications should be contraindicated. CMAJ 2005; 173:502-504. PMID: 16129871  
Meyerhardt J, Giovannucci E, Holmes M et al Physical Activity and Survival after Colorectal Cancer Diagnosis Journal of Clinical Oncology, 2006 24: 3527- 3534  
Meyerhardt J, Heselstine D, Niedzweicki D, et al.: Impact of Physical Activity o n Cancer Recurrence and Survival in 
Patients with Stage III Colon Cancer: Findings from CALGB 89803, Journal of Clinical Oncology, 2006; 22: 3535-3541 
Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. ASPB10 insulin induction of increased mitogenic res ponses 
and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin- like 
growth factor -I receptor. Mol Carcinog 1997; 18:19- 25. PMID: 9022809 
Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case- control study. Acta 
Diabetol 2008 Dec 10. DOI 10.1007/s00592- 008-0083- 2. PMID: 19082520  
Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 
16:797- 803. PMID: 16096426 
Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007; 106:39 -47. PMID: 17221153  
Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004; 24:9726 -9735. PMID: 15509777 
Nunez NP, Oh W -J, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovs.ki L, 
Hursting SD, Vinson C. Accelerate d tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer 
Res 2006; 66:5469- 5476. PMID: 16707476  
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program randomized trial. The effect of Metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Int Med 2005; 142:611 -619. PMID: 15838067 
Ou HY, Cheng JT, Yu EH, Wu TJ. Metformin increases insulin sensitivity and plasma beta -endorphin in human 
subjects. Horm Metab Res 2006; 38:106- 111. PMID: 16523411 
Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti- diabetic effects through inhibition of 
complex 1 of the mitochondrial respiratory chain. The Biochemical Journal 2000; 348 Pt 3:607- 614. PMID: 10839993 
Papa V, Belfiore A. Insulin receptors in breast cancer: biological and clinical role. Endocrinol Invest 1996; 19:324-
333. PMID: 8796343  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 68 CONFIDENTIAL Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor 
for breast cancer recurrences. Int J Cancer 2006; 119:236- 238. PMID: 16450399  
Perez- Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. PIK3CA 
mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13:3577- 3584. PMID: 17575221  
Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the Er negative MDA -MB-435 breast cancer model. Breast Cancer Res Treat 2009; 113:101- 111 PMID: 18256928  
Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al -Delaimy WK, Bardwell 
WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L , Stefanick ML. Influence of a diet very high in 
vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007; 298:289 -298. PMID: 17635889 
Pollak MN , Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KI. Insulin resistance, 
estimated by serum C -peptide level, is associated with reduced event -free survival for postmenopausal women in 
NCIC CTG MA.14 adjuvant breast cancer trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006; 524.  
Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391- 406. PMID: 16011472 
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin- like growth factor -
binding protein -3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels 
in tumors with poor prognostic features. J Natl Cancer Inst 1996; 88:601- 606. PMID: 8609661  
Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, Baselga J, Ramon y Cajal S. 4E -binding protein 1, a 
cell signaling hallmark in breast cancer that correlates with pathologic gr ade and prognosis. Clin Cancer Res 2007; 
13:81- 89. PMID: 17200342 
Romualdi D, Costantini B, Selvaggi L, Giuliani M, Cristello F, Macri F, Bompiani A, Lanzone A, Guido M. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008; 
23:2127- 2133. PMID: 18567896 
Rose DP, Haffner SM, Baillargeon J. Adiposity, the Metabolic Syndrome and Breast Cancer in African- American and 
White American Women. Endocrine Reviews 2007; 28: 763- 777 
Saal LH, Holm K, Maurer M, Memeo  L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, 
Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Rese arch 2005; 65:2554- 2559. PMID: 
15805248 
Saal LH, Johansson P, Holm K, Gruvberger -Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, 
Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R. Poor prognosis in carcinoma 
is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad 
Sci USA 2007; 104:7564- 7569. PMID: 17452630 
Sachdev D, Singh R, Fujita -Yamaguchi Y, Yee D. Down -regulation of insulin receptor by antibodies aga inst the type 
I insulin -like growth factor receptor: implications for anti -insulin- like growth factor therapy in breast cancer. Cancer 
Res 2006; 66:2391- 2402. PMID: 16489046  
Sachdev D, Yee D. Disrupting insulin- like growth factor signaling as a potential c ancer therapy. Mol Cancer Ther 
2007; 6:1- 12. PMID: 17237261  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 69 CONFIDENTIAL Salpeter SR, Greyber E, Pasternak GA, Saltpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in 
type 2 diabetes mellitus. Arc Intern Med 2003; 163:2594- 602. PMID: 14638559 
Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 
22:2954- 2963. PMID: 15254063 
Santomauro Junior AC, Ugolini MR, Santomauro AT, Souto RP. Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome. Arq Bras Endocrinol Metabol 2008; 52:120 -125. PMID: 18345405 
Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Current Opinion in Cell Biology 2005; 17:596- 603. PMID: 16226444 
Saxena T, Maheshwari S, Goya l RK. Serum insulin assay: an important therapeutic tool in management of freshly 
diagnosed type 2 diabetes mellitus. J Assoc Physicians India 2000; 48:815- 817. PMID: 11273476 
Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insuli n-like growth factors, their 
binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 699- 704 PMID: 15767352 
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase direct ly activates AMP -activated kinase and regulates apoptosis in response to energy stress. Proceedings of 
the National Academy of Sciences of the United States of America 2004; 101:3329- 3335. PMID: 14985505 
Stambolic V, Woodgett JR, Fantus GI, Pritchard KI, G oodwin PJ. Utility of metformin in breast cancer treatment, is 
neoangiogenesis a risk factor? Breast Cancer Res Treat 2009; 114:387 -389 PMID: 18438706 
Tankova T, Dakovska L, Kirilov G, Koev D. Metformin in the treatment of obesity in subjects with normal g lucose 
tolerance. Rom J Intern Med 2003; 41:269- 275. PMID: 15526510 
Toropainen E, Lipponen P, Syrjanen K. Expression of insulin -like growth factor I (IGF -I) in female breast cancer as 
related to established prognostic factors and long- term prognosis. Eur J  Cancer 1995; 31A:1443- 1448. PMID: 
7577069 
Towler MC, Hardie DG. AMP -activated protein kinase in metabolic control and insulin signaling. Circulation 
Research 2007; 100:328- 341. PMID: 17307971 
Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G. 
Com parative evaluation of simple indices of insulin resistance. Metabolism 2004; 53: 1522- 1526. PMID: 15562393 
Vatten LJ, Holly JM, Gunnell D, Tretli S. Nested case -control study of the association of circulating levels of serum 
insulin- like growth factor I a nd insulin- like growth factor binding protein 3 with breast cancer in young women in 
Norway. Cancer Epidemiol Biomarkers Prev 2008; 17: 2097- 2100. PMID: 18708402 
Vazquez- Martin A, Oliveras -Ferraros C, del Barco S, Martin -Castillo B, Menendez JA. The antidi abetic drug 
metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 2009; 20:592 -595. PMID: 19153119 
Vivanco I, Sawyers CL. The phosphatidylinositol 3- Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 
2:489- 501. PMID: 12094235 
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008; 14:7192- 7198 PMID: 19084933  
Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo- controlled trial of letrozole after 5 years of 
tamoxifen in postmenopausal women. J Clin Oncol 2005;  23:6931 -6940. PMID: 16157934 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 70 CONFIDENTIAL White SJ and Freedman LS. Allocation of patients to treatments groups in a controlled clinical study, British J Cancer 
1978; 37:849- 857 
Witters LA. The blooming of the French lilac. The Journal of Clinical Investigation 2001;  108:1105- 1107. PMID: 
11602616 
Wolf A, Hunter D, Colditz G, et al.: Reporducability and Validity of a Self -Administered Physical Activity 
Questionnaire Internatonal Journal of Epidemiology, 1994; 23: 991 -999 
Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, Trink B, 
Sidransky D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7:R609- 616. PMID: 16168105 
Yakar S, Nunez PN, Pennisi P, Brodt P, Sun H, Fallavollita L , Zhao H, Scavo L, Novosyadlyy R, Kurshan N, Stannard 
B, East -Palmer J, Smith NCP, Perkins SN, Fuchs -Young R, Barrett JC, Hursting SD, LeRoith D. Increased tumor 
growth in mice with diet -induced obesity: impact of ovarian hormones. Endocrinol 2006; 147:5826 -5834. PMID: 
16959846 
Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2- targeting strategies. Oncogene 2000; 19:6115- 6121. 
PMID: 11156524  
Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin Is an AMP Kinase -Dependent Growth 
Inhibi tor for Breast Cancer Cells. Cancer Res 2006; 66: 10269- 10273 PMID: 17062558 
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk- Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman 
MF, Goodyear LJ, Moller DE. Role of AMP -activated protein kinase in mec hanism of metformin action. The Journal 
of Clinical Investigation 2001; 108:1167 -1174. PMID: 11602624 
Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the 
Akt/mammalian target of rapamycin/4E -BP1 pathw ay by ErbB2 overexpression predicts tumor progression in breast 
cancers. Clin Cancer Res 2004; 10:6779- 6788. PMID: 15501954  
Zhuang Y, Miskimins KW. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, 
downregulation of cyclin D1, and requires p27KipI or p21CipI. Journal of Molecular Signaling 2008; 3:18 PMID: 19046439 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 71 CONFIDENTIAL APPENDIX I -  PATIENT EVALUATION FLOW SHEET  
Required Investigations  Pre-
study*  6 
mo 12 
mo 24 
mo 36 
mo 48 
mo 60 
mo Post study 
treatment  
History & Physical          
Waist & Hip Circumference , Blood Pressure  X X X X X X X  
Performance Status  X        
Weight , BMI  X X X X X X X X 
Height  X        
Medical History , Menopausal Status  X        
Concomitant Meds  X        
Hematology*          
Hemoglobin  X X X X X X X  
WBCs,  X X X X X X X  
Granulocytes  X X X X X X X  
Platelets  X X X X X X X  
MCV  X X X X X X X  
Biochemistry*          
AST  X X X X X X X  
ALT  X X X X X X X  
Alkaline Phosphatase  X X X X X X X  
Serum Creatinine  X X X X X X X  
Serum Bilirubin  X X X X X X X  
Serum Vitamin B 12 X  X  X  X  
Fasting Glucose, Fasting Insulin (same draw)  X X    X   
Radiology          
Mammogram  X  X X X X X X 
Chest X -ray (or Chest CT)  X        
Bone Scan (as necessary)  X        
CT Abdomen (as necessary)  X        
Other Investigations          
TNM Classification, Histologic Grade  X        
ER / PgR Status  X        
HER2 Status  X        
Initiation of new anti -diabetes medication (or confirmed 
diagnosis of diabetes). Cardiovascular hospitalization 
(stroke, myocardial infarction) or death   X X X X X X X 
Blood Sample for Correlative Science (serum, plasma, 
DNA) (optional)  X X    X   
Adverse Events          
CTC AE (version 4)  Grade 3, 4 and 5 only  X X X X X X X X 
Quality of Life (888 subjects)  sample size achieved 2011NOV04         
EORTC QLQ -C30 X X X X X X X  
Trial Specific Checklist  X X X X X X X  
Physical Activity & Diet          
Block Alive Screener (Diet)  X X X X X X X  
Physical Activity Items (NHS II)  X X X X X X X  
* Please see protocol section 6 for timing of pre -study investigations  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 72 CONFIDENTIAL APPENDIX II -  PERFORMANCE STATUS SCALES/SCORES  
 
PERFORMANCE STATUS CRITERIA  
Karnofsky and Lansky performance scores are intended to be multiples of 10.  
ECOG (Zubrod)  Karnofsky  Lansky*  
Score Description Score  Description Score  Description 
0 Fully active, able to carry on all pre-disease performance without restriction.  100 Normal, no complaints, no evidence of disease.  100 Fully active, normal.  
90 Able to carry on normal activity; minor signs or symptoms of disease.  90 Minor restrictions in physically strenuous activity.  
1 Restricted in physically strenuous activity but 
ambulatory and able to carry 
out work of a light or sedentary 
nature, e.g. light housework, 
office work.  80 Normal activity with effort; some signs or symptoms of disease.  80 Active, but tires more quickly.  
70 Cares for self, unable to carry on 
normal activity or do active work.  70 Both greater restriction of and less time spent in play activity.  
2 Ambulatory and capable of all 
selfcare but unable to carry out 
any work activities. Up and 
about more than 50% of waking 
hours.  60 Requires occasional assistance, but 
is able to care for most of his/her 
needs.  60 Up and around, but minimal active play; keeps busy with quieter activities.  
50 Requires considerable assistance and frequent medical care.  50 Gets dressed, but lies around much of the day; no active play; 
able to participate in all quiet 
play and activities.  
3 Capable of only limited 
selfcare; confined to bed or 
chair more than 50% of waking hours.  40 Disabled, requires special care and assistance.  40 Mostly in bed; participates in quiet activities.  
30 Severely disabled, hospitalization indicated. Death not imminent.  30 In bed; needs assistance even for 
quiet play.  
4 Completely disabled. Cannot 
carry on any selfcare. Totally confined to bed or chair.  20 Very sick, hospitalization indicated. Death not imminent.  20 Often sleeping; play entirely 
limited to very passive activities.  
10 Moribund, fatal processes 
progressing rapidly.  10 No play; does not get out of bed.  
* The conversion of the Lansky to ECOG scales is intended for NCI reporting purposes only.  
 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 73 CONFIDENTIAL APPENDIX III -  DRUG DISTRIBUTION, SUPPLY AND CONTROL  
 
Detailed information and instructions about drug distribution, transfer, returns, destruction and 
accountability will be provided in a separate document, in time for you to review this information and 
consider your participation in this clinical trial.  
 
General  
 In order to initiate study drug distribution, C CTG must receive the address and the name of a contact person 
to whom the study drug will be shipped at each site. This will be accomplished as part of the local activation 
process.  
 
Distribution  
 
Metformin and Placebo will be  provided by Apotex Inc. and  supplied free -of-charge , through CCTG,  to 
study participants. Study drugs will be organized into patient specific treatment “kits” . Each treatment “kit”  
will contain  one bottle of  either blinded Metformin or Placebo. Participating sites will be pre -stocked with 
treatment kits. In North America once a patient has been successfully randomized through the C CTG 
electronic data capture system, the identity of the treatment kit which should b e given to the patient will be 
transmitted back to the submitter. Site Pharmacy stock will be re -supplied automatically as treatment kits 
are used. Kits to be re -supplied to each patient will be identified and communicated to the site automatically 
prior t o each patient follow -up visit. All drug orders will be shipped directly to the Pharmacist designated 
responsible for MA.32 Study Drugs.  
 Each treatment bottle will be l abeled  with the following:  
 
1. NCIC CTG MA32.  
2. Treatment Box Number  
3. Number of Tablets  
4. Instructions (Safety/Handling)  
5. Storage Instructions  
6. Blank line for Investigator name & phone #  
7. Lot Number/ Expiry Date  
8. Blank line for patient initials  
 
Questions about drug orders, transfers, returns, destruction or accountability should be addressed to:  
 
CCTG  
MA.32 Team (RE: Drug Supply & Distribution)  
10 Stuart Street 
Queen’s University 
Kingston Ontario, Canada  Phone: 613- 533-6430 
K7L 3N6 Fax: 613- 533-2814 
 
 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 74 CONFIDENTIAL Drug Accountability  
 
The Investigator, or a responsible party designated by the Investigator (e .g. the responsible Pharmacist), 
must maintain a careful record of the receipt, disposition return and destruction of drugs received for use in 
this clinical trial us ing the NCI Investigational Agent Accountability record available on the NCI home 
page ( http://ctep.info.nih.gov) or MA.32 Trial Page. (Please note that the original accountability logs 
provided by the study are  to be continued for this trial.) As this is a double blinded study, a separate 
Investigational Agent Accountability Record must be maintained for each C CTG patient on this protocol 
as required by regulation.  
 
Subject Compliance  
 
Subjects are to bring stu dy drug bottles to every protocol -mandated visit (to assist in assessing patient –
reported compliance). Both patient reported compliance and a pill count will be employed. Returns and 
destruction of same should be documented in the NCI Accountability Log f or each patient. Patient returns 
and expired drug should be destroyed on site as per local standard operating procedures and documented 
on the Investigational Agent Accountability record. Instructions on handling of unused drug will be 
provided by the CCTG  at trial closure.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 75 CONFIDENTIAL APPENDIX IV -  DOCUMENTATION FOR STUDY  
 
Follow -up is required for patients from the time of randomization and will apply to all randomized patients.  
 
This trial will use a web -based Electronic Data Capture (EDC) system for all data collection except Quality 
of Life, Physical Activity, Diet  and SAE reporting. For details of accessing the EDC system and completing 
the on- line Case Report Forms please refe r to the “ CCTG EDC Generic Data Management Guidebook” 
posted on the MA.32 area of the CCTG web -site ( www.ctg.queensu.ca ).  
 
The electronic CRFs to be used in this trial, through the EDC system, are as follows:  
 
Electronic Folder  Required at  To be completed 
electronically  Supporting Documentation* 
Mandatory 
Submission  
To be submitted 
immediately after the report 
they refer to has been 
submitted elec tronically  Submission On 
Request  
To be submit ted 
immediately after  
request  
Eligibility Checklist  At time of 
randomization  At time of 
randomization  Consent form**, 
copies of protocol 
mandated base line 
radiology, operative , 
and diagnostic 
pathology reports  additional clinical,  
laboratory or  
imaging reports 
that may impact 
on decision 
regarding 
eligibility  Baseline Report  At time of 
randomization  Within 6 weeks of 
randomization  
Telephone Follow -up 
Report  One month after start 
of study drug  Within 2 weeks of 
telephone contact    
Correlative Studies 
Report  
(Tumour and Blood)  At time of 
randomization  Within 6 weeks of 
drawing of 6 month 
sample  Diagnostic pathology 
report  
(for tumour tissue 
only)   
Treatment Report  At time of clinic visit  Within 6 weeks of 
clinic visit  Mammogram reports  additional clinical , 
laboratory or  
imaging reports 
that 
may inform  
evaluation of 
safety  
End of Treatment 
Report  As soon as off 
treatment status is 
confirmed  Within 2 weeks of 
end of treatment    
Relapse/Progression 
Report  Upon disease 
progression  Within 6 weeks of 
confirmation  Copies of protocol -
mandated imaging 
and non- protocol 
mandated imaging 
relevant to disease 
assessment  , operative 
and pathology reports   
table continued on next page …  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 76 CONFIDENTIAL Electronic Folder  Required at  To be completed 
electronically  Supporting Documentation* 
Mandatory 
Submission  
To be submitted 
immediately after the report 
they refer to has been 
submitted electronically  Submission On 
Request  
To be submitted  
immediately after  
request  
Short Follow -up Report  Annually after off 
treatment  Within 6 weeks of 
clinic visit  Mammogram reports 
(as appropriate – 
please see protocol 
section 9) , Radiology 
reports  for protocol  
-mandated imaging  
and non- protocol  
mandated imaging if  
relevant to disease  
assessment  Additional clinical  
,laboratory or  
imaging reports 
that may inform  
evaluation of 
safety  
Death Report  Upon patient death  Within 6 weeks of 
patient death  Autopsy report if 
autopsy was done  Additional 
clinical,  
laboratory or  
imaging reports 
that may inform  
evaluation of 
cause  of death  
SAE Report*** Within 24 hours of 
event  Complete report 
within 10 days   Additional 
clinical,  
laboratory or  
imaging reports 
that may inform  
evaluation of 
safety  including, 
admission  and 
discharge  
summaries/notes  
*** See section 11.0 Serious Adverse Event Reporting for details.  
** For Canadian centres, it is acceptable to submit only the signature page(s) of the main consent and only the check 
box page(s)/signature page(s) of the optional consent provided that the version date of the consent form is indicated. Centres are expected to redact the participant’s name and signature on the submitted copy, leaving only a portion visible (e.g. initials or loops) to confirm that a person has signed but that cannot identify that individual.  
*  Source documents other than those listed above may be requested to confirm eligibility, compliance, endpoints, 
and/or serious adverse events. Supporting documents should be submitted immediately after the report they 
refer to has been submitted electronica lly. EDC forms submitted without supporting documentation are not 
considered submitted and will be reflected in the Centre Performance Index (CPI) as not submitted. All relevant patient identifiers, other than the CCTG patient ID assigned at enrollment, an d any other prohibited personal 
information must be fully and completely redacted (blacked- out) on all source documentation, per national and 
local privacy protection regulations and requirements,. Acceptable methods include:  
•  fully opaque sticker/tab p laced over the identifiers prior to s ubmission  
•  fully opaque black marker; prior to submission please ensure that the information is no longer visible on the 
scanned document  
•  electronic black box placed over identifiers in PDF document that is subsequently printed.  
•  fully opaque black marker; please ensure that the information under the marker cannot be still be seen on the 
scanned document (often markers are translucent and the identifiers can in fact be seen after scanning)  
Note that supporting documents must include the participant’s trial code, CCTG patient  serial number, and 
participant initials (or a two/three masking letter code assigned by your centre). 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 77 CONFIDENTIAL The CRFs to be used in this trial outside the EDC system are as follows:  
 
Report  To be completed  Due at CCTG  Supporting Documentation 
Required  
Quality of Life, Physical 
Activity, Diet 
Questionnaires  At intervals defined in 
Appendix I  Within 6 weeks of 
completion of 
questionnaires   
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 78 CONFIDENTIAL APPENDIX V -  NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS  
 
The descriptions and the grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4 will be utilized for  Adverse Event (AE) reporting. All appropriate 
treatment areas should have access to a copy of the CTCAE  version 4 . Please note that only Grade 3, 4 and 
5 events are to be collected – except if an event qualifies as an SAE or if the event is recorded as a reason 
for going off study treatment. A copy of the CTCAE version 4 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 79 CONFIDENTIAL APPENDIX VI -  QUALITY OF LIFE ASSESSMENT  
 
Introduction  
 
Data derived from Quality of Life measured in clinical trials can help to select the optimal intervention, 
describe patient’s experience or provide prognostic information. Studies have shown that measuring Quality 
of Life provides additional information compared to measuring adverse events alone. Current literature 
reveals interesting things; two in particular are:  
• additional and useful information may be obtained from quality of life measurements  
• a growing consensus that the goal of medical care today for most patients is the preservation of function and well -being in everyday life.  
 
We have reached the stage where the collection of information about psychological distress, social 
disruption, emotional trauma and painful side -effects is not only necessa ry but a routine component in many 
protocols.  
 Quality of life data can be used in a variety of ways:  
• to try to achieve the best possible outcome for patients  
• to evaluate the extent of change in the quality of life of an individual or group across time  
• to evaluate new treatments and technologies  
• to support approval of new drug applications  
• to try to provide the best value for health care dollars  
• to compare costs and benefits of various financial and organizational aspects of health care services  
 
In the fut ure, approval of not only drugs but also new therapies or methods of delivery will most likely be 
based on a combination of quality of life, survival, response, and adverse event data.  
 
Instructions for Administration of a Quality of Life Questionnaire . The instructions below are intended as 
a guide for the administration of the Quality of Life questionnaire.  
 
1. Preamble  
 
Quality of life data are collected for research purposes, and will usually not be used for the patient’s 
individual medical care. The assessment is in the form of a self report questionnaire. Therefore, it must 
be completed by the patient only, without translation, coaching or suggestions as to the "correct" answer 
by relatives or health care personnel.  
 
The usual scheduled times to obta in the questionnaires are as follows:  
• pre-randomization or pre -registration (baseline)  
• during treatment  / follow -up 
 
The information provided by the patient in the completed questionnaire is confidential and should not 
be discussed with or shown to anyone who is NOT mentioned in the consent form signed by the patient.  
 
If a particular question has not been answered, please document the reason(s) in the appropriate space 
on the questionnaire. If the whole questionnaire has not been completed, please document  the reason(s) 
on the appropriate case report forms.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 80 CONFIDENTIAL 2. Pretreatment Assessment  
 
It should be explained to the patient that the purpose of the questionnaire is to assess the impact of 
treatment on different areas of the patient's life, e .g.: psychological  distress, social disruption, side -
effects, et cetera.  
 
The CRA should collect the questionnaire as soon as it has been completed, check to see that each question has been answered and gently remind the patient to answer any inadvertently omitted 
questions . If a patient states that s/he prefers not to answer some questions and gives a reason(s), the 
reason(s) should be noted on the questionnaire. If a specific reason is not given, this also should be 
noted on the questionnaire.  
 
3. Assessments During Treatm ent 
 
The quality of life questionnaire should be given to the patient before being seen by the doctor, and 
prior to treatment on the day of treatment, as required by the schedule in the protocol. If the patient 
does not have a doctor visit scheduled, or if it was not possible for the patient to complete the 
questionnaire bef ore being seen by the doctor, s he should still complete the questionnaire prior to 
treatment.  
 
A patient may, on occasion, be reluctant to complete the questionnaire beca use they feel 
unwell. In that case, you may express sympathy that things are below par, but state that this 
is exactly the information we require if we are to understand more about how quality of 
life is affected. You may also remind them that it takes only a few minutes to complete.  
 
It defeats the whole purpose of the assessment if it is delayed until the patient feels better!  
 
4. What If . . .   
 
The patient should complete the questionnaires at the clinic. The exception is that the design of some 
trials may require the patient to take the questionnaire home with them after leaving the clinic, and 
complete it on the specific day, because a return visit to the clinic is not scheduled.  
 
There may be circumstances when the patient does not complete the  questionnaire as required in the 
clinic. Three situations are described below. In these cases, it is beneficial if quality of life data can still 
be collected.  
 
A. The patient leaves the clinic before the questionnaire could be administered, or someone forgets to give the questionnaire to the patient.  
 
Contact the patient by phone informing him or her that the questionnaire was not completed. Ask the patient if s/he is willing to complete one:  
If yes , mail a blank questionnaire to the patient, and make ar rangements for return of the 
questionnaire in a timely fashion. Record the date it was mailed and the date received on the questionnaire.  
 
If this is not feasible, then  ask the patient if s/he is willing to complete a questionnaire over 
the phone. If the patient agrees, read out the questions and range of possibilities, and record the answers. Make a note on the questionnaire that the questionnaire was completed over the phone.  
 
If no , note the reason why the questionnaire was not completed on the appropriate case report 
form.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 81 CONFIDENTIAL B. The patient goes on an extended vacation for several months and won't attend the clinic for regular 
visit(s).  
 
Ensure that the patient has a supply of questionnaires, with instructions about when to complete them, and how to return them. If it is known beforehand, give the patient blank questionnaires at 
the last clinic visit; if the extended absence is not known in advance, mail the blank questionnaires 
to the patient. Written instructions may help ensure that the patient stays on schedule as much as 
possible.  
 
C. The patient does not want to complete the questionnaire in clinic.  
 
Should the patient not wish to answer the questionnaire in the clinic but insists on taking it home, and 
failing to comply with the patient's wishes is likely to result in the questionnaire not being completed 
at all, then the patient may take the questionnaire home with instructions that it is to be completed the 
same day. When the questionnaire is returned, the date on which the questionnaire wa s completed 
should be noted and a comment made on the questionnaire as to why the patient took it away from the clinic before completion.  
 
5. Waiving the Quality of Life Component  
 
The only time that we will not require a patient to complete the quality o f life questionnaires is if s/he 
is not literate in either English or French (or other languages that the questionnaire may be available 
in). In other words, if the assistance of a translator is required to comprehend the questions and reply, 
the questionnaires should not be completed. Translation of the questions is not acceptable. Please 
indicate on questionnaire.  
 
6. Unwillingness to Complete Quality of Life Questionnaire  
 
If a patient speaks and reads English or French (or other languages that the questionnaires may be available in), but does not wish to complete the questionnaires then s he is NOT eligible and should 
NOT be put on study.  
 
7. Inability to Complete Quality of Life Questionnaire (for reason other than illiteracy in English or 
French)  
 
An eligible patient may be willing but physically unable to complete the questionnaires, because of blindness, paralysis, etc. If the patient is completing the QOL asses sment in the clinic, the questionnaire 
should be read to them and the answers recorded by a health care professional ( e.g. preferably the 
clinical research associate assigned to the trial, but another clinic nurse, a doctor or social worker who is familiar  with the instructions for administering the questionnaires would be acceptable). If the patient 
is completing the questionnaire at home, and a telephone interview by the clinical research associate is 
not possible, then a spouse or friend may read the que stions to the patient and record the answers. 
However, this method should be a last resort, and the spouse or friend should be instructed to not coach 
or suggest answers to the patient. Whichever method is used, it should be recorded on the questionnaire.  
 
If these special arrangements are not possible or feasible, then the patient would not be required to 
complete the questionnaires, and this should be reported on the appropriate case report form.  
 
The Quality of Life Questionnaires will be administered to  the first 888 eligible English/French 
speaking subjects. English- speaking subjects from this sub- set of 888 subjects will also do the Physical 
Activity and Diet Questionnaires. (The Physical Activity and Diet Questionnaire are available and 
validated only in English.)  
 
 
 
CONFIDENTIAL 82 CONFIDENTIAL Quality of Life Questionnaire –  ENGLISH  
 
NCIC CTG Trial: MA.32  
 
This page  to be completed by the Clinical Research Associate  
 
Patient Information  
CCTG Patient Serial No: ___________   Patient Initials:  ____ ____ ____  
 (first -middle -last)  
Institution: ___________________________________________  Investigator: ______________________________  
 
Scheduled time to obtain quality of life assessment: please check ( √) 
 Prior to randomization  
During protocol therapy:  
 6 months   12 months   24 months   36 months   48 months   60 months  
Were ALL questions answered?  ___ Yes ___ No If no, reason:  ________________________________________ 
Was assistance required? ___ Yes ___ No If yes, reason:  ________________________________________ 
Where was questionnaire completed:  home   clinic   another centre  
Comments: ____________________________________________________________________________________ 
_____________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 Date Completed:  __ __ __ __ -  __ __ __ -  __ __  
        yyyy            mmm         dd  
 
PLEASE ENSURE THIS PAGE IS FOLDED BACK BEFORE HANDING  
TO THE PATIENT FOR QUESTIONNAIRE COMPLETION.  
 
 
CCTG use only  
Logged: _______ 
______ - ____ - ____  Study Coord: _______  
______ - ____ - ____  Res Assoc: _______  
______ - ____ - ____  Data Ent’d: 
_________ Verif:  
_________ 
 
NCIC CTG Trial MA.32. Quality of Life Questionnaire  Page 1 of 1  Quality of Life Questionnaire ( MA.32 ) 
 
The MA.32 study will employ, in a sub- set of 888 subjects, 2 instruments:  
 
1. EORTC QLQ C -30 
2. Trial Specific Checklist  (last 7 questions of QoL questionnaire)  
 
The first 888 English or French- speaking eligible subje cts to be enrolled will comprise this sub -set of subjects. These 
instruments will all be made available, to active sites, in paper format, for completion by subjects. Links to the instruments 
are provided here to facilitate their presentation to your local  REB, with the protocol and consent form, for approval.  
 
The time required for subjects to complete each questionnaire is as follows:  
 
Questionnaire  Time Required to 
Complete  
EORTC QLQ C -30 
 
http://www.eortc.be/home/qol/downloads/f/C30/QLQ -C30%20English.pdf  
 
http://www.eortc.be/home/qol/downloads/f/C30/QLQ -
C30%20FrenchCanadian.pdf  
 
 20 minutes  
Trial Specific Checklist  
 
31. Did you have bloating of your abdomen (stomach or belly)?  
 Avez -vous ressenti un ballonnement à l'abdomen (à l'estomac ou au ventre)?  
32. Did you have pain or cramps in your abdomen (stomach or belly)?  
 Avez -vous ressenti de la douleur ou des crampes a l'abdomen (a l'estomac 
ou au ventre)?  
33. Did you have heartburn?  
 Avez -vous ressenti (souffert de) brûlures d’estomac?  
34. Did you have gas?  
 Avez -vous eu des gaz?  
35. Did you limit your activities because of gastro -intestinal problems?  
 Avez -vous limité vos activités en raison de problèmes gastro -intestinaux?  
36. Did you have a metallic taste?  
 Avez -vous eu un goût métallique?  
37. Do you have aching muscles or joints?  
 Avez -vous ressenti des douleurs aux muscles ou aux jointures?  
 5 minutes  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 84 CONFIDENTIAL  APPENDIX VII  - PHYSICAL ACTIVITY AND DIETARY QUESTIONNAIRES  
 
On the same sub- set of 888 MA.32 subjects, physical activity and dietary intake behaviours will also be 
addressed through the use of the following two  instruments:  
 
1. Physical Activity Items of the Nurses Health Study II Questionnaire  
2. Block Alive Screener (Diet)  
 Physical activity patterns and dietary intakes will be assessed in order to measure changes in these 
behaviours over time and to evaluate differences in these changes between Metformin and placebo groups. 
It will then be possible to adjust for changes in diet and physical activity in assessment of study outcomes.  
 The Physical Activity and Diet Questionnaires will be administered to the English -speaking subjects in the 
888 subject sub- set because the Physical Activity and Diet Questionnaires are available and validated only 
in English.  
 These instruments will all be made available, to active sites, in paper format, for completion by subjects. Copies of the instruments are provided here to facilitate their presentation to your local REB, with the 
protocol and consent form, for approval . 
 
Questionnaire  Time Required to 
Complete  
Physical Activity Items of the  
Nurses Health Study II Questionnaire  
   
(Sample available in this Appendix)  
 5 minutes  
Block Alive Screener  
 
(Sample available in this Appendix)  
 10 minutes  
 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 85 CONFIDENTIAL  

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 86 CONFIDENTIAL  AMEND #1: 2011- AUG- 15 

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 87 CONFIDENTIAL   AMEND #1: 2011- AUG- 15 

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 88 CONFIDENTIAL   AMEND #1: 2011- AUG- 15 

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 89 CONFIDENTIAL   AMEND #1: 2011- AUG- 15 

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 90 CONFIDENTIAL   AMEND #1: 2011- AUG- 15 
 
  

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 91 CONFIDENTIAL  APPENDIX VIII -  7TH EDITION OF THE TNM CLASSIFICATION OF MALIGNANT TUMOURS  
 
The 7th Edition of the TNM Classification of Malignant Tumours has recently been released. To facilitate 
this process, educational resources have been made available to promote the use of staging (visit http://www.cancerstaging.org/staging/posters/breast8.5x11.pdf  and 
http://www.cancerstaging.org/staging/changes2010.pdf ).  
These staging criteria should be used  for new trials.  
 
Onco type DX analyzes a panel of 21 genes within a tumor to determine a Recurrence Score. The Recurrence 
Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence 
within 10 years of the initial diagnosis. In MA.32, an Oncotype Dx score >  25 is considered an adverse 
prognostic factor when assessing eligibility of women with node negative breast cancer measuring between 
1 and 2 cm.  
 • Recurrence Score lower than 18 : This suggests a low risk of re currence. The benefit of 
chemotherapy is likely to be small and will not outweigh the risks of side effects.  
• Recurrence Score between 18 and 31 : This score suggests an “intermediate” risk of recurrence. 
It’s unclear whether the benefits of chemotherapy out weigh the risks of side effects.  
• Recurrence Score greater than 31 : A high risk of recurrence, and the benefits of chemotherapy 
are likely to be greater than the risks of side effects.  
 
Ki67  
Ki67 is a molecule that can be easily detected in growing cells in  order to gain an understanding of the rate 
at which the cells within a tumor are growing.  
 
Detection of Ki67 is carried out on biopsies, samples of tumor tissue. The goal of this assay is to evaluate 
an important characteristic of the cells within the tumor, the percentage of tumor cells that are actively 
dividing and giving rise to more cancer cells. The number obtained through this examination is termed the 
S-phase, growth, or proliferative fraction. This information can play an important part in deciding the best 
treatment for a cancer patient.  
 
Estrogen and Progesterone Receptor Positive  
 
Estrogen and progesterone receptor status must be known. (Receptor positive by immunohistochemistry: 
ERICA or PgRICA versus both receptors negative. It is recommended that ER and PgR assays be 
considered positive if there are at least 1% positive tumour nuclei in the sample on testing in the presence 
of expected reactivity of internal [normal epithelial elements] and external control. 
[Hammond 2010]  
  HER2 Positive versus Negative definition  
 
Positive = 3+ over -expression by IHC in > 30% of invasive tumour cells  
OR 
HER2 gene amplification by FISH/CISH > 6 HER2 gene copies per nucleus  
OR 
a FISH/CISH ratio: HER2 gene copies to chromosome 17 signals of > 2.2  
 
All other results will be considered negative.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 92 CONFIDENTIAL  APPENDIX IX – EVALUATION METHODOLOGIES  
 
It is important that at least one individual, at each participating centre be trained to do the anthropometric 
measurements in a correct and  consistent fashion so that the data may be compared over time. While these 
measurements are simple in concept, they should be performed, for this trial, according to the following 
procedures to ensure accuracy and consistency.  
 
Height  
 
Height will be meas ured in stocking feet using a stadiometer. Height should be recorded in metres.  
 
Weight  
 Weight will be measured in indoor clothing (without shoes) using an appropriate clinical weight scale. 
Weight should be recorded in kilograms.  
 
Waist and Hip Circumf erence  
 
The circumference should be measured on subjects without heavy outer garments in a standing position. 
The contents of all pockets must be removed. All tight clothing, including the belt, must be loosened. The 
participant should stand with the feet fairly close together (about 12- 15cm) with weight equally distributed 
on each leg. Participants should be asked to breathe out gently at the time of the reading of the measurement to prevent them from contracting their muscles or from holding their br eath. The tape should be held firmly 
in a horizontal position. It is recommended that the observer is sitting by the participant while taking the 
measurement.  
 
The waist measurement should be recorded at the level midway between the lower rib margin and the iliac 
crest, in centimeters, rounded to the nearest .0 or.5 cm.  
 The hip measurement should be recorded from the maximum circumference over the largest portion of the 
buttocks, in centimeters rounded to the nearest .0 or.5 cm.  
 
BMI  
 
SI units  
 
Imperial units  
  

 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 93 CONFIDENTIAL  Blood Pressure  
 
Hypertension – Detection, Diagnosis and Management  
 
Measurements should be taken with a sphygmomanometer known to be accurate  and by a health care 
provider or CRA who has been adequately trained in the measurement of blood pressure . A recently 
calibrated aneroid or a validated and recently calibrated electronic device can also be used.  Use the arm 
not affected by surgery. In the case of bilateral breast carcinoma, choose one arm for measurement and use 
it consistently.  
 
Reference:  Canadian Hypertension Education Program. 2007 CHEP recommendations for the 
management of hypertension. 2007 (www.hypertension.ca/chep/ ). 
 NEW YORK  HEART ASSOCIATION CLASSIFICATION OF CARDIAC DISEASE  
 
Clinical Evaluation of Functional Capacity of Patients  with Heart Disease in Relation to Ordinary Physical 
Activity  
Class  Cardiac Symptoms  Limitations  Need for 
Additional  Rest * Physical Ability 
to Work ** 
I None  None  None  Full time  
II Only moderate  Slight  Usually only slight 
or occasional  Usually full time  
III Defined, with less than 
ordinary activity  Marked  Usually moderate  Usually part time  
IV May be present even at 
rest, and any activity 
increases discomfort  Extreme  Marked  Unable to work  
* To control or relieve symptoms, as determined by the patient, rather than as advised by the physician.  
** At accustomed occupation or usual tasks.  
Reference: Bruce, RA: Mod Concepts Cardiovasc Dis 25:321, 1956. (Modified from New York Heart Association, 1953)  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 94 CONFIDENTIAL  APPENDIX X – CORRELATIVE SCIENCE PROCEDURES, BLOOD SAMPLING, PROCESSING 
AND SHIPPING 
 
Blood 
 After an overnight fast of at least 12 hours, participants will provide the following blood specimens:  
 
 1 tube for immediate glucose analysis,  
 3 light green topped tubes (containing lithium heparin -  for insulin & plasma),  
 1 red topped tube (for serum) and  
 1lavender topped tube (for DNA).  
 
• The green topped tubes will be centrifuged within half an hour of collection and the collected 
plasma frozen immediately in 1cc aliquots at - 80°C.  
• The red topped tube will sit for 30 minutes at room temperature and then centrifuged and the 
collected serum frozen immediately in 1 cc aliquots at - 80°C.  
• The lavender topped tube (whole blood in EDTA) will be collected and frozen in 1 ml aliquots 
at -80°C for su bsequent thawing and DNA extraction.  
 
Specimens will be stored at participating centers immediately after collection and then shipped to a central 
laboratory, frozen on dry ice, in batches of 10 sets or more (1 set = entire blood collection from one patie nt 
visit) , for subsequent storage and ultimate analysis. Our plan to collect lymphocytes for DNA at baseline , 
6 months  and at 48 months of treatment will provide the necessary sample to evaluate not only germline 
DNA but also potential changes in DNA methylation as a result of the metformin intervention.   
 
Research Blood Samples Taken at Baseline and Again at 6 Months   
and at 48 Months of Study Treatment  
 
Type of 
Tube  One Tube     (7 ml)  
(1.4 teaspoons)  Light Green Top Tubes  
(3 x 4.5 ml)  
(2.7 teaspoons)  Red Top Tube  
(2 x 6 ml)  
(2.4 teaspoons)  Lavender Top Tube  
(1 x 6 ml)  
(1.2 teaspoons)  
To be used 
for Plasma for Fasting 
Glucose  
(done locally 
according to 
institution’s 
procedures & 
mandatory)  Insulin 
(done centrally & 
mandatory)  
 
Plasma for storage for 
future research  
(optional)  Serum for storage 
for future 
research  
(optional)  DNA extraction  
(done centrally & optional)  
Lavender topped tubes for DNA 
should be collected even for patients 
who consent to blood banking but 
refuse genetic testing. DNA may be 
used to study gene expression without 
fitting the definition of genetic testing. 
(Please see the MA.32 Sample 
Consent Form for definitions.  
TOTAL VOLUME DRAWN = 38.5 ML ( 7.8 Teaspoons, 2.6 Tablespoons)  
 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 95 CONFIDENTIAL  Tumour blocks will be reques ted by the Queen’s Department of Pathology and instructions will be 
included in the request as to where blocks should be sent. The request will be sent to the person named in 
the Correlative Studies Report. All blood frozen and stored at participating site s will be shipped, in 
batches, at intervals, on dry ice to:  
Attn: Shakeel Virk  
Pathology Coordinator  
Canadian Cancer  Trials Group Tumour Bank  
Department of Pathology  
4th Floor Richardson Labs Building 
Stuart Street 
Queen’s University  
Kingston, ON K7L 3N6  
Tel: 613-533-2906  
Fax: 613 548- 2486  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 96 CONFIDENTIAL  APPENDIX XI  – CANCER TRIALS SUPPORT UNIT (CTSU) PARTICIPATION PROCEDURES  
 
Registration/Randomization  
 
Prior to the recruitment of a patient for this study, investigators must be registered members of the CTSU. 
Each investigator must have an NCI investigator number and must maintain an “active” investigator 
registration status through the annual submission of a complete investigator registration packet (FDA Form 
1572 with original signature, current CV, Supplemental Investigator Data Form with signature, and 
Financial Disclosure Form with original signature) to the Pharmaceutical Management Branch, CTEP, 
DCT D, NCI. These forms are available on the CTSU registered member Web site or by calling the PMB at 
301-496-5725 Monday through Friday between 8:30 a.m. and 4:30 p.m. Eastern time.  
 
Each CTSU investigator or group of investigators at a clinical site must obt ain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office before 
they can enroll subjects. Study centers can check the status of their registration packets by querying the 
Regulatory Support Syste m (RSS) site registration status page of the CTSU member web site at 
http://www.ctsu.org   
 All forms and documents associated with this study can be downloaded from the MA.32 page on the CTSU 
registered member Web site ( https://www.ctsu.org ). Subjects can be randomized only after pre -treatment 
evaluation is complete, all eligibility criteria have been met, and the study site is listed as ‘approved’ in the 
CTSU RSS.  
 
In order to participate in MA.32, sites must submit the “ CCTG MA.32 Application to Participate”, by fax, 
to CCTG. Both the site candidate and the CTSU Regulatory Office will be notified simultaneously by 
CCTG if the site meets the requirements to move forward with site registration.  
 
Requirements for MA.32 site registration : 
 
• CTSU IRB Certification  
• CTSU IRB/Regulatory Approval Transmittal Sheet  
• IRB-approved consent form  
 
Pre-study requirements for patient enrollment on MA.32  
 • Patient must meet all inclusion criteria, and no exclusion criteria should apply  
• Patient has signed and dated all applicable consents and authorization forms  
• All baseline laboratory tests and pre -study evaluations performed within the time period specified in 
the protocol. Plea se consult protocol section 6.0 for baseline investigations and protocol section 13 for 
blood banking and tumour banking information. Please do not send any tumour blocks until requested 
to do so by CCTG.  
• Patient completed baseline QOL forms, Physical Activity Questionnaire and Diet Questionnaire per 
protocol section 6.0 and Protocol Appendices VI & VII.  
 
CTSU Procedures for Patient Enrollment  
 
1.  Contact the CTSU Patient Registration Office by calling 1 -888-462-3009 between 9:00 a.m. and 5:30 
p.m. Easter n Time, Mon -Fri.. Leave a voicemail to alert the CTSU Patient Registrar that an enrollment 
is forthcoming. For immediate registration needs, e.g. within one hour, call the registrar cell phone at 
1-301-704-2376.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 97 CONFIDENTIAL  2.  Complete the following forms: 
 
CTSU Patient Enrollment Transmittal Form 
Eligibility Checklist  
 
3.  Fax these forms to the CTSU Patient Registrar at 1 -888-691-8039 between the hours of 9:00 a.m. and 
5:30 p.m., Mon- Fri, Eastern Time (excluding holidays); however, please be aware that registrations 
received after 5:00 p.m. will be processed the next day. The CTSU registrar will check the investigator 
and site information to ensure that all regulatory requirements have been met. The registrar will also 
check that forms are complete and will follow -up with the site to resolve any discrepancies.  
 
4.  Once investigator eligibility is confirmed and enrollment documents are reviewed for compliance, the 
CTSU registrar will access the C CTG’s on -line registration system, to obtain assignment of a treatment 
arm  and assignment of a unique patient ID (to be used on all future forms and correspondence). The CTSU registrar will confirm registration by fax.  
 
Data Submission and Reconciliation  
 
The Me didata RaveTM web-based system will be used for electronic data capture (EDC). management and 
reporting on this trial. All case report forms (CRFs), with the exception of completed Quality of Life 
Questionnaires, Physical activity Questionnaires and Diet Q uestionnaires, will be electronic. Sites will be 
granted access to the EDC system following approval of all site registration documentation by the CTSU office. Questionnaires must either be downloaded from the MA.32 protocol web page located on the CTSU registered member web site ( https://www.ctsu.org
) or will be provided by CCTG to approved sites. Sites 
must use the current form versions and adhere to the instructions and submission scheduled outlined in the 
protocol. Submission of supporting documentation will also be required for this study. Supporting 
documents can be mailed or directly scanned/uploaded into the EDC system based on centre 
preference/capability. Mailed supporting documents should be sent directly t o CCTG.  
 
Completed electronic CRFs must be submitted directly to C CTG, electronically, via the EDC system. 
Submit all paper questionnaires and supporting documents directly to the C CTG at the address on the “Final 
Page” of the protocol. Do not send study data to the CTSU.  
 The CCTG will send query notices and delinquency reports directly to the site for reconciliation. These will 
be issued electronically, either directly through the EDC system (data queries for electronic CRFs) or by e -
mail (data queries for paper questionnaires and delinquency reports). Please send query response and 
delinquent data to the CCTG via the appropriate route (electronic or paper) as applicable in each case, and 
do not copy the CTSU Data Operations. Each site should have a desi gnated CTSU Administrator and Data 
Administrator and must keep their CTEP IAM Account contact information current. This will ensure timely communication between the clinical site and the C CTG.  
 
Special Materials or Substudies  
 Tumour tissue blocks (optional) and blood specimens (mandatory for insulin and glucose level 
determination) will be collected for MA.32 subjects. For details of specimen collection, please see protocol 
section 13 and the Sample Consent Form in Protocol Appendix XII.  
 
Please do not se nd any tumour blocks until requested by the C CTG to do so.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 98 CONFIDENTIAL  Quality of Life, Physical Activity and Nutrition Sub -studies (Protocol Appendices VI & VII)  
 
Order hard copy booklets from C CTG and submit completed forms, as outlined in the protocol, to C CTG 
at the address appearing on the protocol’s “Final Page”.  
 
Serious Adverse Event (AE) Reporting ( Protocol Section 11)  
 Please consult protocol section 11 for Serious Adverse Event Reporting.  
 
Secondary AML/MDS/ALL reporting: Report occurrence of secondary AML, MDS, or ALL via the 
NCI/CTEP AML- MDS Report Form in lieu of AdEERS. Submit the completed form and supporting 
documentation as outlined in the protocol.  
 
Drug Procurement (Protocol Appendix III)  
 
1. Information on drug formulation, procurement, storage and accountability, administration, and potential toxicities are outlined in Appendix III of the protocol and a more  detailed guide will be 
provided prior to  site activation. Sites will be pre -stocked with an initial supply of blinded 
Metformin/Placebo and re -stocked according to use (which will be monitored by the C CTG “Mango” 
System)  
 
2. You may navigate to the drug f orms by selecting Pharmacy Forms from the document center tree on 
the MA.32 Web page.  
 
Regulatory and Monitoring 
 
Study Audit  
 
To assure compliance with Federal regulatory requirements [CFR 21 parts 50, 54, 56, 312, 314 and HHS 45 CFR 46] and National Cancer Institute (NCI)/ Cancer Therapy Evaluation Program (CTEP) Clinical 
Trials Monitoring Branch (CTMB) guidelines for the conduct of clinical trials and study data validity, all 
protocols approved by NCI/CTEP are subject to audit.  
 
Responsibility for assig nment of the audit will be determined by the site’s primary affiliation with a 
Cooperative Group or CTSU. For Group- aligned sites, the audit of a patient registered through CTSU will 
become the responsibility of the Group receiving credit for the enrollment. For CTSU Independent Clinical 
Research Sites (CICRS), the CTSU will coordinate the entire audit process.  
 
For subjects enrolled through sites affiliated with the CTSU, you may request the accrual be credited to any 
Group for which you have an affiliation provided that Group has an active clinical trials program for the 
primary disease type being addressed by the protocol. Per capita reimbursement will be issued by the 
credited Group provided they have endorsed the trial, or by the CTSU if the Group has not endorsed the 
trial. 
 
Details on audit evaluation components, site selection, patient case selection, materials to be reviewed, site 
preparation, on- site procedures for review and assessment, and results reporting and follow -up can be found 
in the CTMB M onitoring Guidelines and are available for download from the CTEP web page 
http://ctep.cancer.gov/monitoring/guidelines.html . 
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 99 CONFIDENTIAL  Health Insurance Portability and Accountability Act of 1996 (HIPAA)  
 
The HIPAA Privacy Rule establishes the conditions under which protected health information may be used 
or disclosed by covered entities for research purposes. Research is defined in the Privacy Rule referenced 
in HHS 45 CFR 164.501. Templated language addr essing NCI -U.S. HIPAA guidelines are provided in the 
HIPAA Authorization Form located on the CTSU website.  
 
The HIPAA Privacy Rule does not affect participants from outside the United States. Authorization to 
release Protected Health Information is NOT re quired from subjects enrolled in clinical trials at non -US 
sites.  
 
Clinical Data Update System (CDUS) Monitoring 
 
This study will be monitored by the Clinical Data Update System (CDUS) Version 3.0. Cumulative CDUS 
data will be submitted quarterly to CTEP b y electronic means. The sponsoring Group fulfills this reporting 
obligation by electronically transmitting to CTEP the CDUS data collected from the study -specific case 
report forms.  
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 100 CONFIDENTIAL  APPENDIX XII  - A HEALTHY LIFESTYLE AFTER BREAST CA NCER  
 
Both the English and French copies of this document are available and posted on the MA.32 trial webpage.  
 Many patients with breast cancer are interested in adopting a healthy lifestyle. This often involves changes 
in diet and physical activity. The American Cancer Society has developed information that may be helpful 
to breast cancer patients who would like to make lifestyle changes. This information can be found on the American Cancer Society website ( www.cancer.org ). Four helpful documents are provided here:  
 
1. Benefits of Good Nutrition  
2. Nutrition After Treatment Ends  
3. Make Exercise Work for You  
4. Fitting in Fitness  
 Additional information is available on the American Cancer Society website.   
 We encourage you to adopt a healthy lifestyle and suggest that you discuss planned changes in lifestyle with your health care team so ensure they are right for you.  
 
Benefits of Good Nutrition  
 
Good nutrition  is especially important if you have cancer because the illness itself, as well as its treatments, 
can affect your appetite. Cancer and cancer treatments can also affect your body's ability to tolerate certain 
foods and to use nutrients . 
 
The nutrient need s of people with cancer vary from person to person. Your doctor, nurses, and a registered 
dietitian can help you identify your nutrition goals and plan ways to help you meet them. Eating well while 
you are being treated for cancer can help you:  
• feel better  
• keep up your strength and energy  
• keep up your weight and your body’s store of nutrients  
• tolerate treatment- related side effects  
• lower your risk of infection  
• heal and recover quickly  
•  
Eating well means eating a variety of foods that will give you the nutri ents you need to protect your health 
while fighting cancer. These nutrients include protein , carbohydrates , fat, water , vitamins , and minerals . 
 
Nutrients  
 Protein  
 We need protein for growth, to repair body tissue, and to keep our immune systems healthy. When your 
body doesn't get enough protein, it takes you longer to recover from illness and you have lower resistance 
to infection. People with cancer often need more protein than usual. After surgery, chemotherapy, or 
radiation therapy, extra protein is us ually needed to heal tissues and to help prevent infection. Good sources 
of protein include lean meat, fish, poultry, dairy products, nuts, dried beans, peas and lentils, and soy foods.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 101 CONFIDENTIAL  Fats 
 
Fats play an important role in nutrition. Fats and oils provide  a rich source of energy for the body. They are 
used to store energy, insulate body tissues, and transport some types of vitamins through the blood. They also play an important role in food preparation by enhancing food flavor, making baked products tender , 
and conducting heat during cooking. You may have heard that some fats are better for you than others. When considering the effects of fats on your heart and cholesterol level, choose unsaturated fats (monounsaturated and polyunsaturated).  
 
Monounsaturate d fats  are found mainly in vegetable oils such as canola, olive, and peanut oils. They are 
liquid at room temperature.  
 
Polyunsaturated fats  are found mainly in vegetable oils such as safflower, sunflower, corn, flaxseed, and 
canola oils. Polyunsaturated f ats are also the main fats found in seafood. They are liquid or soft at room 
temperature. Certain polyunsaturated fatty acids , such as linoleic acid and alpha- linolenic acid, are called 
essential fatty acids, because the body cannot make them. They are needed to build cells and make hormones. Essential fatty acids must come from foods we choose.  
 
Saturated fats  (or saturated fatty acids) are mainly found in animal sources such as meat and poultry, 
whole or reduced- fat milk, and butter. Some vegetable oils like coconut, palm kernel oil, and palm oil are 
saturated. Saturated fats are usually solid at room temperature.  
 
Trans fatty acids  are formed when vegetable oils are processed into margarine or shortening. Sources of 
trans fats in the diet  include snack foods and baked goods made with partially hydrogenated vegetable oil 
or vegetable shortening. Trans fats also are found naturally in  some animal products, such as dairy products.  
 Carbohydrates  
 
Carbohydrates give the body the fuel it needs for physical activity and for proper organ function. There are 
also good and bad sources of carbohydrates. The best sources of carbohydrates -- fruits, vegetables, and 
whole grains  -- supply needed vitamins and minerals, fiber , and phytonutrients  to the body’s cells. Other 
sources of carbohydrates include bread, potatoes, rice, spaghetti, pasta, cereals, dried beans, corn, peas, and 
beans. Sweets (de sserts, candy, and drinks with sugar) can supply carbohydrates, but provide very few 
nutrients.  
 
Water  
 
Water and fluids  are vital to our health. All body cells need water to function. If you do not take in enough 
fluids or if you are vomiting or have diar rhea, you may become dehydrated. In general, a person should 
drink about eight 8- oz. glasses of water or clear liquid each day to be sure that all the body cells get the 
fluid they need.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 102 CONFIDENTIAL  Vitamins and minerals  
 
Vitamins and minerals are needed for proper growth and development. They also allow the body to use the 
energy ( calories ) supplied in foods. A person who eats a balanced diet with enough calories and protein 
usually gets plenty of vitamins and minerals. But it can be hard to eat a balanced diet when you are being 
treated for cancer and have treatment side effects that last for long periods of time. When that is the case, 
your doctor or dietitian may suggest a daily multivitamin and mineral supplement. If you are thinking of taking a vitamin or supplem ent, be sure to discuss this with your doctor first. Some people with cancer take 
large amounts of vitamins, minerals, and other dietary supplements to try and boost their immune system 
or even destroy cancer cells. Some of these substances can be harmful,  especially when taken in large doses. 
In fact, large doses of some vitamins and minerals may reduce the effectiveness of chemotherapy and 
radiation therapy. During treatment, it may be best to choose one with no more than the Daily Value (DV) 
for all nutr ients and one without iron, unless your doctor thinks that you need iron. Again, discuss this with 
your doctor first.  
 
Antioxidants  
 
Antioxidants  are substances that protect the body's cells from damage caused by free radicals  (by-products 
of the body’s normal processes). Examples of antioxidants include vitamin C, vitamin E, vitamin A (beta 
carotene), and selenium. If you want to take in more antioxidants, health experts recommend eating a variety 
of fruits and vegetables, which are good sources of antioxi dants. Taking large doses of antioxidant 
supplements is usually not recommended while having chemotherapy and radiation therapy. Talk with your doctor to determine the best time to take antioxidant supplements.  
 Herbs  
 Herbs have been used to treat disease  for hundreds of years. Today, herbs are found in many products, such 
as pills, liquid extracts, teas, and ointments. While many of these products are harmless and safe to use, 
others can cause severe and harmful side effects. Some may even interfere with proven cancer therapies, 
including chemotherapy, radiation therapy, and recovery from surgery. If you are interested in using 
products containing herbs, talk about it with your doctor or nurse first.  
 Safety considerations  
 Many people believe that if they find a pill or supplement in stores , it is safe and effective. The Food and 
Drug Administration (FDA) put out new rules in 2007 to help ensure that supplements contain what their labels claim they do. However, some of these rules will not be fully in eff ect until 2010. Even then, the 
supplement's safety and its effect on the body are not addressed by the new FDA rules. The FDA does not 
require manufacturers of these products to print possible side effects on their labels. The FDA cannot pull 
a dietary supplement or herbal product from the market unless it can prove that the product is unsafe.  
 
Tell your health care team about any herbal products and supplements that you are using or are thinking 
about using. Bring the bottle(s) of the supplement to your doctor to talk about the dose and to be sure that 
the ingredients do not interfere with your health or cancer treatments. Some other safety tips:  
• Ask your doctor or nurses for reliable information on dietary supplements.  
• Check the product labels for both the  quantity and concentration of active ingredients contained in 
each product.  
• Stop taking the product immediately and call your doctor if you have side effects such as wheezing, 
itching, numbness, or tingling in your limbs.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 103 CONFIDENTIAL  Some people with cancer take large amounts of vitamins, minerals, and other dietary supplements in an 
effort to enhance their immune systems or even destroy cancer cells. Some of these substances can be 
harmful. In fact, large doses of some vitamins and mi nerals may reduce the cancer -fighting effects of 
chemotherapy and radiation therapy. If you would like to learn more about herbs and supplements, call us at 1-800-ACS -2345 or visit our web site at www.cancer.org . 
 
Nutrition After Treatment Ends  
 
Most eating -related side effects of cancer treatments go away after the treatment ends. Sometimes side 
effects such as poor appetite, dry mouth, change in taste or smell, trouble swallowing, or significant weight 
loss may la st for some time. If this happens to you, talk to your health care team and work out a plan to 
address the problem.  
As you begin to feel better, you may have questions about eating a healthful diet. Just as you wanted to go 
into treatment with the necessa ry nutrient stores that your diet could give you, you'll want to do the best for 
yourself at this important time. There's very little research to suggest that the foods you eat will keep your 
cancer from coming back. But eating well will help you regain your strength, rebuild tissue, and feel better 
overall. And certainly, what you eat can help  reduce risk for other cancers.  
 
Suggestions for healthy eating after cancer:  
 
• Check with your doctor for any food or diet restrictions.  
• Ask your dietitian to help y ou create a nutritious, balanced eating plan.  
• Choose a variety of foods from all the food groups. Try to eat at least 5 to 7 servings a day of fruits 
and vegetables, including citrus fruits and dark- green and deep -yellow vegetables.  
• Eat plenty of high- fiber foods, such as whole grain breads and cereals.  
• Buy a new fruit, vegetable, low -fat food, or whole grain product each time you shop for groceries.  
• Decrease the amount of fat in your meals by baking or broiling foods.  
• Choose low -fat milk and dairy pro ducts.  
• Avoid salt -cured, smoked, and pickled foods.  
• If you choose to drink, drink alcohol only occasionally.  
• If you are overweight, consider losing weight by reducing the amount of fat in your diet and increasing your activity. Choose activities that yo u enjoy. Check with your doctor before starting any exercise 
program.  
• See " Nutrition and Physical Activity During and After Cancer Treatment: Answer s to Common 
Questions " to help choose foods for a we ll-balanced meal plan.  
 
Make Exercise Work for You  
 
No matter when you start, exercise improves health. Even people who start exercising later in life appear 
to gain many of the same health benefits as pe ople who've exercised their whole lives, according to research 
at Stanford University School of Medicine.  
 
Physical activity throughout life can help protect against some cancers. For breast and prostate cancer, it 
may help by regulating hormone levels. For colon cancer, physical activity speeds up the digestive process, shortening the exposure of the bowel lining to harmful substances Exercise also helps reduce cancer risk 
by helping people maintain a healthy weight.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 104 CONFIDENTIAL  Choose Your Game  
 
It's impor tant to enjoy what you're doing so you won't get bored or think of it as a chore. To choose an 
activity that's right for you, ask yourself these questions:  
 
Do you like to be social, or would you prefer time to yourself?  
• Social butterflies should try activ ities that connect them with other people. Try to walk with friends, 
join a team or recreation association, or go line dancing.  
• If you need time to yourself, walking, running, swimming, or gardening can give you time to reflect.  
 
Do you need to get energiz ed or wind down?  
• For an energy boost, try aerobic activities that get the heart pumping.  
• Reduce stress with activities like yoga or tai chi.  
 
Are you goal -oriented, or do you like to stay flexible?  
• If you like to feel a sense of accomplishment, choose acti vities where you can chart and monitor your 
progress like training for a run, or take up an activity with rising skill levels, like martial arts.  
• For a more flexible routine, try walking or find an exercise video you can do at home.  
 
Do you want to get away from it all or get involved? 
• If you want to get away, choose outdoor activities like hiking, biking, or rollerblading.  
• Make your workplace more health conscious with the ACS program Active for Life . Participants 
choose their own physical activities, form teams of coworkers, and enjoy a friendly competition for 
the highest number of minutes spent exercising.  
• To get involved in the community, consider building homes for t he disadvantaged, participating in 
charity walks and runs, helping an elderly neighbor with yard work, or tidying up a local school.   
 
How Much Activity Should You Be Doing?  
 That depends on you.  
• If you haven't been active, you should start with moderate activities and gradually increase the duration, frequency, and intensity as you become more fit. Work your way up to 30 minutes or more 
five or more days a week.  
• If you are active but want to do m ore, increase the intensity, duration, or frequency of what you 
currently do. Moderate to vigorous activity for 45 minutes or more five of more days a week will 
increase your health benefits.  
• If you are active and want to maintain your current level of fi tness, try adding new activities to your 
routine to use different muscles and keep your interest.  
 
Strike a Balance  
 
Ads for expensive exercise equipment and special diets can make healthy living look complicated. But the 
truth is there's no secret to achi eving the weight you want. It is as simple as balancing the calories you burn. 
When that doesn't happen, you gain weight.  
 
Remember that everything you eat contains calories, and everything you do uses calories. For example, if 
you weight 150 pounds and ar e active, you need approximately 2,250 calories per day to maintain that 
weight, versus 1,950 calories if you are sedentary.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 105 CONFIDENTIAL  It helps to know that one pound of body fat equals 3,500 calories. That means that to lose one pound per 
week, you need to reduce your total calories by 500 per day. You can do this by eating 250 fewer calories 
a day, and burning an extra 250 calories through physical activity (e.g. walking 2.5 miles).  
 To Burn Off a Large Order of Fries (400 Calories)  
 A 160 pound person could burn off 400 calories in the time and activities shown below:  
 
Activity  Minutes  
Moderate walking  95 
Scrubbing Floors  89 
Dancing  70 
Bicycling  39 
Running  28 
 
To plan the physical activity for weight loss, you'll want a ballpark idea of how many calories are burned 
in different activities. For example, if you weigh 150 pounds and did the following activities for an hour, 
you'd burn 324 calories gardening, 297 in brisk walking, and 216 calories playing with kids.  
 
Less vigorous activities use fewer  calories but still help in weight control. For a 150 pound person, an hour 
of strolling uses 206 calories, vacuuming or mopping—150 calories. Watching TV burns only 72 calories 
per hour. Find calorie counts for many other activities with our online calcul ator. 
 
Staying Motivated  
 
Be specific and choose variety.  Rather than having general goals like "getting in shape" or "exercising 
more," choose concrete goals such as walking 30 minutes on Tuesdays and Thursdays, and doing stretching 
exercises five minutes  each morning. The more variety you have, the more likely you will continue. A well -
rounded exercise program that includes aerobic exercise, strength training using weights, and flexibility 
exercises - even when performed regularly in small increments -  is key, according to the American College 
of Sports Medicine.  
 Incorporate fitness into your lifestyle.  Begin to see exercise as an everyday opportunity. For example, 
use the stairs instead of the elevator, walk during lunch, or bike to work. Combine fitnes s with your family 
chores and activities, such as raking leaves or gardening.  
 
Motivate yourself.  Try visualization techniques to help your motivation. Imagine yourself being in shape 
and how it feels. Create a vision of yourself looking fit. Rather than f ocusing on feeling out of shape, picture 
yourself feeling energized after your workout. Also, reward yourself when you meet each of your goals.  
 Get a support system.  Build a support system of family, friends, co- workers, and/or neighbors. They can 
help encourage you when your motivation is low. You can also exercise with someone else. Try to find a 
buddy who shares similar fitness interests. Many shopping malls have mall -walker programs where you 
can meet others.  
 
Expect setbacks and prepare for obstacles.  Things like time, illness, or bad weather may occasionally 
get in the way. Disruptions are inevitable. Accept them and move on. If you go off your program, you can 
always adapt and resume. Some exercise is always better than none at all.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 106 CONFIDENTIAL  If you are a ma le older than 45 , or a female over 55, and have not been regularly active, or have any health 
concerns, consult your physician before you begin an exercise program. Regardless of your age, if you have 
two or more of the following risk factors, consult your physician:  
• High blood pressure  
• High cholesterol  
• Diabetes  
• You currently smoke  
• Family history of early onset heart disease (first degree relative with heart disease before age 65 for female relatives, or before age 55 for male relatives.)  
 
Fitting in Fitness  
 Simple Steps Add Up  
 
Did you know you benefit from even small amounts of moderate activity throughout the day? Regular 
physical activity is easier to fit in than you may realize and can significantly lower your lifetime risk for 
cancer --and heart disease and diabetes, too.  
 
You'll find the American Cancer Society's physical activity guidelines for adults and children below. These 
recommendations are based on the latest scientific information to help reduce the risk of developing cancer. 
Read on for ways to fit in fitness that may surprise you, then learn how many calories are burned in common 
activities and exercises.  
 
ACS Physical Activity Guidelines  
 
Adults : Engage in at least 30 minutes of moderate to vigorous activi ty, above usual activities, on 5 or more 
days of the week; 45 to 60 minutes of intentional physical activity are preferable.   
 Children and adolescents : Engage in at least 60 minutes per day of moderate to vigorous physical activity 
for at least 5 days per  week.  
 Moderate Activity  is anything that makes you breath as hard as you do during a brisk walk. During 
moderate activities, you'll notice a slight increase in heart rate and breathing, but you may not break a sweat.  
 
Vigorous Activities  generally engage  large muscle groups and cause a noticeable increase in heart rate, 
breathing depth and frequency, and sweating.  
 
Other beneficial activities include those that improve strength and flexibility such as weight lifting, stretching, or yoga.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 107 CONFIDENTIAL  Examples of Mode rate and Vigorous Physical Activities  
  Moderate Activities  Vigorous Activities  
Exercise and 
Leisure  Walking, dancing, leisurely bicycling, 
ice-skating or roller -skating, horseback 
riding, canoeing, yoga  Jogging or running, fast bicycling, 
circuit weight training, aerobic dance, 
martial arts, jump rope, swimming  
Sports  Volleyball, golfing, softball, b aseball, 
badminton, doubles tennis, downhill 
skiing  Soccer, field hockey or ice hockey, 
lacrosse, singles tennis, racquetball, 
basketball, cross -country skiing  
Home 
Activities  Mowing the lawn, general lawn and 
garden maintenance  Digging, carrying and hauling, 
masonry, carpentry  
Occupational 
Activity  Walking and lifting as part of the job 
(custodial work, farming, auto or 
machine repair)  Heavy manual labor (forestry, construction, fire fighting)  
 Active Substitutions  
 
Looking for more ways to work in activity during your day? Think about how much time you spend sitting 
rather than being active. Then consider these simple substitutions that can help you get moving.  
• Use stairs rather than an elevator.  
• Walk or bike to your destination.  
• Exercise at lunch with your workmates, family, or friends.  
• Take a 10 -minute exercise break at work to stretch or take a quick walk.  
• Walk to visit co -workers instead of sending an email.  
• Go dancing with your spouse or friends.  
• Plan active vacations rather than o nly driving trips.  
• Wear a pedometer every day and watch your daily steps increase.  
• Join a sports team.  
• Use a stationary bicycle or treadmill while watching TV.  
 
No matter what kind of activity you choose, the important thing is to get moving. Try to fi t in at least 30 
minutes of exercise on 5 or more days of the week, and look for other opportunities to be active throughout 
the day.  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 108 CONFIDENTIAL  APPENDIX XIII -  EQUIVALENT HEMATOLOGY UNITS  
 
The following units are equivalent to 109/L: 
 
103/mm3  
103/uL  
103/cmm  
103/cumm  
103/mcL  
1000/mm3  
1000/uL   
1000/cmm   
1000/cumm   
1000/mcL  
K/mm3  
K/uL  
K/cmm  
K/cumm  
K/mcL  mil/mm
3  
mil/uL  
mil/cmm  
mil/cumm  
mil/mcL  
thou/mm3  
thou/uL  
thou/cmm  
thous/cumm  
thous/mcL  
E9/L  
GIGA/L  For example  
 if the WBC count is 5.3 x10
3/uL 
this is the same as  
5.3 x109/L 
 if platelets are 250 thou/mm
3 
this is the same as  250 x10
9/L 
The following units are equivalent to cells/mm3: 
 
cells/uL  
cells/cmm  
cells/cumm  
cells/mcL  
/mm3  
/uL  
/cmm  
/cumm  
/mcL  For example  
 if the WBC count is 5300 cells/uL  
this is the same as  
5300 cells/mm
3 
 if platelets are 250,000 /uL  
this is the same as  250,000 cells/mm
3 
 
  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL 109 CONFIDENTIAL  APPENDIX XIV  - EMERGENCY SITUATIONS AND COMPLIANCE  
 
Management of Protocol Variances in Emergency Situations  
 
Compliance with the trial protocol, its amendments and any information that may be added to this document 
or provided as a part of the conduct of this trial as well as any associated sub- studies should be ensured to 
every extent possible, however in emergency situations, spec ific variances from the protocol that occur as 
a result of efforts to minimize or eliminate hazards and protect the safety and well- being of patients are 
permissible.  
 
In these rare circumstances, minor deviations that do not impact patient safety or willingness to participate 
or trial integrity , which have been justified and documented in the medical record by the QI/SI will not be 
considered to be REB reportable deficiencies requiring action, but must be reported to CCTG (e.g. in 
Electronic Data Capture ( EDC) or using trial specific deviation logs as directed by CCTG) within 4 weeks 
of the end of the Emergency Situation, unless otherwise instructed by CCTG, and to your REB at the next 
amendment or annual approval.  
 
Centres should also discuss these reporti ng requirements with their local REB, and review the trial website 
for additional guidance specific to the trial.  
 
Minor Protocol Deviations : 
• Missed or delayed protocol mandated visits or investigations on treatment or in follow up.  
• Changes in study drug distribution (e.g. drug distributed remotely or IV drug given at satellite site), providing permitted by local SOPs, or written procedure established and is approved by CCTG or 
acceptable per further instruction from CCTG. Note there will be no exceptions for injectable/IV 
investigational agents as must be administered at participating site.  
• Alternative methods for safety assessments (e.g. telephone contact, virtual visit, alternative location for 
assessment).  
• Patient care and evaluati ons provided by non- research staff, providing overseen by QI/SI who must 
make all treatment decisions and ensure that all required information and results will be reported to 
allow central data submission. Includes physical exam, clinical laboratory tests,  research blood 
collections that can be shipped centrally, imaging, non -investigational drug therapy*, standard radiation 
therapy, surgery, and other interventions that do not require protocol -specified credentialing*.  
*Must be approved by CCTG or acceptable per further instruction from CCTG.  
• Re-treatment following extended treatment delays if protocol specifies that excessive delays require 
discontinuation, providing other protocol requirements for discontinuation have not been met and either discussed wi th CCTG or acceptable per further instruction from CCTG.  
 
Note:  
− Applicable only to COVID -19 and other CCTG designated emergency situations.  
− No waivers will be given for eligibility, including performance of protocol mandated tests/imaging.  
− Deficiencies w ill be issued if patients are enrolled when trial is on accrual hold, for unreported Serious 
Adverse Events as well as changes in drug distribution/administration and/or re -treatment after 
extended treatment delays when not discussed and approved by CCTG or acceptable per further 
instruction from CCTG.  
− Deviations or changes that are believed to impact patient safety, compromise the study integrity or 
affect willingness to participate are still considered Major Protocol Violations and must be reported to 
CCTG and your REB. These include more than a minimal delay in protocol therapy administration.  
 
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL Final Page  CONFIDENTIAL LIST OF CONTACTS  
 Contact  Tel. #  Fax #  
ELIGIBILITY CHECKLIST  
Must  be completed prior to 
requesting a randomization . Amy Hawkins  
Clinical Trials Assistant  
CCTG  
 
Email : 
ahawkins @ctg.queensu.ca   
613-533-6430  613-533-2814  STUDY SUPPLIES  
Guides , Protocols  Available on CCTG Website:  
http://www.ctg.queensu.ca  
under: Clinical Trials  
PRIMARY CONTACTS FOR 
GENERAL PROTOCOL -
RELATED QUERIES  
(including eligibility questions and protocol management)  Paul Stos  
Study Coordinator  
CCTG  
 
Email : 
pstos @ctg.queensu.ca  
or: 
Dr. Wendy Parulekar  
Senior Investigator  
CCTG  
 
Email : 
wparulekar@ctg.queensu.ca  613-533-6430  
416-586-8605  613-533-2814  
416-586-8659  
STUDY CHAIR  
 Dr. Pamela Goodwin  
Study Chair  
Email : 
pgoodwin@mtsinai.on.ca  
SERIOUS ADVERSE EVENT 
REPORTING  
See protocol Section 11.0 for 
details of reportable events.  Dr. Wendy Parulekar  
Senior Investigator  613-533-6430  613-533-2814  
or: 
Paul Stos  
Study Coordinator  
CCTG  613-533-6430  613-533-2814  
DRUG ORDERING 
See Appendix III for full details.  Amy Hawkins  
Clinical Trials Assistant(s)  
CCTG  
 
Email : 
ahawkins @ctg.queensu.ca  
 613-533-6430  613-533-2814  
 PROTOCOL  AMENDMENT #5 : 2021- APR -01 
 NCIC CTG TRIAL:  MA.32 
 
 
CONFIDENTIAL Final Page  CONFIDENTIAL  AMEND #4: 2016- FEB-04 
Cancer Trials Support Unit (CTSU) Address and Contact Information  
 
To submit site registration 
documents:  For patient enrollments:  Submit study data directly to the 
Lead Cooperative Group unless 
otherwise specified in the 
protocol:  
CTSU Regulatory Office  
1818 Market Street, Suite 1100  
Philadelphia, PA 19103 
Phone – 1- 866-651-CTSU  
Fax – 215- 569-0206  CTSU Patient Registration  
 
Please consult Appendix XI: Cancer 
Trials Support Unit (CTSU) Participation Procedures  Data management will be 
performed by the C CTG by means 
of a web -based Electronic data 
Capture (EDC) System. Electronic case report forms must be submitted electronically. Clinical reports and supporting documentation may be submitted by mail to:  
 NCIC CTG – MA.32  
Cancer Research Institute  
10 Stuart Street,  
Queen’s University  
Kingston, Ontario, Canada  
K7L 3N6  
Phone – 613- 533-6430  
Fax – 613- 533-2814  
 
Do not submit study data or forms to CTSU Data Operations. Do not copy the CTSU on data 
submissions.  
For patient eligibility or treatment -related questions   
Contact the Study Coordinator of the Coordinating Group.  
 
For questions unrelated to patient eligibility, treatment, or data submission  contact the CTSU Help Desk by 
phone or e -mail:  
CTSU General Information Line – 1 -888-823-5923, or ctsucontact@westat.com . All calls and correspondence will 
be triaged to the appropriate CTSU representative.  
The CTSU Public Web site is located at: www.ctsu.org  
The CTSU Registered Member Web site is located at https://members.ctsu.org  
 
CTSU logistical information is located in Appendix XI  
 